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PROTECTION OF CELLS FROM 
ALU-RNA-INDUCED DEGENERATION AND 
INHIBITORS FOR PROTECTING CELLS 
RELATED APPLICATIONS 
This application claims priority from International Patent 
Application No. PCT/US2012/046928 filed Jul. 16, 2012, 
which claims priority to U.S. Provisional Application Ser. 
No. 61/508,867 filed Jul. 18, 2011 and U.S. Provisional 
Application Ser. No. 61/543,038 filed Oct. 4, 2011, the entire 
disclosures of each of which are incorporated herein by this 
reference. 
GOVERNMENT INTEREST 
This invention was made with govermnent support under 
R01EY018350, R01EY018836, R01EY020672, 
R01EY022238, R21EY019778, RC1EY020442 awarded by 
the National Eye Institute of the National Institutes of 
Health. The govermnent has certain rights in the invention. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to inhibi-
tion of inflarmnosome, MyD88, IL-18, VDAC1, VDAC2, 
Caspase-8, and NFKB; inhibitors of inflarmnosome, MyD88, 
IL-18, VDAC1, VDAC2, Caspase-8, and NFKB, methods 
protecting a cell, and screening methods for identifying 
inhibitors. 
INTRODUCTION 
2 
This Summary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
Summary is merely exemplary of the numerous and varied 
5 embodiments. Mention of one or more representative fea-
tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 
to other embodiments of the presently-disclosed subject 
10 
matter, whether listed in this Summary or not. To avoid 
excessive repetition, this Summary does not list or suggest 
all possible combinations of such features. 
The presently-disclosed subject matter includes methods 
15 for identifying MyD88 inhibitors, and methods and compo-
sitions for inhibiting MyD88 and uses thereof. The pres-
ently-disclosed subject matter includes methods for identi-
fYing inflammasome inhibitors, and methods and 
compositions for inhibiting an inflammasome and uses 
20 thereof. The presently-disclosed subject matter includes 
methods for identifying inhibitors of components of inflam-
mosome, and methods and compositions for inhibiting a 
component of inflammasome and uses thereof. Components 
of inflammasome include, for example, NLRP3, PYCARD, 
25 and Caspase-1. The presently-disclosed subject matter 
includes methods for identifYing IL-18 inhibitors, and meth-
ods and compositions for inhibiting IL-18 and uses thereof. 
The presently-disclosed subject matter includes methods for 
identifying VDAC1 and VDAC2 inhibitors, and methods 
30 and compositions for inhibiting VDAC1 and VDAC2 and 
uses thereof. The presently-disclosed subject matter includes 
methods for identifYing caspase-8 inhibitors, and methods 
and compositions for inhibiting caspase-8 and uses thereof. 
Age-related macular degeneration (AMD), which is as 
prevalent as cancer in industrialized countries, is a leading 35 
cause of blindness worldwide. In contrast to the neovascular 
The presently-disclosed subject matter includes methods for 
identifying NFkB inhibitors, and methods and compositions 
for inhibiting NFkB and uses thereof. Also provided are 
form of AMD, for which many approved treatments exist, 
the far more cormnon atrophic form of AMD remains poorly 
understood and without effective clinical intervention. 
Extensive atrophy of the retinal pigment epithelium (RPE) 
leads to severe vision loss and is termed geographic atrophy, 
the pathogenesis of which is unclear. Geographic atrophy 
causes blindness in millions of people worldwide and there 
is currently no approved treatment. 
methods and compositions for imaging activated caspase-1 
in an eye of a subject. 
The presently-disclosed subject matter includes methods 
40 including inhibiting one or more of an inflammasome, 
MyD88, and IL-18 of a cell. In some embodiments, the 
presently-disclosed subject matter includes methods includ-
ing inhibiting one or more of MyD88, IL-18, VDAC1, 
The present inventors have shown a dramatic reduction of 45 
the RNase DICER1 in the retinal pigmented epithelium 
(RPE) of human eyes with geographic atrophy (Kaneko et 
VDAC2, NFKB, caspase-8, caspase-1, NLRP-3, PYCARD, 
and an inflammasome, including a component of an inflam-
masome (e.g., caspase 1, NLRP-3, PYCARD) of a cell. In 
some embodiments, the presently-disclosed subject matter 
includes methods including administering one or more 
inhibitors selected from inhibitors of MyD88, IL-18, 
a!. Nature 2011, which is incorporated herein by this refer-
ence). The present inventors have also demonstrated that 
DICER1 deficiency leads to an accumulation of Alu RNA 
transcripts, which is also observed in the RPE of human eyes 
with geographic atrophy. These Alu RNA transcripts induce 
cell death of human RPE cells and RPE degeneration in 
mice. The precise mechanisms of cytotoxicity of Alu tran-
scripts are unknown. 
As described herein the present inventors have now found 
that DICER1 deficit or Alu RNA exposure activates the 
NLRP3 inflammasome and triggers toll-like receptor-inde-
pendent MyD88 signalling via IL-18 both in the RPE of 
mice and in human and mouse RPE cells. 
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
50 VDAC1, VDAC2, NFKB, caspase-8, caspase-1, NLRP-3, 
PYCARD, and an inflammasome, including a component of 
an inflmasome (e.g., caspase 1, NLRP-3, PYCARD). 
In some embodiments of the method, the cell is selected 
from an RPE cell, a retinal photoreceptor cell, or a choroidal 
55 cell. In some embodiments, the cell is an RPE cell. In some 
embodiments, the cell is the cell of a subject. In some 
embodiments, the cell is a cell of a subject having, suspected 
of having, or at risk of having a condition of interest. In some 
embodiments, the cell is a cell of a subject having, suspected 
60 of having, or at risk of having age-related macular degen-
eration. In some embodiments, the cell is a cell of a subject 
having, suspected of having, or at risk of having geographic 
atrophy. In some embodiments, the cell is a cell of a subject 
having, suspected of having, or at risk of having geographic 
65 atrophy and the cell is an RPE cell. In some embodiments, 
a subject having age-related macular degeneration can be 
treated using methods and compositions as disclosed herein. 
US 9,453,226 B2 
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In some embodiments of the method the cell is protected 
against Alu-RNA-induced degeneration. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Alu RNA does not activate or function via toll-like 
receptors (TLRs) (A-E) pA!u, but not pNull, induces RPE 
degeneration in WT (A), Tlr3_1_ (B), Tlr7_1_ (C), Unc93bl 
4 
Fundus photographs, top row; Z0-1 stained (red) flat 
mounts, bottom row. Degeneration outlined by blue arrow-
heads. n=S-12. Scale bars, 20 f.tm (C,D,G,H). Representative 
images shown. See also FIG. 11. 
FIG. 4. Alu RNA induces mitochondrial ROS production 
and NLRP3 priming (A) pA!u induces NLRP3 and ILlS 
mRNAs in WT and Mydss-/- mouse RPE cells. (B) pA!u 
induces generation of reactive oxygen species (ROS) in 
human RPE cells as monitored with the fluorescent probe mt mice, which are functionally deficient in TLRs-3,7,9 (D), 
and Tlr4_1_ mice (E). Representative images shown. n=S-12. 
Fundus photographs, top row; Flat mounts stained for 
zonula occludens-1 (Z0-1; red), bottom row. Degeneration 
outlined by blue arrowheads. Scale bars, 20 f.tm. (F) Stimu-
lation of HEK293 cell lines expressing various TLRs with 
either of two different Alu RNA sequences does not elicit 
NF -KB activation. Positive ( +) controls using TLR -specific 
ligands activated NF-KB. n=3. Data are represented as 
mean+/-SEM. See also FIG. 8. 
10 H2 DCFDA (A.U, arbitrary units). (C) DPI blocks pAin-
induced NLRP3 and ILlS mRNAs in human RPE cells. (D) 
DPI protects WT mice from pAin-induced RPE degenera-
tion. (E) pA!u induces generation of mitochondrial reactive 
oxygen species in human RPE cells as detected by the 
15 fluorescence of MitoSOX Red (green pseudocolor), colo-
calized with respiring mitochondria labeled by MitoTracker 
Deep Red (red). (F) PMA, but not pA!u, induces phago-
somal ROS generation, as assessed by fluorescent Fe OXY-
BURST Green assay in human RPE cells. (A.U, arbitrary FIG. 2. Alu RNA induces RPE degeneration via MyDSS 
(A) pA!u does not induce RPE degeneration in Mydss-/-
mice. (B) pAin-induced RPE degeneration in WT mice is 
inhibited by a MyDSS homodimerization peptide inhibitor 
(MyDSSi), but not by a control peptide. (C) pAin-induced 
RPE degeneration in WT mice is inhibited by cholesterol-
conjugated MydSS siRNA but not control siRNA. (D and E) 
siRNA targeting MyDSS (siMyDSS) reduces target gene (D) 
and protein (E) abundance in mouse RPE cells compared to 
control siRNA. n=3, *p<0.05 by Student t-test. (F) pA!u 
does not induce RPE degeneration in MydSS heterozygous 
(het) mice. (G) Western blot of Alu RNA-induced IRAKl 
and IRAK4 phosphorylation in human RPE cells. Image 
representative of 3 experiments. (H) pA!u reduces cell 
viability ofWT but not MydSS mouse RPE cells. (I) Loss of 
human RPE cell viability induced by pA!u is rescued by 
MyDSSi. (J) AAVl-BESTl-Cre, but not AAVl-BESTl-
GFP, protected Mydssftf mice from pAin-induced RPE 
degeneration. (K) pA!u induces IL-lS secretion from human 
RPE cells measured by ELISA. IL-l~ secretion is barely 
detectable. n=3, *p<0.05 by Student t-test. (L) Recombinant 
IL-lS induces RPE degeneration in WT but not Mydss-/- 40 
mice. (M and N) pAin-induced RPE degeneration in WT 
mice is rescued by IL-lS neutralizing antibody (N) but not 
20 units). (G) MitoTempo and MitoQ, but not vehicle or dTPP 
controls, prevent Alu RNA-induced RPE degeneration in 
WT mice. (H) NADPH oxidase inhibitor gp9lds-tat or a 
scrambled peptide do not prevent Alu RNA-induced RPE 
degeneration in WT mice. (I) Alu RNA induces RPE degen-
25 eration mice deficient in Cybb (which encodes the gp9lphox 
subunit of NADPH oxidase). (J and K) siRNAs targeting 
VDACl and VDAC2, but not VDAC3 or scrambled control, 
prevent pAin-induced mROS generation (J) and upregula-
tion ofNLRP3 and ILlS mRNAs (K) in human RPE cells. 
30 mROS visualized with MitoSox Red dye and cell nuclei 
with Hoechst stain. n=3-4, *p<0.05 by Student t-test (A-C, 
K), NS, not significant by Student t-test (F). Representative 
images shown. n=S-12. Z0-1 stained (red) flat mounts. 
Scale bars, 20 nm (D, E, G-I), n=3-4. Scale bar, 100 flill (J). 
35 See also FIG. 11. 
by IL-l~ neutralizing antibody (M). Representative images 
shown. n=S-12. Fundus photographs, top row; Z0-1 stained 
(red) flat mounts, bottom row. Degeneration outlined by blue 45 
arrowheads. Scale bars, 20 f.tm (A-C,F,J,L-N). n=3, *p<0.05 
by Student t-test. Data are represented as mean+/-SEM 
(D,E,H,I,K). See also FIG. 9. 
FIG. 3. Alu RNA induces RPE degeneration via NLRP3 
inflammasome (A) Western blot of Caspase-1 activation 50 
(p20 subunit) by Alu RNA in human RPE cells. (B) Western 
blot of pAin-induced IL-lS maturation in RPE celllysates in 
wild-type mice impaired by Caspase-1 peptide inhibitor. (C) 
Caspase-1 peptide inhibitor protects WT mice from pAin-
induced RPE degeneration. (D and E) pA!u does not induce 55 
RPE degeneration in Casp 1-/- mice or (E) cytotoxicity in 
Caspl_1_ mouse RPE cells. (F) Alu RNA and LPS+ATP 
induce formation of PYCARD clusters in human RPE cells 
transfected with GFP-PYCARD. (G and H) pA!u does not 
induce RPE degeneration in Nlrp3_1_ (G) or Pycard_;_ (H) 60 
mice. (I) Nlrp3_1_ and Pycard_;_ mouse RPE cells are 
protected against pAin-induced loss of cell viability. (J) 
siRNAs targeting NLRP3 or PYCARD rescued human RPE 
cells from pAin-induced cytotoxicity, compared to control 
siRNA. n=3-4, *p<0.05 by Student t-test (A,B,E,F,I,J). 65 
Images representative of 3 experiments. Densitometry val-
ues normalized to Vinculin are shown in parentheses (A,B). 
FIG. 5. RPE degeneration does not occur via pyroptosis 
(A and B) Glycine inhibits human RPE cell death induced by 
LPS+ATP (A) but not by pA!u (B). (C) Recombinant IL-lS 
induces RPE degeneration in Caspl_;_ mice. n=3-4 (A,B), 
*p<0.05 by Student t-test. Representative images shown. 
n=S-12. Fundus photographs, top row; Z0-1 stained (red) 
flat mounts, bottom row. Degeneration outlined by blue 
arrowheads. Scale bars, 20 flill (C). 
FIG. 6. DICERl loss induces cell death via inflam-
masome (A) Western blot of Alu RNA-induced Caspase-1 
cleavage (p20) inhibited by DICERl overexpression in 
human RPE cells. (B and C) DICERl overexpression 
reduces Alu RNA-induced Caspase-1 activation in human 
RPE cells (measured by cleavage (B left panel, green) of 
Caspalux®l fluorescent substrate). Fluorescence quantifica-
tion shown in right panel. (C) Western blot of increased 
Caspase-1 activation (p20 subunit) in RPE cell lysates of 
BESTl-Cre; Dicer]flf mice compared to BESTl-Cre or 
Dicer]flf mice. (D) Western blot of increased Caspase-1 
activation (p20 subunit) and IL-lS maturation in RPE cell 
lysates ofDicer]flf mice treated withAAVl-BESTl-Cre. (E 
and F) RPE degeneration induced by AAVl-BESTl-Cre in 
Dicer]flf mice is rescued by peptide inhibitors of either 
Caspase-1 (E) or MyDSS (F). (G) MyDSS inhibitor rescues 
loss of human RPE cell viability induced by DICERl 
antisense (AS) treatment. (H) DICERl antisense (AS) treat-
ment of human RPE cells reduces DICERl and increases 
IRAKl and IRAK4 phosphorylation. (I) MyDSS inhibitor 
rescues loss of cell viability in Dicer]flf mouse RPE cells 
treated with adenoviral vector coding for Cre recombinase 
(Ad-Cre). (J) Ad-Cre induced global miRNA expression 
deficits in Dicer]flf mouse RPE cells compared to Ad-Null. 
US 9,453,226 B2 
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No significant difference in miRNA abundance between 
MyDSS inhibitor and control peptide-treated Dicerl 
depleted cells. n=3 (A,B,F-H). Densitometry values normal-
ized to Vinculin are shown in parentheses (A, C). Degenera-
tion outlined by blue arrowheads. n=S (E,F). *p<0.05 by 5 
Student t-test (G,I). Images representative of 3 experiments 
(A,B,C,D,H). See also FIG. 12. 
FIG. 7. NLRP3 Inflammasome and MyDSS activation in 
human GA (A) NLRP3 and ILlS abundance was signifi-
cantly elevated in macular GA RPE (n=13) compared to 10 
normal age-matched controls (n=12). *p<0.05 by Marm-
Whitney U-test. There was no significant difference between 
groups (p=0.32 by Marm-Whitney U-test) in ILlB abun-
dance. (B-D) Increased immunolocalization ofNLRP3 (B), 
PYCARD (C) and Caspase-1 (D) in macular GA RPE 15 
compared to age-matched normal controls. Scale bar, 20 f.tm. 
(E) Western blots of macular RPE lysates from individual 
human donor eyes show that abundance of NLRP3, 
PYCARD, and phosphorylated IRAKl/4, normalized to the 
levels of the housekeeping protein Vinculin, is reduced in 20 
geographic atrophy (GA) compared to age-matched normal 
controls. Data are represented as mean+/-SEM (A). Repre-
sentative images shown. n=6 (B-E). See also FIG. 13. 
FIG. 8. Alu RNA does not activate several RNA sensors. 
(A and B) p7SL (a 7SL expression vector) (A) and in vitro 25 
synthesized 7SL RNA (B) do not induce RPE degeneration 
in wild-type mice. (C) RPE degeneration induced by sub-
retinal injection of pA!u in wild-type mice is not blocked by 
a TLR4 antagonist. (D-E) Mice deficient in Mda5 (D) or 
Prkr (E) are susceptible to pAin-induced RPE degeneration. 30 
(F) Dephosphorylated (Dep) Alu RNA induces RPE degen-
eration in wild-type mice just as well as Alu RNA. (G) Mice 
deficient in Mays are susceptible to pAin-induced RPE 
degeneration. pNull does not induce RPE degeneration in 
any strain of mice. Degeneration outlined by blue arrow- 35 
heads. Fundus photographs, top rows; Z0-1 stained (red) 
RPE flat mounts, bottom rows. n=S (A-G). (H) A schematic 
of the innate immune pathways that are not activated by Alu 
RNA. 
6 
treatment. Fluorescence quantification shown in right panel. 
(B) Western blot of Alu RNA-induced Caspase-1 activation 
(p20 subunit) in THP-1 and HeLa cells, normalized to 
Vinculin expression. (C) Caspase-1 inhibitor peptide blocks 
Alu RNA-induced substrate cleavage in human RPE cells. 
n=3. (D) Subretinal injection of Alu RNA does not induce 
RPE degeneration in Caspl_;_ mice. (E) Alu RNA or LPS+ 
ATP induce the appearance of a brightly fluorescent cluster 
of GFP-PYCARD visible in the cytoplasm of human RPE 
cells. Area in insets shown in higher magnification. Images 
representative of3 experiments. (F and G) Subretinal injec-
tion of Alu RNA does not induce RPE degeneration in 
Nlrp3_1_ (F) or Pycard_;_ (G) mice. (H) The abundance of 
NLRP3 in HEK293 cells transfected with an NLRP3 expres-
sion vector and of PYCARD in human RPE cells is reduced 
by transfection of siRNAs targeting these genes, compared 
to control (Ctrl) siRNAs. n=3, *p<0.05 compared to Ctrl 
siRNAs by Student t-test. (I) Alu RNA-induced Caspase-1 
activation (p20 subunit) in human RPE cells is unaffected by 
MyDSS inhibitory peptide, normalized to Vinculin expres-
sion. (J) MyDSS inhibitory peptide does not reduce Alu 
RNA-induced cleavage activity of Caspase-1 in human RPE 
cells (top panel). Fluorescence quantification (bottom 
panel). (K) Caspase-1 activation (p20 subunit) in RPE cell 
lysates of wild-type mice treated with subretinal pA!u 
administration is unimpaired by intravitreous administration 
of anti-IL-lS neutralizing antibodies. (L) Alu RNA-induced 
phosphorylation of IRAKl/4 is reduced by Caspase-1 
inhibitory peptide in human RPE cells, normalized to Vin-
culin expression. Vehicle control injections also do not 
damage the RPE. Fundus photographs, top rows; Z0-1 
stained (red) RPE flat mounts, bottom rows. n=S (D,F,G). 
Images representative of 3 experiments (A,B,I,J-L). 
FIG. 11. NLRP3 does not physically interact with Alu 
RNA, and VDAC knockdown by siRNA. (A) RNA-binding 
protein immunoprecipitation (RIP) assay in human RPE 
cells transfected with pA!u and pNLRP3-FLAG Immuno-
precipitation of protein-RNA complexes with antibodies 
FIG. 9. Alu RNA induces RPE degeneration via MyDSS, 
not TRIP or IFNy, (A) Subretinal administration of pA!u 
induces RPE degeneration in Ticaml_;_ mice. (B) Alu RNA 
does not induce RPE degeneration in Mydss-/- mice. (C) 
Subretinal administration of a different Alu expression plas-
mid (pA!u(2)) also induces RPE degeneration in wild-type 
but not Mydss-/- mice. (D) Alu RNA does not induce RPE 
degeneration in Mydss+l- heterozygous (het) mice. (E) 
MyDSS inhibitory peptide reduces Alu RNA-induced phos-
phorylation ofiRAKl/4, normalized to Vinculin expression. 
40 against NLRP3 or FLAG did not reveal interaction between 
NLRP3 and Alu RNA. RNA isolated from an equal amount 
of cell lysate (not subjected to IP) was used as input for Alu 
PCR. Relative abundance of Alu RNA in the immunopre-
cipitate, assessed by real-time RT-PCR using Alu-specific 
45 primers, was normalized to levels obtained with control IgG 
immunoprecipitation. N=3. (B) The abundance ofVDACl, 
VDAC2, and VDAC3 mRNAs in human RPE cells is 
reduced by transfection of siRNAs targeting these genes 
compared to control (targeting Luc) siRNA. N=3. *p<0.05 
50 compared to Control siRNA by Student t-test. (F) Subretinal injection of AAVl-BESTl-Cre, but not 
AAVl-BESTl-GFP, protects MydSsftf mice fromA!u RNA-
induced RPE degeneration. (G) pA!u and Alu RNA induces 
RPE degeneration in wild-type mice receiving Mydss-/-
bone marrow (Mydss-1-~wild-type) but did not do so in 
Mydss-/- mice receiving wild-type bone marrow (wild-
type~Mydss-1-). (H-K) Subretinal administration ofpA!u 
induces RPE degeneration in Ifng_;_ (H), Ifngrl_;_ (I), and 
Illrl_ 1_ mice (J) but not in Il1Srl_ 1_ mice (K). pNull 
administration does not induce RPE degeneration in any 
strain of mice. Degeneration outlined by blue arrowheads. 60 
Fundus photographs, top rows; Z0-1 stained (red) RPE flat 
mounts, bottom rows. n=S (A-D, F-K). 
FIG. 12. DICERl is a negative regulator of Caspase-1 
activation by Alu RNA, (A) Knockdown of DICERl by 
antisense oligonucleotides (AS) in human RPE cells 
increases cleavage activity of Caspase-1, as monitored by 
55 Caspalux, a fluorescent (green in overlay) reporter of sub-
strate cleavage compared to control AS treatment. (B) Inhi-
bition of Alu RNA by AS treatment reduces Caspalux 
fluorescence in human RPE cells treated with DICERl AS. 
FIG. 10. Alu RNA induces RPE degeneration via NLRP3 
inflammasome activation, (A) Alu RNA or LPS+ATP induce 
activation of Caspase-1 in human RPE cells as assessed by 65 
increased cleavage of Caspalux®l (green, left panel), a 
fluorescent-linked peptide substrate as compared to mock 
Mean values of Caspalux fluorescence shown in parenthe-
ses. Images representative of 3 experiments. 
FIG. 13. Schematic representation of proposed model of 
NLRP3 inflammasome activation by DICERl deficit-in-
duced Alu RNA that leads to RPE degeneration and geo-
graphic atrophy. Alu RNA induces priming of NLRP3 and 
ILlS mRNAs via generation of reactive oxygen species 
(ROS). Activation of the NLRP3 inflammasome triggers 
cleavage of pro-IL-lS by activated Caspase-1 to mature 
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IL-18. IL-18 signals via MyD88 to phosphorylate IRAKl 
and IRAK4, which leads to RPE cell death. 
FIG. 14. Intravitreous administration of Caspase-8 inhibi-
tor protects wild-type mice from pAin-induced RPE degen-
eration. Representative images shown. n=S-12. Fundus pho- 5 
tographs, top row; Z0-1 stained (red) flat mounts, bottom 
8 
type mouse. 2-days later, DyeLight782-VAD-FMK3 was 
injected into the vitreous humor of both eyes. From baseline 
(0 hours) to 24 hours thereafter, photographs of the fundus 
(retina) were taken through the ICG filter of a Topcon 50IX 
camera. In the IL-lS-injected eye, white fluorescent areas 
corresponding to bioactive caspase generation were 
row. observed in the area ofiL-18 injection. No such widespread 
FIG. 15. Caspase-8 inhibitor protects human RPE cells areas were observed in the vehicle-injected eye. 
fromA!u induced cytotoxicity. Caspase-8 inhibitory peptide FIG. 28. Representative images show that subretinally 
Z-IETD-FMK (100 f.LM) but not the control peptide Z-FA- 10 injected Alu RNA (l flg)-induced RPE degeneration is 
FMK (100 f.LM) protects human RPE cells from Alu RNA- blocked by intravitreous administration of the MyD88 pep-
induced cytotoxicity. 
FIG. 16. Caspase-8 inhibitor protects human RPE cells tide inhibitor DRQIKIWFQNRRMKWKKRDV-
from pAin-induced cytotoxicity. Caspase-8 inhibitory pep- LPGTCVWSIASE (2 flg). Top panels show color fundus 
tide Z-IETD-FMK (100 f.LM) but not the control peptide 15 photographs. Bottom panels show retinal flat mount prepa-
Z-FA-FMK (100 f.LM) protects human RPE cells from pA!u- rations stained with an anti-ZOl antibody (red). Alu RNA-
induced cytotoxicity. induced RPE degeneration (left panels) is evidenced by 
FIG. 17. IL-18 induced caspase-8 activation. Subretinal depigmentation seen on color photos (top left) and dysmor-
injection of IL-18 in wild-type mice induced activation of phic appearing RPE cells (bottom left). Treatment with the 
caspase-8, as monitored by fluorometric plate assay. 20 MyD88 peptide inhibitor prevents those degenerative 
FIG. 18. pA!u does not induce RPE degeneration in changes and preserves normal RPE anatomy. 
CD95-/- mice. Representative images shown. n=S-12. Fun-
dus photographs, top row; Z0-1 stained (red) flat mounts, 
bottom row. 
FIG. 19. Alu RNA does not induce RPE degeneration in 25 
CD95-/- mice. Representative images shown. n=S-12. Fun-
dus photographs, top row; Z0-1 stained (red) flat mounts, 
bottom row. 
FIG. 20. Recombinant IL-18 does not induce RPE degen-
eration in CD95-/- mice. Representative images shown. 30 
n=S-12. Fundus photographs, top row; Z0-1 stained (red) 
flat mounts, bottom row. 
FIG. 21. pA!u does not induce RPE degeneration in Fasig 
mice. Representative images shown. n=S-12. Fundus pho-
tographs, top row; Z0-1 stained (red) flat mounts, bottom 35 
row. 
FIG. 22. Alu RNA does not induce RPE degeneration in 
Fasig mice. Representative images shown. n=S-12. Fundus 
photographs, top row; Z0-1 stained (red) flat mounts, bot-
tom row. 40 
BRIEF DESCRIPTION OF THE SEQUENCE 
LISTING 
SEQ ID NO: 1. IMG-2005-1 peptide sequence: DRQIKI-
WFQNRRMKWKKRDVLPGT, wherein the last 7 amino 
acids are required for inhibition of MyD88 homodimeriza-
tion, while the preceding amino acid sequence is an Anten-
nopedia cell permeation sequence that enables the inhibitory 
peptide to enter the cell, so that it can block MyD88. 
SEQ ID NO: 2. Control peptide sequence: DRQIKIW-
FQNRRMKWKK 
SEQ ID NO: 3. MyD88 siRNA #1 sense: 5'-GAGAAGC-
CUUUACAGGUdTdT-3' 
SEQ ID NO: 4. MyD88 siRNA #1 antisense: 5'-ACCU-
GUAAAGGCUUCUCdTdT-3' 
SEQ ID NO: 5. MyD88 siRNA #2 sense: 5'-CAGAG-
CAAGGAAUGUGAdTdT-3' 
SEQ ID NO: 6. MyD88 siRNA #2 antisense: 5'-UCA-
CAUUCCUUGCUCUGdTdT-3' 
SEQ ID NO: 7 NLRP3 siRNA-5'-GUUUGACUAUCU-
GUUCUdTdT-3' 
FIG. 23. Recombinant IL-18 does not induce RPE degen-
eration in Fasig mice. Representative images shown. n=S-
12. Fundus photographs, top row; Z0-1 stained (red) flat 
mounts, bottom row. 
FIG. 24. Alu RNA does not induce RPE degeneration in 
Nfkbl-/- mice. Representative images shown. n=S-12. Fun-
dus photographs, top row; Z0-1 stained (red) flat mounts, 
bottom row. 
SEQ ID NO: 8: NLRP3 siRNA-5'-GGAUCAAACUA-
45 CUCUGUGA-3' 
FIG. 25. Alu RNA or vehicle (PBS) was injected into the 
subretinal space of fellow eyes of a wild-type mouse. 3-days so 
later, DyeLight782-VAD-FMK3 was injected into the vitre-
ous humor of both eyes. 24-hours later, RPE flat mount 
preparations were visualized under fluorescent microscopy 
SEQ ID NO: 9: NLRP3 siRNA-5'-UGCAAGAUCU-
CUCAGCAAA-3' 
SEQ ID NO: 10: NLRP3 siRNA-5'-
GAAGUGGGGUUCAGAUAAU-3' 
SEQ ID NO: 11: NLRP3 siRNA-5'-GCAAGAC-
CAAGACGUGUGA-3' 
SEQ ID NO: 12: PYCARD siRNA-5'-GAAGCUC-
UUCAGUUUCAdTdT-3' 
to visualize areas of bioactive caspase (green fluorescence), 
which corresponded to the area of Alu RNA injection. 
SEQ ID NO: 13: PYCARD siRNA-5'-GGCUGCUG-
55 GAUGCUCUGUACGGGAA-3' 
FIG. 26. Alu RNA or vehicle (PBS) was injected into the 
subretinal space of fellow eyes of two wild-type mice (left 
and right panels). 3-days later, DyeLight782-VAD-FMK3 
was injected into the vitreous humor of both eyes. From 
baseline (0 hours) to 8 hours thereafter, photographs of the 60 
fundus (retina) were taken through the ICG filter of a Topcon 
50IX camera. In the Alu RNA-injected eye, white fluores-
cent areas corresponding to bioactive caspase generation 
were observed in the area of Alu RNA injection. No such 
widespread areas were observed in the vehicle-injected eye. 65 
FIG. 27. Recombinant IL-18 or vehicle (PBS) was 
injected into the subretinal space of fellow eyes of a wild-
SEQ ID NO: 14: PYCARD siRNA-5'-UUC-
CCGUACAGAGCAUCCAGCAGCC-3'. 
SEQ ID NO: 15: siRNA of the human Pyrin coding 
sequence: GCTGGAGCAGGTGTACTACTTC. 
SEQ ID NO: 16: siRNA of the human NLRP3 coding 
sequence CAGGTTTGACTATCTGTTCT. 
SEQ ID NO: 17: siRNA of the 3' UTR of the human 
caspase-1 GTGAAGAGATCCTTCTGTA. 
SEQ ID NO: 18: Oligonucleotide primer for human MB, 
forward 5'-TTAAAGCCCGCCTGACAGA-3'. 
SEQ ID NO: 19: Oligonucleotide primer for human MB, 
reverse 5'-GCGAATGACAGAGGGTTTCTTAG-3'). 
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SEQ ID NO: 20: Oligonucleotide primer for human ILlS, 
forward 5'-ATCACTTGCACTCCGGAGGTA-3'. 
SEQ ID NO: 21: Oligonucleotide primer for human ILlS, 
reverse 5'-AGAGCGCAATGGTGCAATC-3'. 
10 
SEQ ID NO: 52: Alu AS-5'-CCCGGGTTCACGCCAT-
TCTCCTGCCTCAGCCTCA-
CGAGTAGCTGGGACTACAGGCGCCCGACAC-
CACTCCCGGCTAATTTTTTGTATTTTT-3'. 
SEQ ID NO: 22: Oligonucleotide primer for human 5 
NLRP3, forward 5'-GCACCTGTTGTGCAATCTGAA-3'. 
SEQ ID NO: 53: Control for Alu AS-5'-GCATGGCCA-
GTCCATTGATCTTGCACGCTTGCC-
TAGTACGCTCCTCAACCTATCCTCCTAGCCCG~ 
TACTTGGTGCCACCGGCG-3'. SEQ ID NO: 23: Oligonucleotide primer for human 
NLRP3, reverse 5'-TCCTGACAACATGCTGATGTGA-3'. 
SEQ ID NO: 24: Oligonucleotide primer for human 
PYCARD, forward 5'-GCCAGGCCTGCACTTTATAGA- 10 
SEQ ID NO: 54: Oligopeptide for inhibiting MyD88 
homodimerization: RDVLPGT. 
SEQ ID NO: 55: Oligopeptide for inhibiting MyD88 
homodimerization: RDVVPGG. 3'. 
SEQ ID NO: 25: Oligonucleotide primer for human 
PYCARD, reverse 5'-GTTTGTGACCCTCGCGATAAG-3'. 
SEQ ID NO: 26: Oligonucleotide primer for human 
VDACI, forward 5'-ACTGCAAAATCCCGAGTGAC-3'. 
SEQ ID NO: 27: Oligonucleotide primer for human 
VDACI, reverse 5'-CTGTCCAGGCAAGATTGACA-3'. 
SEQ ID NO: 28: Oligonucleotide primer for human 
VDAC2, forward 5'-CAGTGCCAAATCAAAGCTGA-3'. 
SEQ ID NO: 29: Oligonucleotide primer for human 
VDAC2, reverse 5'-CCTGATGTCCAAGCAAGGTT-3'). 
SEQ ID NO: 30: Oligonucleotide primer for human 
VDAC3, forward 5'-TTGACACAGCCAAATCCAAA-3'. 
SEQ ID NO: 56. MyD88 siRNA: UUAUUUC-
CUAA WGGGUCdTdT. 
SEQ ID NO: 57. VDACI siRNA sense (5'-CG-
15 GAAUAGCAGCCAAGUdTdT-3'). 
20 
SEQ ID NO: 58. VDAC2 siRNA sense (5'-CCCUG-
GAGUUGGAGGCUdTdT-3'). 
SEQ ID NO: 59. VDAC3 siRNA sense (5'-GC-
UUUAAUCGAUGGGAAdTdT-3'). 
SEQ ID NO: 60. MyD88 inhibitor: DRQIKIWFQNRRM-
KWKKRDVLPGTCVWSIASE. 
SEQ ID NO: 61. MyD88 inhibitor: RDVLPGTCVW-
SIASE. 
SEQ ID NO: 31: Oligonucleotide primer for human 25 
VDAC3, reverse 5'-GCCAAAACGGGTGTTGTTAC-3'. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
SEQ ID NO: 32: Oligonucleotide primer for human ISS 
rRNA, forward 5'-CGCAGCTAGGAATAATGGAATAGG-
3'. 
SEQ ID NO: 33: Oligonucleotide primer for human ISS 
rRNA, reverse 5'-GCCTCAGTTCCGAAAACCAA-3'. 
SEQ ID NO: 34: Oligonucleotide primer for mouse 
Myd88, forward 5'-CACCTGTGTCTGGTCCATTG-3'. 
SEQ ID NO: 35: Oligonucleotide primer for mouse 
Myd88, reverse 5'-AGGCTGAGTGCAAACTTGGT-3'. 
SEQ ID NO: 36: Oligonucleotide primer for mouse 
Nlrp3, forward 5'-ATGCTGCTTCGACATCTCCT-3'. 
SEQ ID NO: 37: Oligonucleotide primer for mouse 
Nlrp3, reverse 5'-AACCAATGCGAGATCCTGAC-3'. 
SEQ ID NO: 38: Oligonucleotide primer for mouse IllS, 
forward 5'-GACAGCCTGTGTTCGAGGAT-3'. 
SEQ ID NO: 39: Oligonucleotide primer for mouse IllS, 
reverse 5'-TGGATCCATTTCCTCAAAGG-3'. 
SEQ ID NO: 40: Oligonucleotide primer for mouse ISS 
rRNA, forward 5'-TTCGTATTGCGCCGCTAGA-3'. 
SEQ ID NO: 41: Oligonucleotide primer for mouse ISS 
rRNA, reverse 5'-CTTTCGCTCTGGTCCGTCTT-3'. 
SEQ ID NO: 42: Mouse miR-184-5'-TGGACGGA-
GAACTGATAAGGGT-3; 
SEQ ID NO: 43: Mouse miR-221/222-5'-AGCTA-
CATCTGGCTACTGGGT-3; 
SEQ ID NO: 44: Mouse miR-320a-5'-AAAAGCTGGGT-
TGAGAGGGCGA-3', and 
SEQ ID NO: 45: Mouse mouse miR-484-5'-TCAG-
GCTCAGTCCCCTCCCGAT-3'. 
SEQ ID NO: 46: U6 snRNA-5'-AAATTCGTGAAGCGT-
TCC-3'. 
SEQ ID NO: 47: VDACI siRNA sense-5'-CG-
GAAUAGCAGCCAAGUdTdT-3'. 
The presently-disclosed subject matter includes methods 
for identifying MyD88 inhibitors, and methods and compo-
sitions for inhibiting MyD88 and uses thereof. The pres-
30 ently-disclosed subject matter includes methods for identi-
fYing inflammasome inhibitors, and methods and 
compositions for inhibiting an inflammasome and uses 
thereof. The presently-disclosed subject matter includes 
methods for identifying inhibitors of components of inflam-
35 mosome, and methods and compositions for inhibiting a 
component of inflammasome and uses thereof. Components 
of inflammasome include, for example, NLRP3, PYCARD, 
and Caspase-1. The presently-disclosed subject matter 
includes methods for identifYing IL-18 inhibitors, and meth-
ods and compositions for inhibiting IL-18 and uses thereof. 
40 The presently-disclosed subject matter includes methods for 
identifying VDACI and VDAC2 inhibitors, and methods 
and compositions for inhibiting VDACI and VDAC2 and 
uses thereof. The presently-disclosed subject matter includes 
methods for identifYing caspase-8 inhibitors, and methods 
45 and compositions for inhibiting caspase-8 and uses thereof. 
The presently-disclosed subject matter includes methods for 
identifying NFkB inhibitors, and methods and compositions 
for inhibiting NFkB and uses thereof. Also provided are 
methods and compositions for imaging activated caspase-1 
so in an eye of a subject. 
The presently-disclosed subject matter includes methods 
including inhibiting one or more of an inflammasome, 
MyD88, and IL-18 of a cell. In some embodiments, the 
presently-disclosed subject matter includes methods includ-
55 ing inhibiting one or more of MyD88, IL-18, VDACI, 
VDAC2, NFKB, caspase-8, caspase-1, NLRP-3, PYCARD, 
and an inflammasome, including a component of an inflam-
masome (e.g., caspase I, NLRP-3, PYCARD) of a cell. 
SEQ ID NO: 48: VDAC2 siRNA sense-5'-CCCUG- 60 
GAGUUGGAGGCUdTdT-3'. 
In some embodiments of the method, the cell is selected 
from an RPE cell, a retinal photoreceptor cell, or a choroidal 
cell. In some embodiments, the cell is an RPE cell. In some 
embodiments, the cell is the cell of a subject. In some 
embodiments, the cell is a cell of a subject having, suspected 
of having, or at risk of having a condition of interest. In some 
embodiments, the cell is a cell of a subject having, suspected 
SEQ ID NO: 49: VDAC3 siRNA sense-5'-GC-
UUUAAUCGAUGGGAAdTdT-3'. 
SEQ ID NO: 50: DICERI antisense oligonucleotide (AS)-
5'-GCUGACCTTTTTGCTUCUCA-3'. 
SEQ ID NO: 51: Control for DICERI AS-5'-TTGG-
TACGCATACGTGTTGACTGTGA-3'. 
65 of having, or at risk of having age-related macular degen-
eration. In some embodiments, the cell is a cell of a subject 
having, suspected of having, or at risk of having geographic 
US 9,453,226 B2 
11 
atrophy. In some embodiments, the cell is a cell of a subject 
having, suspected of having, or at risk of having geographic 
atrophy and the cell is an RPE cell. In some embodiments, 
a subject having age-related macular degeneration can be 
treated using methods and compositions as disclosed herein. 
As used herein, the term "subject" refers to a target of 
treatment. The subject of the herein disclosed methods can 
be a vertebrate, such as a mammal, a fish, a bird, a reptile, 
12 
to a receptor), an aptamer, a dominant negative plasmid or 
vector, or a virus-encoded inflammasome. 
or an amphibian. Thus, the subject of the herein disclosed 
methods can be a human or non human. Thus, veterinary 10 
therapeutic uses are provided in accordance with the pres-
ently disclosed subject matter. 
The terms "polypeptide", "protein", and "peptide", which 
are used interchangeably herein, refer to a polymer of the 20 
protein amino acids, or amino acid analogs, regardless of its 
size. The terms "polypeptide fragment" or "fragment", when 
used in reference to a reference polypeptide, refers to a 
polypeptide in which amino acid residues are deleted as 
compared to the reference polypeptide itself, but where the 
remaining amino acid sequence is usually identical to the 
corresponding positions in the reference polypeptide. Such 
deletions can occur at the amino-terminus or carboxy-
terminus of the reference polypeptide, from internal portions 
of the reference polypeptide, or a combination thereof. A 
fragment can also be a "functional fragment," in which case 
the fragment retains some or all of the activity of the 
reference polypeptide as described herein. 
In some embodiments, the inhibiting one or more of an 
inflammasome, MyD88, IL-18, VDAC1, VDAC2, NLRP3, 15 
PYCARD, caspase-1, caspase-8, and NFKB of a cell 
includes administering an inhibitor to the cell, or to a subject 
wherein the cell is the cell of a subject. Such inhibitors can The terms "modified amino acid", "modified polypep-
tide", and "variant" refer to an amino acid sequence that is 
different from the reference polypeptide by one or more 
amino acids, e.g., one or more amino acid substitutions. A 
variant of a reference polypeptide also refers to a variant of 
a fragment of the reference polypeptide, for example, a 
fragment wherein one or more amino acid substitutions have 
been made relative to the reference polypeptide. A variant 
can also be a "functional variant," in which the variant 
retains some or all of the activity of the reference protein as 
described herein. The term functional variant includes a 
be administered, for example, by intraocular injection (e.g., 
localized interocular therapy); intravitreous injection; sub- 20 
retinal injection; episcleral injection; sub-Tenon's injection; 
retrobulbar injection; peribulbar injection; transscleral 
administration; topical administration, e.g., topical eye drop 
application; suprachoroidal administration; release from a 
sustained release delivery device that is sutured to or 25 
attached to or placed on the sclera, or injected into the 
vitreous humor, or injected into the anterior chamber, or 
implanted in the lens bag or capsule; oral administration; or 
intravenous administration. functional variant of a functional fragment of a reference 
30 polypeptide. As used herein the term "inhibit" or "inhibiting" refers to 
suppressing, reducing, decreasing, or substantially eliminat-
ing the biological activity of a polypeptide, such as MyD88, 
IL-18, VDAC1, VDAC2, caspase-8, NFKB, or a polypeptide 
of an inflammasome (e.g., NLRP3, PYCARD, caspase-1). 
As used herein with reference to a polypeptide being inhib-
ited, "of a cell" refers to a polypeptide that is inside the cell 
(inside the cell membrane), on the cell (in the cell mem-
brane, presented on the cell membrane, otherwise on the 
cell), or outside of a cell, but insofar as the polypeptide is 
outside of the cell, it is in the extracellular mileu such that 
one of ordinary skill in the art would recognize the poly-
peptide as being associated with the cell. For example, 
VDAC1, VDAC2, caspase-8, NFKB, or a polypeptide of an 
inflammasome (e.g., NLRP3, PYCARD, caspase-1 of a cell 
could be in the cell. For another example MyD88 could be 
in the cell or on the cell. For yet another example, IL-18 
could be outside the cell because it is secreted, but it would 
be recognized by one or ordinary skill in the art as being 
associated with the cell. 
As will be understood by those skilled in the art upon 
studying this application, inhibition of an inflmasome, 
MyD88, IL-18, VDAC1, VDAC2, caspase-1, caspase-8, and 
NFKB of a cell can be achieved in a number of marmers. In 
some embodiments the inhibition can be achieved by affect-
ing the transcription or translation of the polypeptide, by 
degrading the polypeptide, by scavenging the polypeptide, 
or otherwise impacting the biological activity of the poly-
peptide Inhibition comprises administering an inhibitor. An 
inhibitor is a compound that affects such inhibition of the 
biological activity of a polypeptide. Such compounds can 
be, for example, a polypeptide (including oligonucleotide, 
and including a polypeptide that binds to the polypeptide-
of-interest to affect inhibition), a small molecule (including 
a small chemical compound), a compound for RNA inter-
ference (including siRNA, miRNA, shRNA), an antibody 
(e.g., a neutralizing antibody against polypeptide of interest, 
an antibody that blocks polypeptide of interest from binding 
In some embodiments, the methods and compositions of 
the presently-disclosed subject matter can be used in a 
subject having, suspected of having, or at risk of having a 
condition of interest. In some embodiments, methods and 
35 compositions of the presently-disclosed subject matter can 
be used for treating a condition of interest. Examples of 
conditions of interest include, but are not limited to: Geo-
graphic atrophy (Kaneko, Dridi eta!. 2011 ); Macular degen-
eration (Kaneko, Dridi eta!. 2011 ); Keratitis (Guo, Gao eta!. 
40 2011 ); Gout (Chen, Shi eta!. 2006); Acne vulgaris (Terhorst, 
Kalali et a!. 2010); Crohn's disease (Reuter and Pizarro 
2004; Abreu, Fukata et a!. 2005; Medvedev, Sabroe et a!. 
2006); Ulcerative colitis (Reuter and Pizarro 2004; Abreu, 
Fukata eta!. 2005; Medvedev, Sabroe eta!. 2006); irritable 
45 bowel disease/irritable bowel syndrome (McKernan, Nolan 
eta!. 2009); Type I diabetes (Devaraj, Tobias eta!. 2011; von 
Herrath, Filippi et a!. 2011 ); Type 2 diabetes (Hutton, 
Soukhatcheva eta!. 2010; Nogueira-Machado, Volpe eta!. 
2011 ); Insulin resistance (Ghanim, Mohanty et a!. 2008; 
50 Tilich and Arora 2011); Obesity (Fresno, Alvarez et a!. 
2011); Hemolytic-Uremic Syndrome (Batsford, Duermuel-
ler et a!. 2011); Polyoma virus infection (Batsford, Duer-
mueller et a!. 2011); Immune complex renal disease (An-
ders, Banas et a!. 2004; Anders and Schlondorff 2007); 
55 Acute tubular injury (Anders, Banas eta!. 2004; Anders and 
Schlondorff 2007); Lupus nephritis (Anders, Banas et a!. 
2004; Anders and Schlondorff 2007); Familial cold autoin-
flmatory syndrome (Mariathasan, Weiss et a!. 2006; 
Meng, Zhang et a!. 2009); Muckle-Wells syndrome and 
60 neonatal onset multisystem inflammatory disease (Mari-
athasan, Weiss et a!. 2006; Meng, Zhang et a!. 2009); 
Chronic infantile neurologic cutaneous and articular auto-
inflammatory diseases, Renal ischemia-perfusion injury (El-
Achkar and Dagher 2006; Robson 2009); Glomerulonephri-
65 tis (E1-Achkar and Dagher 2006; Robson 2009); 
Cryoglobulinemia (Banas, Banas et a!. 2008); Systemic 
vasculitides (Weyand, Ma-Krupa eta!. 2005; Hurtado, Jeffs 
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eta!. 2008; Summers, Steinmetz eta!. 2011 ); IgA nephropa-
thy (Lim, Lee et a!. 2011); Atherosclerosis (Curtiss and 
Tobias 2009); HIV/AIDS (Brichacek, Vanpouille et a!. 
2010); Malaria (Franklin, Ishizaka eta!. 2011); Helminth 
parasites (Babu, Blauvelt eta!. 2005; Venugopal, Nutman et 
a!. 2009); Sepsis and septic shock (Knuefermann, Nemoto et 
14 
associated with a condition of interest; and causing a regres-
sion of the condition of interest or one or more of the 
symptoms associated with the condition of interest. 
In some embodiments, the methods and compositions of 
the presently-disclosed subject matter are useful for protect-
ing the cell against Alu-RNA-induced degeneration. As 
such, in some embodiments, a method includes administer-
ing an inhibitor, wherein the cell is protected against Alu-
RNA-induced degeneration. 
a!. 2002; Opal and Huber 2002; Cristofaro and Opal 2003; 
Chen, Koustova et a!. 2007); Allergic asthma (Slater, 
Paupore et a!. 1998; Park, Gold et a!. 2001); Hay fever 
(Slater, Paupore eta!. 1998; Park, Gold eta!. 2001); Chronic 
obstructive pulmonary disease (Geraghty, Dabo eta!. 2011 ); 
Drug-induced lnng inflannnation (Liu, Yang et a!. 2010); 
Contact dermatitis (Martin, Dudda et a!. 2008; Yokoi, 
Niizeki et a!. 2009); Leprosy (Krutzik, Tan et a!. 2005; 
Terhorst, Kalali et a!. 2010); Burkholderia cenocepacia 
infection (Ventura, Balloy eta!. 2009); Respiratory syncitial 
virus infection (Aeffner, Traylor et a!. 2011 ); Psoriasis 
(Zuany-Amorim, Hastewell eta!. 2002; Barrat and Coffman 
2008; Li, Zhou et a!. 2009); Systemic lupus erythematosus 
20 (Zuany-Amorim, Hastewell eta!. 2002; Barrat and Coffman 
2008; Li, Zhou et a!. 2009); Scleroderma (Zuany-Amorim, 
Hastewell eta!. 2002; Barrat and Coffman 2008; Li, Zhou et 
10 
Inhibiting Inflammasome 
In some embodiments, the presently-disclosed subject 
matter includes a method of protecting a cell, comprising: 
inhibiting an inflammasome of the cell. The method of any 
one of the prior claims, wherein the inflannnasome is 
15 
selected from NLRP3 inflannnasome, NLRP1 inflam-
masome, NLRC4 inflannnasome, AIM2 inflannnasome, and 
IFI16 inflammasome. In some embodiments, the inflam-
masome is the NLRP3 inflammasome. 
a!. 2009); Reactive arthritis (Zuany-Amorim, Hastewell et 
a!. 2002; Barrat and Coffman 2008; Li, Zhou et a!. 2009); 
25 Cystic fibrosis, Syphilis, Sjogren's syndrome (Zuany-Amo-
rim, Hastewell et a!. 2002; Barrat and Coffman 2008; Li, 
Zhou et a!. 2009); Rheumatoid arthritis (Zuany-Amorim, 
Hastewell eta!. 2002; Barrat and Coffman 2008; Li, Zhou et 
a!. 2009); Inflannnatory joint disease (O'Neill 2008); Non-
30 
alcoholic fatty liver disease (Tan, Fie! et a!. 2009); Cardiac 
surgery (peri-/post-operative inflannnation) (Cremer, Martin 
eta!. 1996; Taylor 1996; Dybdahl, Wahba eta!. 2002); Acute 
and chronic organ transplant rejection (Alegre, Leemans et 
a!. 2008; Miller, Rossini et a!. 2008; Taylor, Ehrhardt et a!. 
35 2008; Krams, Wang et a!. 2010; Wang, Schmaderer et a!. 
2010; Shin and Harris 2011; Testro, Visvanathan eta!. 2011); 
Acute and chronic bone marrow transplant rejection 
(Alegre, Leemans et a!. 2008; Miller, Rossini et a!. 2008; 
Taylor, Ehrhardt eta!. 2008; Krams, Wang eta!. 201 0; Wang, 
40 Schmaderer et a!. 201 0; Shin and Harris 2011; Testro, 
Visvanathan eta!. 2011); Alzheimer's disease; and Tumor 
angiogenesis (Frantz, Vincent et a!. 2005; Schmid, Avra-
amides eta!. 2011). 
As used herein, the terms treatment or treating relate to 
45 
any treatment of a condition of interest, including but not 
limited to prophylactic treatment and therapeutic treatment. 
As such, the terms treatment or treating include, but are not 
limited to: preventing a condition of interest or the devel-
opment of a condition of interest; inhibiting the progression 
50 
of a condition of interest; arresting or preventing the devel-
opment of a condition of interest; reducing the severity of a 
condition of interest; ameliorating or relieving symptoms 
In some embodiments the inhibiting the inflannnasome 
includes inhibiting a component of the inflammasome. In 
some embodiments the inflammasome components can 
include a polypeptide encoded by PYCARD. In some 
embodiments the inflammasomse components can include a 
caspase. In some embodiments the inflannnasome compo-
nents can include PYCARD, NLRP3, and caspase-1. 
In some embodiments, the inhibiting the inflannnasome 
comprises administering an inflannnasome inhibitor. The 
inflammasome inhibitor can be an inhibitor of a component 
of the inflammasome. In some embodiments, the inflammo-
some 
As noted above, in some embodiments, inhibiting a 
polypeptide of interest to the presently-disclosed subject 
matter comprises administering an oligonucleotide or a 
small RNA molecule. Such small RNA molecule can target, 
for example, NLRP3 and/or PYCARD. Such nucleotides 
can target and degrade NLRP3 and/or PYCARD. In this 
regard, the presently-disclosed subject matter includes a 
isolated double-stranded RNA molecule that inhibits expres-
sion of NLRP3 and/or PYCARD, wherein a first strand of 
the double-stranded RNA comprises a sequence as set forth 
in Table A, and includes about 14 to 25 nucleotides. As noted 
above, in some embodiments, inhibiting comprises admin-
istering an inflammasome inhibitor that is a dominant nega-
tive vector. In some embodiments, inhibiting inflannnasome 
comprises administering an inhibitor of Caspase-1. In some 
embodiments the inhibitor of Caspase-1 is a peptide inhibi-
tor. 
Examples of inflammasome inhibitors that can be used in 
accordance with the presently-disclosed subject matter 
include, but are not limited to those set forth in Table A. As 
such, embodiments of the presently-disclosed subject matter 
can include administering an inflannnasome inhibitor set 
forth in Table A. 
TABLE A 
Examples of Inflammasome Inhibitors 
Ion channel inhibitors, for example, glybenclamide/glyburide (CAS Number, 10238-21-8) 
(Lamkanfi, et al., 2009). 
IkB-a inhibitors, for example, BAY11-7082 (CAS Number, 195462-67-7; also known as (E)-
3- (4-Methylphenylsulfony1) -2-propenenitrile) (Juliana, et al., 2010). 
Compounds similar to BAYll-7082, for example, other related vinyl sulfone compounds, as 
set forth in Lamkanfi, et al., 2009; Juliana, et al., 2010; deRivero Vaccari, et al., 2008; and 
Newman, et al., 2011, which are incorporated herein by this reference. 
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TABLE A-continued 
Examples of Inflammasome Inhibitors 
Antibodies, for example, Anti-ASC and Anti-NALPl and antibodies based on protein 
sequences selected from, ASC, ALR QTQ PYL VTD LEQ S; NALPl, MEE SQS KEE SNT 
16 
EG-cys (deRivero Vaccari, et al., 2008); and Anti-NALPl (Abeam, Cambridge, MA), anti-
IL-l~ (Cell Signaling Technology, Beverly, MA), anti-IL-18 (R & D Systems, Minneapolis, 
MN), anti-caspase-1 (Millipore, Billerica, MA), anti-caspase-1 (Santa Cruz Biotechnology, 
Santa Cruz, CA), anti-caspase-11 (Alexis Biochemicals, San Diego, CA), anti-caspase-11 
(Santa Cruz Biotechnology). 
Direct inhibitors of Caspase-1 and/or NLRP3, for example, parthenolide (Juliana, et al., 
2010). 
Caspase-1 inhibitors, such as estrogen binding B-box protein (Munding et al., 2006); COP 
(Lee, et al., 2001); ICEBERG (Humke, et al., 2000); and Z-WEHD-FMK (R&D Systems) 
Caspase 1 and/or 4 inhibitors, for example, Ac-YVAD-CHO (Ac-Tyr-Val-Ala-Asp-CHO) 
and Ac-YVAD-CMK (CAS Number, 178603-78-6; N-acetyl-L-tyrosyl-L-valyl-N-[(lS)-
1- (carboxymethyl) -3-chloro-2-oxo-propyl]-L-alaninamide) (Hilbi, et al., 1997) 
Caspase-12 inhibitors (Saleh, et al., 2006) 
Host-derived inhibitors of Caspase-1, for example, cellular PYRIN domain (PYD)-only 
proteins (POP) family, cPOPl and cPOP2 (Stehlik, et al., 2003; Dorfleutner, et al., 2007); 
serpin proteinase inhibitor 9 (PI-9) (Young, et al., 2000); BCL-2 and BCL-xL (Young, et al. 
2000). 
Inhibitors of Nlrplb inflammasome, for example, auranofin (Newman, et al., 2011) 
Virus expressed inhibitors of the inflammasome, for example, PYD homologs M13L-PYD, 
S013L (Benedict, et al., 2005; Dorfleutner, et al., 2007; Johnston, et al., 2005); SPI-2 
homologs CrmA, Serp2, SPI-2, (Komiyama, et al., 1994; Kettle, et al., 1997; Messud-Petit, et 
al., 1998); NSl (Stasakova, et al., 2005); Kaposi Sarcoma-associated Herpesvirus Orf63 
(Gregory, et al., 2011) 
Potassium chloride (KCl) (CAS Number, 7447-40-7 (Schorn, et al. 2011) 
Cathepsin-B inhibitors, for example, CA-074 Me (L-3-trans- (Propylcarbamoyl)oxirane-2-
Carbonyl)-L-Isoleucyl-L-Proline Methyl Ester (Li, et al., 2009). 
Cytochalasin D (Dostert, et al., 2008) 
ROS inhibitors, for example, N-acetyl-L-cysteine (NAC), and (2R,4R)-4-aminopyrrolidine-
2, 4-dicarboxylate (APDC) (Dostert, et al., 2008). 
ASC-1 inhibitors, for example, cellular pyrin domain (PYD) superfamily proteins, also 
known as M013 (Rahman, et al., 2009) 
NLRP3 inflammasome pan-caspase inhibitors, for example, Z-VAD-FMK (Dostert, et al., 
2009). 
Microtubules, for example, colchicine (CAS Number, 64-86-8) (Martinon, et al., 2006) 
An isolated double-stranded RNA molecule that inhibits expression of NLRP3, and which 
can be conjugated to cholesterol or not, and at least one strand including the sequence: 
GUUUGACUAUCUGUUCUdTdT (SEQ ID NO, 7) 
An isolated double-stranded RNA molecule that inhibits expression of NLRP3, at least one 
strand of which includes a sequence selected from: 5'-GGAUCAAACUACUCUGUGA-3' 
(SEQ ID NO, 8); 5'-UGCAAGAUCUCUCAGCAAA-3' (SEQ ID NO, 9); 5'-
GAAGUGGGGUUCAGAUAAU-3' (SEQ ID NO, 10); and 5'-
GCAAGACCAAGACGUGUGA-3') (SEQ ID NO, 11) (Wong, et al., 2011). 
An isolated double-stranded RNA molecule that inhibits expression of PYCARD, at least one 
strand of which includes the sequence of, 5'-GAAGCUCUUCAGUUUCAdTdT-3' (SEQ ID 
NO, 12). 
An isolated double-stranded RNA molecule that inhibits expression of PYCARD, at least one 
strand of which includes a sequence selected from, 5'-GAAGCUCUUCAGUUUCAdTdT-3' 
(SEQ ID NO, 12); 5'-GGCUGCUGGAUGCUCUGUACGGGAA-3' (SEQ ID NO, 13); and 
5' -UUCCCGUACAGAGCAUCCAGCAGCC-3' (SEQ ID NO, 14) (Stealth siRNA oligos 
were designed and obtained with Lipofectamine 2000) 
US 9,453,226 B2 
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Further information regarding Caspase-1 inhibitors and 
probes can be found in Table B. Information found at the 
links set forth in Table B as of the filing date of this 
application is incorporated herein by this reference. 
TABLE B 
Peptide 
Sequence Application Link 
18 
including about 14 to 25 nucleotides: 5'-GUUUGAC-
UAUCUGUUCUdTdT-3' (SEQ ID NO: 7); 5'-GGAU-
CAAACUACUCUGUGA-3' (SEQ ID NO: 8); 5'-UG-
CAAGAUCUCUCAGCAAA-3' (SEQ ID NO: 9); 
Notes 
GWEHDGK fluorescent http,llwww.ncbi.nlm.nih.govlpmclarticlesl Gly-Trp-Glu-His-Asp-Gly-
Lys in vivo PMC1502090I 
YVADAPV fluorescent http,llwww.ncbi.nlm.nih.govlpubmedl801 
2123 
DABCYL-Tyr-Val-Ala-
Asp-Ala-Pro -Val-EDANS 
GFEVD fluorescent http,llwww.ncbi.nlm.nih.govlpmclarticlesl Abz-GXEVD-
PMC1221285Ipdfl10947972.pdf GVY(N02)D 
GYEVD fluorescent http,llwww.ncbi.nlm.nih.govlpmclarticlesl Abz-GXEVD-
PMC1221285Ipdfl10947972.pdf GVY(N02)D 
YVAD fluorescent http,llwww.sciencedirect.comlsciencelarti- BFP-YVAD-GFP 
clelpiiiS1074552199800519 
fluorescent http,llwww.jbc.orglcontentl286l37l Ac-YVAD-CHO 
32513.full 
inhibitor http,llwww.jbc.orglcontentl273l49l 
32608.long 
WEHD fluorescent http, I lj em. rupress. orgl contentl191l11l1819 I KDPC 5G-WEHD-
T1.expansion.html GINGC5 PKGY 
Inhibitor http,llwww.jbc.orglcontentl273l49l 
32608.long 
YVHDAP fluorescent http,llwww.funakoshi.co jpldataldatasheetl Caspalux 
ONCICPL1RE-5.pdf 
YVADAP fluorescent http,llwww.ncbi.nlm nih.govlpubmedl8012123 DABCYL-YVADAP-
EDANS 
YEVD fluorescent http, I lwww. jbc .orglcontentl272l15l9677 .long Ac-YVED-pNA 
YVHDAPVR Kinetic 
substrate 
http,llwww.jbc.orglcontentl272l11l7223l 
Tl.expansion.html 
Small 
molecule 
Sequence Application Link 
VX-765 Inhibitor http,llwww.medkoo.com1Anticancer-
trialsiVX-765.htm 
Notes 
Vertex Pharmaceuticals, 
Reversible, clinical trials 
ML132 Inhibitor http,llwww ncbi.nlm nih.govlbooksiNBK 
562411 
Reversible(?), based on 
VX-765 
VX-740 Inhibitor http,llwww ncbi.nlm.nih.govlpubmedl173 
93315 
Vertex Pharmaceuticals, 
common name: Pralnacasan 
clincal trials halted 
(liver abnormalities) 
VRT-
018858 
Inhibitor http,llwww ncbi.nlm.nih.govlpubmedl178 
45807 
Active metabolite of VX-
740 
CM-269 Reporter http://www.sciencedirect.com/science/arti- Luciferase based reporter 
clelpiiiS1074552110003091#sec5.1 
The presently-disclosed subject matter further includes 
compositions useful for inhibiting an inflarmnasome. Such 
compositions include an inhibitor. As noted above, such 
inhibitors can be, for example, a nucleotide, a polypeptide, 60 
a small (chemical) molecule, etc. In some embodiments, a 
composition can include an isolated RNA molecule. 
The presently-disclosed subject matter includes isolated 
RNA molecules that inhibit expression of a component of 
inflammasome, e.g., NLRP3, caspase-1 and/or PYCARD. In 65 
some embodiments, a first strand of the double-stranded 
RNA comprises a sequence selected from the following, and 
5'-GAAGUGGGGUUCAGAUAAU-3' (SEQ ID NO: 10); 
5'-GCAAGACCAAGACGUGUGA-3' (SEQ ID NO: 11); 
5'-GAAGCUCUUCAGUUUCAdTdT-3' (SEQ ID NO: 12); 
5'-GGCUGCUGGAUGCUCUGUACGGGAA-3' (SEQ ID 
NO: 13); and 5'-UUCCCGUACAGAGCAUCCAGCA-
GCC-3' (SEQ ID NO: 14). 
The presently-disclosed subject matter includes isolated 
RNA molecules that inhibit expression of an inflarmnasome 
component. In some embodiments, the RNA molecule com-
prises a sequence selected from the following: 
US 9,453,226 B2 
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GCTGGAGCAGGTGTACTACTTC, 
CAGGTTTGACTATCTGTTCT, 
and 
GTGAAGAGATCCTTCTGTA. 
(SEQ ID NO, 15) 
(SEQ ID NO, 16) 
(SEQ ID NO, 17) 
The presently-disclosed subject matter further includes 10 
methods of screening candidate inhibitors to identify inflam-
masome inhibitors. In some embodiments, a method of 
identifying an inflammasome inhibitor makes use of a 
cultured cell wherein a cell based-system is provided, which 
measures PYCARD aggregation, Caspase-1 cleavage, or 15 
cleavage/secretion of IL-l~ or IL-18 in response to an 
activator of the inflammasome (e.g., Alu RNA, lipopolysac-
charide+ATP). 
In some embodiments, a screening method for inflam-
masome inhibitors includes stimulating cells (e.g., RPE 20 
cells) or a cell line (e.g., THP-1 or RAW macrophages) that 
has been transfected with a plasmid encoding a fluorescent-
tagged PYCARD with Alu RNA or LPS+ATP; monitoring 
the aggregation of fluorescent PYCARD into a "speck"-an 
aggregosome focus using fluorescent microscopy; and test- 25 
ing the candidate molecules for the degree of inhibition of 
PYCARD "speck" formation. 
In some embodiments, a screening method for inflam-
masome inhibitors includes stimulating cells (e.g., RPE 
20 
body; and testing the candidate molecules for the degree of 
inhibition of Caspase-1 cleaved fragments (plO or p20). 
In some embodiments, a screening method for inflam-
masome inhibitors includes stimulating HEK-Blue™ IL-l~ 
Cells (Invivogen) with Alu RNA or LPS+ARP to detect 
bioactive IL-l~ formation using QUANTI-Blue™ (Invivo-
gen); and testing the candidate molecule for degree of 
inhibition of colometric signal. 
Inhibiting MyD88 
In some embodiments, the presently-disclosed subject 
matter includes a method of protecting a cell, comprising: 
inhibiting MyD88 of the cell. In some embodiments, the 
inhibiting MyD88 comprises administering a MyD88 inhibi-
tor. 
As noted above, in some embodiments, inhibiting a 
polypeptide of interest to the presently-disclosed subject 
matter comprises administering an oligonucleotide or a 
small RNA molecule. Such small RNA molecule can target 
MyD88. Such nucleotides can target and degrade MyD88. In 
this regard, the presently-disclosed subject matter includes a 
isolated double-stranded RNA molecule that inhibits expres-
sion ofMyD88, wherein a first strand of the double-stranded 
RNA comprises a sequence as set forth in Table C, and 
includes about 14 to 25 nucleotides. Examples of MyD88 
inhibitors that can be used in accordance with the presently-
disclosed subject matter include, but are not limited to those 
set forth in Table C. As such, embodiments of the presently-
disclosed subject matter can include administering a MyD88 
inhibitor set forth in Table C. 
TABLE C 
Examples of MyD88 Inhibitors 
A inhibitor comprising the polypeptide sequence of IMG-2005-1 peptide sequence, 
DRQIKIWFQNRRMKWKKRDVLPGT (SEQ ID NO, 1), including about 29 to 100 
nucleotides. 
Oligopeptide for inhibiting MyD88 homodimerization, RDVLPGT (SEQ ID NO, 54 
Oligopeptide for inhibiting MyD88 homodimerization, RDVVPGG (SEQ ID NO, 55 
Loiarro et al. J Biol Chern 2005; 280,15809-14. 
DRQIKIWFQNRRMKWKKRDVLPGTCVWSIASE (SEQ ID NO, 60). 
RDVLPGTCVWSIASE (SEQ ID NO, 61). 
An isolated double-stranded RNA molecule that inhibits expression of MyD88, at least 
one strand of which is about 14 to 25 nucleotides and includes a sequence selected 
from, 5'-GAGAAGCCUUUACAGGUdTdT-3' (SEQ ID NO, 3); 
5'-ACCUGUAAAGGCUUCUCdTdT-3' (SEQ ID NO, 4); 
5'-CAGAGCAAGGAAUGUGAdTdT-3' (SEQ ID NO, 5); 
5'-UCACAUUCCUUGCUCUGdTdT-3' (SEQ ID NO, 6); and 
5'-UAUUUCCUAAWGGGUCdTdT-3' (SEQ ID NO, 56). 
A homodimerization inhibitor, such as Pepinh-MYD (Invitrogen). 
A a dominant negative or splice variant of MyD88, such as a MyD88 splice variants that 
lack exon 2 (also known as the "intermediate domain" (e.g., having sequences set for at 
accession numbers NM_001172566.1 and NM_001172568.1), or other splice variants of MyD88 
(e.g., having sequences set for at accession numbers NM_002468.4 and NM_001172569.1). 
cells) or a cell line (e.g., THP-1 or RAW macrophages with 
Alu RNA or LPS+ATP; monitoring Caspase-1 activity using 
CaspaLux®l-E2D2 assay (Oncoimmunin, Inc.); and testing 
the candidate molecules for the degree of inhibition of 
Caspaslux fluorescence. 
In some embodiments, a screening method for inflam-
masome inhibitors includes stimulating cells (e.g., RPE 
cells) or a cell line (e.g., THP-1 or RAW macrophages with 
Alu RNA or LPS+ATP; monitoring Caspase-1 activity by 
measuring the abundance of cleaved Caspase-1 (p 10 or p20 
isoforms) by Western blotting using an anti-Caspase-1 anti-
55 
As noted above, in some embodiments, inhibiting MyD88 
comprises administering an MyD88 inhibitor that is a domi-
nant negative vector against MyD88, e.g., a dominant nega-
tive inhibitory form of MyD88 (pMyD88-dn) that contains 
60 the truncated llMyD88 (amino acids 152-296) lacking the 
death domain ofMyD88 (Muzio eta!. IRAK (Pelle) Family 
Member IRAK-2 and MyD88 as Proximal Mediators ofiL-1 
Signaling. Science 1997; 278:1612-1615). 
As noted above, in some embodiments, inhibiting MyD88 
65 comprises administering an MyD88 inhibitor that is a small 
molecule (e.g., (1) hydrocinnamoyl-L-valyl pyrrolidine, 
referred to as compound 4a in Bartfai eta!. "A low molecular 
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an indication that the candidate compound is a MyD88 
inhibitor. Such MyD88 inhibitors can have utility for thera-
peutic applications as disclosed herein. 
In some embodiments, the MyD88 can be upregulated 
weight mimic of the Toll/IL-l receptor/resistance domain 
inhibits IL-l receptor-mediated responses." PNAS 2003; 
100: 7971-7976; or (2) ST2825 as described in Carminati, P., 
Gallo, G., Ruggiero, V., Sassano, M., Mastroianni, D. 
"MyD88 homodimerization inhibitors" Patent No. 
W02006067091 and characterized in Loiarro eta! "Inhibi-
tion of MyD88 dimerization and recruitment of IRAKl and 
IRAK4 by a novel peptidomimetic compound." Journal of 
Leukocyte Biology. 2007; 82:801-810; or (3) 4-[(E)-2-(1-
hexylpyridin-1-ium-2-yeethenyl]-N,N-dimethylaniline 
5 using Alu RNA or lipopolysaccharide (LPS), for example, 
by stimulating cells (macrophages or RPE cells) with Alu 
RNA or LPS. In some embodiments, the MyD88 can be 
upregulated using CpG nucleotides, for example, by stimu-
lating cells (macrophages or RPE cells) with synthetic 
10 oligonucleotides containing unmethylated CpG dinucle-
otides, such as 5'-tcg tcg ttt tgt cgt ttt gtc gtt-3' or 5'-ggG 
GGA CGA TCG TCg ggg gg-3'. In some embodiments, the 
MyD88 can be upregulated using interleukin-1 beta or 
interleukin 18, for example, by stimulating cells (macro-
iodide, also known as 4-[(E)-2-(1-hexylpyridin-6-yl)ethe-
nyl]-N,N-dimethyl-aniline Iodide, also known as Chemical 
Structure CID 5716367 in PubChem which blocks MyD88 
interactions, or ( 4) the compounds referred to as 50-Fl2 and 
26-110 in Lee eta!. "Application of ~-Lactamase Enzyme 
Complementation to the High-Throughput Screening of 
Toll-Like Receptor Signaling Inhibitors." Molecular Phar-
macology 2007; 72:868-875), or a natural product (malyn-
gamide F acetate as described in Villa et a!. "Selective 
MyD88-dependent pathway inhibition by the cyanobacterial 20 
natural product malyngamide F acetate." European Journal 
15 phages or RPE cells) with recombinant forms of interleu-
kin-1 beta or interleukin 18. 
of Pharmacology 2010; 629:140-146), or a DNA or RNA 
aptamer generated by SELEX or other screening technology 
that binds or blocks MyD88. 
In some embodiments of the method for identifYing a 
MyD88 inhibitor, a change in the MyD88 can be monitored 
by measuring cell viability, measuring the expression of 
genes known to be induced by MyD88 signaling (e.g., 
Cox-2, Socs3, TNF -alpha) or using other criteria that would 
be recognized by one of ordinary skill in the art, using 
methods known to one of ordinary skill in the art. In some 
embodiments, the cultured cell is an RPE cell. In some 
embodiments, the cell is a retinal photoreceptor cell. In some 
embodiments, the cell is a choroidal cell. 
In some embodiments, a method of identifYing a MyD88 
inhibitor includes providing a cultured cell wherein MyD88 
is upregulated or undergoes oligomerization or induces 
The presently-disclosed subject matter further includes 25 
compositions useful for inhibiting MyD88. Such composi-
tions include an inhibitor. As noted above, such inhibitors 
can be, for example, a nucleotide, a polypeptide, a small 
(chemical) molecule, etc. In some embodiments, a compo-
sition can include an isolated RNA molecule. 30 phosphorylation ofiRAKl or ofiRAK4; and contacting the 
cell with a candidate compound; and determining whether 
the candidate compound results in a change in the MyD88 
levels, or a change in the abundance of dimerized or 
oligomerized MyD88, or a change in the abundance of 
The presently-disclosed subject matter includes isolated 
RNA molecules that inhibit expression of MyD88. In some 
embodiments, a first strand of the double-stranded RNA 
comprises a sequence selected from the following, and 
including about 14 to 25 nucleotides: 5'-GAGAAGC-
CUUUACAGGUdTdT-3' (SEQ ID NO: 3); 5'-ACCU-
GUAAAGGCUUCUCdTdT-3' (SEQ ID NO: 4); 5'-CA-
GAGCAAGGAAUGUGAdTdT-3' (SEQ ID NO: 5); and 
5'-UCACAUUCCUUGCUCUGdTdT-3' (SEQ ID NO: 6). 
35 phosphorylated IRAKl or of phosphorylated IRAK4. In 
some embodiments, the MyD88 is upregulated by: Alu 
RNA, lipopolysacharide, CpG nucleotides, single-stranded 
RNA, interleukin-1 beta, or interleukin 18. In some embodi-
ments, the MyD88 is monitored by measuring cell viability, 
The presently-disclosed subject matter includes isolated 
polypeptide molecules that inhibit expression ofMyD88. In 
some embodiments, the polypeptide molecule comprises a 
sequence selected from the following: DRQIKIWFQN-
RRMKWKKRDVLPGT (SEQ ID NO: 1 ), including about 
29 to 100 amino acids. In some embodiments, the polypep-
tide molecule comprises a sequence selected from the fol-
lowing: RDVLPGT (SEQ ID NO: 54) and RDVVPGG 
(SEQ ID NO: 55). 
40 or measuring the expression of a gene known to be induced 
by MyD88 signaling. In some embodiments, the gene 
known to be induced by MyD88 signaling is selected from 
Cox-2, Socs3, and TNF-a. 
In some embodiments of a screening method for MyD88 
45 inhibitors, cells or cell lines can be stimulated with a known 
activator ofMyD88, e.g., Alu RNA, or LPS. The RNA levels 
of genes such as Cox2, Socs3, or TNF -a can be measured 
using quantitative real-time RT-PCR. Candidate molecules 
In some embodiments, a method of identifYing a MyD88 
inhibitor makes use of a cultured cell wherein MyD88 is 50 
upregulated. Candidate compounds can be screened using 
the cultured cell to determine efficacy in modulating 
MyD88. Candidate compounds include, for example, small 
molecules, biologics, and combinations thereof, such as 
compositions including multiple compounds. The term 55 
small molecules is inclusive of traditional pharmaceutical 
compounds. The term biologics is inclusive of polypeptides 
and nucleotides, and including siRNAs, antibodies, aptam-
ers, and dominant negative plasmids or vectors. 
In some embodiments, the screening method includes 60 
providing a cell in culture wherein MyD88 is upregulated; 
and contacting a candidate compound with the cell. The 
method can further include identifYing a change in MyD88. 
For example, a measurable change in MyD88 levels can be 
indicative of efficacy associated with the candidate com- 65 
pound. In some embodiments, wherein the change in the 
MyD88 is a measurable decrease in MyD88, the change is 
can be tested for degree of inhibition of these gene tran-
scripts. 
In some embodiments of a screening method for MyD88 
inhibitors, cells or cell lines can be stimulated with a known 
activator ofMyD88, e.g., Alu RNA, or LPS. The abundance 
of dimerized or oligomerized MyD88 can be measured by 
Western blotting under non-reducing conditions using an 
anti-MyD88 antibody. The candidate molecule can be tested 
for degree of inhibition of MyD88 dimerization or oligomer-
ization. 
In some embodiments of a screening method for MyD88 
inhibitors, cells or cell lines that have been transfected with 
plasmids coding for a fusion MyD88 protein tagged to 
fragments ofYFP (yellow fluorescent protein) can be stimu-
lated with a known activator of MyD88, e.g., Alu RNA, or 
LPS. The fluorescent signal can be measured using bimo-
lecular fluorescence complementation techniques. The can-
didate molecule can be tested for degree of inhibition of 
fluorescent signal. 
US 9,453,226 B2 
23 
In some embodiments of a screening method for MyD88 
inhibitors, cells or cell lines can be stimulated with a known 
activator ofMyD88, e.g., Alu RNA, or LPS. The abundance 
of phosphorylated forms of IRAK1 or IRAK4 can be 
measured by Western blotting under reducing conditions 
using an anti-phosphoiRAK1 or anti-phosphoiRAK4 anti-
bodies. The candidate molecule can be tested for degree of 
inhibition of IRAK1 or IRAK4 phosphorylation. 
Inhibiting IL-18 
In some embodiments, the presently-disclosed subject 10 
matter includes a method of protecting a cell, comprising: 
inhibiting IL-18 of the cell. In some embodiments, the 
inhibiting IL-18 comprises administering an IL-18 inhibitor. 
As noted above, in some embodiments, inhibiting a 
polypeptide of interest to the presently-disclosed subject 15 
matter comprises administering a binding protein or an 
antibody. Such antibodies can include a neutralizing anti-
body against IL-18, or an antibody that blocks IL-18 binding 
to the IL-18 receptor. In some embodiments, the IL-18 
inhibitor can be an IL-18 binding protein (Novick, et a!., 20 
1999). 
Examples of IL-18 inhibitors that can be used in accor-
dance with the presently-disclosed subject matter include, 
but are not limited to those set forth in Table D. As such, 
embodiments of the presently-disclosed subject matter can 25 
include administering an IL-18 inhibitor set forth in Table D. 
TABLED 
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include an isolated RNA molecule. In some embodiments, a 
composition can include an antibody or a binding protein. 
The presently-disclosed subject matter further includes 
methods of screening candidate inhibitors to identify IL-18 
inhibitors. In some embodiments, a method of identifYing an 
IL-18 inhibitor includes plating recombinant IL-18R1 on a 
solid state surface suitable for surface plasmon resonance 
(SPR); exposing the plated recombinant IL-18R1 to fluo-
rescence-labeled recombinant IL-18; further exposing the 
system to a putative IL-18 inhibitor which would displace 
IL-18:IL-18R1 binding; and measuring fluorescence to 
determine degree of inhibition. 
In some embodiments, a method of identifYing an IL-18 
inhibitor includes stimulating cells (e.g., RPE cells) or a cell 
line (e.g., THP-1 or RAW macrophages) with recombinant 
IL-18; measuring MyD88 activation, e.g., by measuring 
increased MyD88 dimerization (through Western blotting) 
or by measuring increased phosphorylation of IRAK1 or of 
IRAK4. 
Inhibiting VDAC1 and/or VDAC2 
In some embodiments, the presently-disclosed subject 
matter includes a method of protecting a cell, comprising: 
inhibiting VDAC1 and/or VDAC2 of the cell. In some 
embodiments, the inhibiting VDAC1 and/or VDAC2 com-
prises administering an VDAC1 and/or VDAC2 inhibitor. 
Examples of IL-18 Inhibitors 
A neutralizing antibody against IL-18, or an antibody that blocks 
IL-18 binding to the IL-18 receptor, e.g., IL-18 neutralizing antibody 
(MBL International); IL-18 neutralizing antibody (R&D Systems); or 
IL-18R1 neutralizing antibody (R&D Systems); or IL-18R1 neutralizing 
antibody (Genetex). 
As noted above, in some embodiments, inhibiting a 
polypeptide of interest to the presently-disclosed subject 
matter comprises administering an oligonucleotide or a 
small RNA molecule. Such small RNA molecule can target 
30 VDAC1 and/or VDAC2. Such nucleotides can target and 
degrade VDAC1 and/or VDAC2. In this regard, the pres-
ently-disclosed subject matter includes a isolated double-
stranded RNA molecule that inhibits expression ofVDAC1 
and/or VDAC2, wherein a first strand of the double-stranded 
An IL-18 binding protein as described by Novick, et al., 1999. 
IL18BP (an endogenous, naturally occurring IL-18 binding protein) 
The presently-disclosed subject matter further includes 
compositions useful for inhibiting IL-18. Such compositions 
include an inhibitor. As noted above, such inhibitors can be, 
for example, a nucleotide, a polypeptide, a small (chemical) 
molecule, etc. In some embodiments, a composition can 
35 RNA comprises a sequence as set forth in Table E, and 
includes about 14 to 25 nucleotides. Examples ofVDAC1 
and/or VDAC2 inhibitors that can be used in accordance 
with the presently-disclosed subject matter include, but are 
not limited to those set forth in Table E. As such, embodi-
40 ments of the presently-disclosed subject matter can include 
administering a VDAC1 and/or VDAC2 inhibitor set forth in 
Table E. 
TABLE E 
Examples of VDAC1 and/or VDAC2 Inhibitors 
An isolated double-stranded RNA molecule that inhibits expression of VDACl, at least one 
strand of which is about 14 to 25 nucleotides and includes the sequence of: 5'-
CGGAAUAGCAGCCAAGUdTdT-3' (SEQ ID NO, 47). 
An isolated double-stranded RNA molecule that inhibits expression of VDAC2, at least one 
strand of which is about 14 to 25 nucleotides and includes the sequence of: 5'-
CCCUGGAGUUGGAGGCUdTdT-3' (SEQ ID NO, 48). 
Any phosphorothioate oligonucleotide randomer (Trilink Industries) , which all inhibit VDAC 
(Stein & Marco Colombini. Specific VDAC inhibitors: phosphorothioate oligonucleotides. J 
Bioenerg Biomembr 2008; 40,157-62; Tan et al. Phosphorothioate oligonucleotides block the 
VDAC channel. Biophys J. 2007; 93,1184-91) 
Cyclosporin A-blocks VDAC1 
Superoxide dismutase 1-blocks VDAC1 
4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS) -blocks VDAC1 
Bcl-x(L) BH4(4-23) -blocks VDAC 
TR019622-blocks VDAC 
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The presently-disclosed subject matter further includes 
compositions useful for inhibiting VDACl and/or VDAC2. 
Such compositions include an inhibitor. As noted above, 
such inhibitors can be, for example, a nucleotide, a poly-
peptide, a small (chemical) molecule, etc. In some embodi-
ments, a composition can include an isolated RNA molecule. 
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TABLE F 
Examples of Caspase-8 Inhibitors 
Z-IETD-FMK (BD Biosciences) 
Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-
Ala-Pro-Ile-Glu-Thr-Asp-
CHO (EMD Millipore) 
Z-Ile-Glu(OMe)-Thr-Asp(OMe)-CH2F (EMD Millipore) 
Cellular [as-associated death domain-like interleukin-1-13-
converting enzyme-inhibitory protein (L), i.e. c-FLIP(L), a.k.a. 
FLICE, a.k.a. MACH, a.k.a. Mch5 
The presently-disclosed subject matter includes isolated 
RNA molecules that inhibit expression of VDACl and/or 
VDAC2. In some embodiments, a first strand of the double- 10 
stranded RNA comprises a sequence selected from the 
following, and including about 14 to 25 nucleotides: 5'-CG-
GAAUAGCAGCCAAGUdTdT-3' (SEQ ID NO: 47) and 
5'-CCCUGGAGUUGGAGGCUdTdT-3' (SEQ ID NO: 48). 
The presently-disclosed subject matter further includes 
compositions useful for inhibiting caspase-8. Such compo-
sitions include an inhibitor. As noted above, such inhibitors 
15 can be, for example, a nucleotide, a polypeptide, a small 
(chemical) molecule, etc. In some embodiments, a compo-
sition can include an isolated RNA molecule. 
The presently-disclosed subject matter further includes 
methods of screening candidate inhibitors to identify 
VDACl and/or VDAC2 inhibitors. In some embodiments, 
cell or cell line-based methods are used. The presently-disclosed subject matter further includes 
methods of screening candidate inhibitors to identifY cas-
20 pase-8 inhibitors. In some embodiments, cell or cell line-
based methods are used. 
Inhibiting Caspase-8 
In some embodiments, the presently-disclosed subject 
matter includes a method of protecting a cell, comprising: 
inhibiting caspase-8 of the cell. In some embodiments, the 
inhibiting caspase-8 comprises administering a caspase-8 
inhibitor. 
Inhibiting NFKB 
In some embodiments, the presently-disclosed subject 
matter includes a method of protecting a cell, comprising: 
25 inhibiting NFKB of the cell. In some embodiments, the inhibiting NFKB comprises administering a caspase-8 
inhibitor. Examples of caspase-8 inhibitors that can be used in 
accordance with the presently-disclosed subject matter 
include, but are not limited to those set forth in Table F. As 
such, embodiments of the presently-disclosed subject matter 
can include administering a caspase 8 inhibitor set forth in 
Table F. 
Examples of NFKB inhibitors that can be used in accor-
dance with the presently-disclosed subject matter include, 
but are not limited to those set forth in Table G. As such, 
30 embodiments of the presently-disclosed subject matter can 
include administering a NFKB inhibitor set forth in Table G. 
TABLE G 
Examples of NFKB Inhibitors 
Any one or more of the following NFKB inhibitors 
Antioxidants that have been shown to inhibit activation ofNF-kB 
a-Lipoic acid 
a-tocopherol 
Aged garlic extract (allicin) 
2-Amino-1-methyl-6-phenylimidazo[ 4,5-b ]pyridine (PhiP) 
N-acetyldopamine dimers (from P. cicadae) 
Allopurinol 
Anetholdithiolthione 
Apocynin 
Apple juice/extracts 
Aretemsia p7F (5,6,3',5'-tetramethoxy 7,4'-hydroxyflavone) 
Astaxanthin 
Autunm olive extracts; olive leaf extracts 
Avenanthramides (from oats) 
Bamboo culm extract 
Benidipine 
his-eugenol 
Bruguiera gynmorrhiza compounds 
Butylated hydroxyanisole (BHA) 
Cepharanthine 
Caffeic Acid Phenethyl Ester 
(3 ,4-dihydroxycinnamic acid, CAPE) 
Carnosol 
beta-Carotene 
Carvedilol 
Catechol Derivatives 
Centaurea L (Asteraceae) extracts 
Chalcone 
Chlorogenic acid 
5-chloroacetyl-2-amnio-1 ,3-selenazoles 
Cholestin 
Chroman-2-carboxylic acid N-substituted phenylamides 
Cocoa polyphenols 
Coffee extract (3-methyl-1,2-cyclopentanedione) 
Crataegus pinnatifida polyphenols 
Sen et al, 1998; Suzuki et al, 1992 
Islam et al, 1998 
Ide & Lau, 2001; Lang et al, 2004; Hasan et al, 2007 
Yun et al, 2005 
Xu et al, 2006 
Gomez-Cabrera et al, 2006 
Sen et al, 1996 
Barbieri et al, 2004 
Shi & Jiang, 2002; Daviset al, 2006; Jung et al, 2009 
Lee et al, 2004 
Lee et al, 2003 
Wang et al, 2007; Wanget al, 2008 
Guo et al, 2007; Sur et al, 2008 
Lee et al, 2008 
Matsubara & Hazegawa, 2004 
Murakami et al, 2003 
Homhual et al, 2006 
Israel et al, 1992; Schulze-Osthoff et al, 1993 
Okamoto et al, 1994;Tamatani et al, 2007 
Natarajan et al, 1996;Nagasaka et al, 2007 
Lo et al, 2002; Huang et al, 2005 
Bai et al, 2005;Guruvayoorappan & Kuttan, 2007 
Yang et al, 2003 
Suzuki & Packer, 1994;Zheng et al, 2008 
Karamenderes et al, 2007 
Liu et al, 2007 
Feng et al, 2005 
Nam et al, 2008 
Lin et al, 2007 
Kwak et al, 2008 
Lee et al, 2006 
Chung et al, 2007 
Kao et al, 2007 
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TABLE G-continued 
Examples of NFKB Inhibitors 
Any one or more of the following NFKB inhibitors 
Curcumin (Diferulolylmethane); 
dimethoxycurcumin; EF24 analog 
Dehydroepiandrosterone (DHEA) and 
Dibenzylbutyrolactone lignans 
Diethyldithiocarbamate (DDC) 
Diferoxarnine 
Dihydroisoeugenol; isoeugenol; 
epoxypseudoisoeugenol-2-methyl butyrate 
Dihydrolipoic Acid 
Dilazep + fenofibric acid 
Dimethyldithiocarbamates (DMDTC) 
Dimethylsulfoxide (DMSO) 
Disulfiram 
Ebselen 
Edaravone 
EPC-K1 (phosphodiester compound 
of vitamin E and vitamin C) 
Epigallocatechin-3-gallate (EGCG; green tea polyphenols) 
Ergothioneine 
Ethyl Pyruvate (Glutathione depletion) 
Ethylene Glycol Tetraacetic Acid (EGTA) 
Eupatilin 
Exercise 
Fisetin 
Flavonoids (Cmtaegus; Boerhaavia diffusa root; xanthohumol; 
Eupatorium arnottianwn; genistein; 
kaempferol; quercetin, daidzein; flavone; isorhanmetin; 
naringenin; pelargonidin; finestin; Sophora 
flavescens; Seabuckthorn fruit berry) 
Flavonoid-7-glycosides (chamomile flowers extract) 
Folic acid 
Gamma-glutamylcysteine synthetase (ganuna-GCS) 
Ganoderma lucidum polysaccharides 
Garcinol (from extract of Garcinia indica fruit rind) 
Ginkgo biloba extract 
Glutathione 
Guaiacol (2-methoxyphenol) 
Hematein 
Hinokitiol 
HMC05 herbal extract 
Hydroquinone 
23-hydroxyursolic acid 
IRFI 042 (Vitamin E-like compound) 
Iron tetrakis 
Isosteviol 
Isovitexin 
Isoliquiritigenin 
Justicia gendarussa root extract 
Kallistatin 
Kangen-karyu extract 
L-cysteine 
Lacidipine 
Lazaro ids 
Ligonberries 
Lupeol 
Lutein 
Magnolol 
Maltol 
Manganese superoxide dismutase (Mn-SOD) 
Extract of the stem bark of Mangifera indica L. 
Melatonin 
21 (alpha, beta)-methylmelianodiol 
Mulberry anthocyanins 
N-acetyl-L-cysteine (NAC) 
Nacyselyn (NAL) 
Nordihydrognaiaritic acid (NDGA) 
al, 1993; Staalet al, 1993 
Ochnaflavone 
Onion extract (2,3-dihydro-3,5-
dihydroxy-6-methyl-4H-pyranone) 
Ortbophenanthroline 
N-(3-oxo-dodecanoyl) homoserine lactone 
Paricalcitol 
Phenolic antioxidants (Hydroquinone 
and tert-butyl hydroquinone) 
Olive oil phenols (extra-virgin olive oil) 
alkenylphenols from Piper obliquum 
Singh & Aggarwal, 1995;Pae et al, 2008; Kasinskiet al, 2008 
DHEA-sulfate (DHEAS) Iwasaki et al, 2004; Liu et al, 2005 
Cho et al, 2002 
Schreck et al, 1992 
Sappey et al, 1995;Schreck et al, 1992 
Murakami et al, 1995Tark et al, 2007; Ma et al, 2008 
Suzuki et al, 1992, 1995 
Sonoki et al, 2003; Yanget al, 2005 
Pyatt et al, 1998 
Kelly et al, 1994 
Schreck et al, 1992 
Schreck et al, 1992 
Kokura et al, 2005; Ariiet al, 2007; Yoshida et al, 2007 
Hirano et al, 1998 
Lin & Lin, 1997; Yang et a1,1998; Hou et al, 2007; Jiang et al, 2012 
Rahman et al, 2003 
Song et al, 2004; Tsung et al, 2005; Jimenez-Lopezet al, 2008 
Janssen et al, 1999 
Lee et al, 2008 
Goto et al, 2007 
Park et al, 2006; Sung et al, 2007 
Zhang et al, 2004; Chene! al, 2004; Pandey et al, 2005; Albini 
et al, 2005;Colgate et al, 2006;Clavin et al, 2007; 
Hamalainen et al, 2008;Zheng et al, 2008; Junge! al, 2008; 
Mishra et al, 2008 
Bulgari et al, 2012 
Au-Yeung et al, 2006 
Manna et al, 1999 
Zhang et al, 2003; Ho et al, 2007 
Liao et al, 2004 
Chen et al, 2003 
Cho et al, 1998; Schrecket al, 1992; Wang et al, 2007 
Murakami et al, 2007 
Choi et al, 2003 
Byeon et al, 2008 
Kim et al, 2007 
Pyatt et al, 1998; Yang et al, 2006 
Shin et al, 2004 
Alta villa et al, 2001 
Kang et al, 2001 
Xu et al, 2008 
Lin et al, 2005 
Kumar et al, 2007; Kimel al, 2008; Kim et al, 2008 
Kumar et al, 2011 
Sherr et al, 2008 
Satoh et al, 2005;Yokozawa et al, 2007 
Mihm et al, 1991 
Cominacini et al, 1997 
Marubayashi et al, 2002 
Wang et al, 2005 
Saleem et al, 2004; Lee et al, 2007 
Kim et al, 2008 
Chen et al, 2002; Ou et al, 2006; Kim et al, 2007 
Yang et al, 2006 
Manna et al, 1998 
Leiro et al, 2004; Garridoet al, 2005 
Gilad et al, 1998; Mohanet al, 1995; Li et al, 2005 
Zhou et al, 2007 
Chen et al, 2006 
Schreck et al, 1991 
Antonicelli et al, 2002 
Brennan & O'Neill, 1998;Israel et a1,1992; Schulze-Osthoff et 
Suh et al, 2006 
Ban et al, 2007; Tang et al, 2008 
Schreck et al, 1992 
Kravchenko et al, 2008 
Tan et al, 2008 
Ma et al, 2003 
Sangiovanni et al, 2012 
Valdivia et al, 2008 
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TABLE G-continued 
Examples of NFKB Inhibitors 
Any one or more of tbe following NFKB inhibitors 
alpha-phenyl-n-tert-butyl-nitron (PBN) 
Phenylarsine oxide (PAO, tyrosine phosphatase inhibitor) 
Phyllantbus urinaria 
Phytosteryl ferulates (rice bran) 
Piper longum Linn. extract 
Pitavastatin 
Prodelphinidin B2 3, 3' cli-O-gallate 
Pterostilbene 
Pyrrolineditbiocarbamate (PDTC) 
Quercetin 
Kotake et al, 1998;Lin et al, 2006 
Arbault et al, 1998 
Chularojmontri et al, 2005; Sherr et al, 2007 
Islam et al, 2008; Jung et al, 2008 
Singh et al, 2007 
Tounai et al, 2007; Wang& Kitajima, 2007 
Hou et al, 2007 
Cichocki et al, 2008; Panel al, 2009 
Schreck et al, 1992 
Musonda & Chipman, 1998; Shih et al, 2004;Garcia-
30 
Red orange extract 
Red wine 
Mediavilla et al, 2006; Ruiz et al, 2007;Min et al, 2007; Kim et al, 2007 
Cimini et al, 2008 
Ref-1 (redox factor 1) 
Rg(3), a ginseng derivative 
Rotenone 
Roxithromycin 
Rutin 
S-allyl-cysteine (SAC, garlic compound) 
Salogaviolide (Centaurea ainetensis) 
Sauchinone 
Schisandrin B 
Silybin 
Spironolactone 
Strawberry extracts 
Sulfuretin 
Taxifolin 
Tempo! 
Tepoxaline (5-(4-chlorophenyl)-N-hydroxy-
(4-metboxyphenyl)-N-metbyl-1H-pyrazole-3-propanamide) 
Blanco-Colio et al, 2000;Cui & He, 2004 
Ozaki et al, 2002 
Keum et al, 2003 
Schulze-Ostboff et al, 1993 
Ueno et al, 2005; Ou et al, 2008 
Kyung et al, 2008 
Geng et al, 1997 
Ghantous et al, 2008 
Lee et al, 2003; 
Giridharan et all, 2011 
Gazak et al, 2007 
Han et al, 2006 
Wang et al, 2005 
Lee et al, 2012 
Wang et al, 2005 
Cuzzocrea et al, 2004 
Kazmi et al, 1995; Ritchieet al, 1995 
Thio avarol derivatives Amigo et al, 2007; Amigoet al, 2008 
Thymoquinone El Gazzar et al, 2007;1Setbi et al, 2008 
Tocotrienol (palm oil) Wu et al, 2008 
8-(Tosylamino)quinoline Jung et al, 2012 
Tomato peel polysaccharide De Stefano et al, 2007 
UDN glycoprotein (Ulmus davidiana Nakai) Lee & Lim, 2007 
Vaccinium stamineum (deerberry) extract Wang et al, 2007 
Vanillin (2-hydroxy-3-metboxybenzaldehyde) Murakami et al, 2007 
Vitamin C Staal et al, 1993; Son et al, 2004 
Vitamin B6 Yanaka et al, 2005 
Hwang et al, 2003 
Vitamin E and derivatives Suzuki & Packer, 1993;Ekstrand-Hammarstrom et al, 2007; 
Glauert, 2007 
a-torphryl succinate 
a-torphryl acetate 
PMC (2,2,5,7 ,8-pentametbyl-6-hydroxychromane) 
Yakuchinone A and B 
Proteasome and proteases inhibitors tbat inhibit Rel/NF-kB 
Proteasome inhibitors 
Peptide Aldehydes: 
ALLnL 
(N-acetyl-leucinyl-leucynil-norleucynal,MG 101) 
LLM (N-acetyl-leucinyl-leucynil-metbional) 
Z-LLnV 
( carbobenzoxyl-leucinyl-leucynil-norvalinal,MG 115) 
Z-LLL 
(carbobenzoxyl-leucinyl-leucynil-leucynal, MG132) 
Staal et al, 1993; Suzuki & Packer, 1993 
Suzuki & Packer, 1993 
Suzuki & Packer, 1993 
Chun et al, 2002 
Palombella et al, 1994; Grisham et al, 1999; Jobin et al, 1998 
MG262 Pujois et al, 2012 
Lactacystine, beta-lactone Fenteany & Schreiber, 1998; Grisham et al, 1999 
Boronic Acid Peptide Grisham et al, 1999; Iqbal et al, 1995 
Ditbiocarbamate complexes witb metals Cvek & Dvorak, 2007 
CEP-18770 Piva et al, 2007 
Ubiquitin Ligase Inhibitors Yaron et al, 1997 
PS-341 (Bortezomib) Adams, 2004 
Salinosporamide A (1, NPI-0052) Macherla et al, 2005; Ahnet al, 2007 
Cyclosporin A Frantz et al, 1994; Kunz et al, 1995; Marienfeld et al, 1997; 
McCaffrey et al, 1994;Meyer et al, 1997; Wechsler et al, 1994 
FK506 (Tacrolimus) Oksmoto et al, 1994; Venkataraman et al, 1995 
Deoxyspergualin Tepper et al, 1995 
Disulfiram Lovborg et al, 2005 
PT-11 0 Momose et al, 2007 
Protease inhibitors 
APNE (N -acety 1-D L-pheny !alanine-b-naphtby lester) 
B lEE (N-benzoyl L-tyrosine-etbylester) 
DCIC (3,4-dichloroisocoumarin) 
DFP (diisopropyl fluorophosphate) 
TPCK (N-a-tosyl-L-phenylalanine chlorometbyl ketone) 
Higuchi et al, 1995 
Rossi et al, 1998 
D'Acquisto et al, 1998 
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TABLE G-continued 
Examples of NFKB Inhibitors 
Any one or more of the following NFKB inhibitors 
TLCK (N-a-tosyl-L-lysine chloromethyl ketone) 
IkBa phosphorylation and/or degradation inhibitors 
Molecule 
Desloratadine; diphenhydramine Histamine H1 receptor 
Bikunin 
Ron Tyrosine kinase receptor 
TAK-242 
Salmeterol, fluticasone propionate 
CPU0213 
Doxazosin 
Erbin overexpression 
Protein-bound polysaccharide from basidiomycetes 
Anti-CD146 antibody AA98 
Calagualine (fern derivative) 
NS3/4A (HCV protease) 
golli BG21 (product of myelin basic protein) 
NPM-ALK oncoprotein 
NS5A (Hepatitis C virus) 
LY29 and LY30 
Shiga toxin (Enterohemorrhagic E coli) 
Evodiamine (Evodiae Fructus component) 
Rituximab (anti-CD20 antibody) 
Kinase suppressor of ras (KSR2) 
Cholecystokinin ocatpeptide (CCK-8)p38 kinase 
M2L (Vaccinia virus) 
Pefabloc (serine protease inhibitor)upstream of IKK 
Rocaglamides (Aglaia derivatives) 
Ymer 
Epoxyquinol B 
Betaine 
TNAP 
Selected peptides 
Biochanin 
Desflurane 
Geldanamycin 
Grape seed proanthocyanidins 
Laretia acaulis azorellane diterpenoids 
MC160 (Molluscum contagiosum virus) 
NS5B (Hepatitis C protein) 
Pomegranate fruit extract 
Tetrandine (plant alkaloid) 
BMS-345541 (4(2'-Aminoethyl)amino-1,8-
dimethylimidazo(1 ,2-a) quinoxaline) 
and 4-arnino derivatives 
IKKa and IKKb kinase activity 
1-0-acetylbritannilactone 
2-amino-3-cyano-4-aryl-6-(2-hydroxy-
phenybpyridine derivatives 
Acrolein 
Anandamide 
AS602868 
benzoxathiole( 6 ,6-dimethy 1-2-(phenylimino )-6, 7 -dihydro-
5H-benzo-[1,3]oxathio1-4-one (and its analogs) 
Cobrotoxin 
Core protein (Hepatitis C) 
1-[2-cyano-3 ,12-dioxooleana-1 ,9(11 )-dien-28-oyl]imidazole 
Dihydroxyphenylethanol 
Heibimycin A 
Inhibitor 22 
Isorhapontigenin 
ManumycinA 
6-methyl-2-propolyimino-6,7-dihydro-5 
H -benzo[1 ,3]oxathiol-4-one 
Point of Inhibition 
Wu et al, 2004; Scadding, 2005; 
LPS receptor agonists 
Suppresses TNF production 
TLR4 intracellular domain 
beta2 agonists 
Endothelin receptor antagonist 
alphal-adrenergic receptor antagonist 
NOD2 inhibitor 
LPS-CD14 interaction 
upstream of!KK 
upstream of!KK (TRAF2-NIK) 
upstream of!KK 
upstream of IKK (PKC) 
Traf2 inhibition 
Traf2 inhibition 
PI3 Kinase inhibitors 
PI3 Kinase inhibitor 
AKT-IKK interaction 
up-regulates Raf-1 kinase inhibitor 
MEKK3 inhibitor 
ERK2 inhibitor 
Tando et al, 2002 
upstream of!KK 
Binds to Ub-RIP 
TAK1 crosslinker 
NIK/IKK 
NIK 
NEMO binding to Ub 
upstream of IKK/ phosphorylates of IKBa 
IKK complex formation with TNF-Rl 
IKK complex formation 
IKKa activity 
IKKa activity 
IKKa activity 
IKKa activity 
IKKa activity 
IKKa activity 
Burke et al, 2002; Yang et al, 2006; 
IKKb activity 
IKKb activity 
IKKb activity/p50 DNA binding 
Vallacchi et al, 2005; 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity/p50 DNA 
binding Park et al, 2005 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb 
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TABLE G-continued 
Examples of NFKB Inhibitors 
Any one or more of tbe following NFKB inhibitors 
MLB120 (small molecule) 
Naphtbopyrones (6-metboxycomaparvin and 
6-metbooxycomaparvin 5-metbyl etber) 
Novel Inhibitor 
viRF3 (KSHV) 
Nitric oxide 
SC-514 (small molecule) 
Thienopyridine 
Acetyl-boswellic acids 
Amino-pyrimidine derivative 
Benzoimidazole derivative 
BMS-345541 
Butein 
Beta-carboline 
CYL-19s and CYL-26z, two synthetic alpha-metbylene-
garnma-butyrolactone derivatives 
ACHP (2-amino-6-[2-(cyclopropylmetboxy)-6-
hydroxyphenyl]-4-piperidin-4-yl nicotinonitrile 
Berberine 
Compound A 
Flavopiridol 
Cyclopentones 
Dehydroascorbic acid (Vitamin C) 
Gossypyin or Gossypiwn extracts 
M protein (SARS-Cornonavirus protein) 
IMD-0354 
Jesterone dimer 
KINK-! 
LCY-2-CHO 
Prolyl hydroxylase-! 
Naphtbopyrones (Echinoderm Comantbus parvicirrus) 
Neuropeptides CGRP, PACAP and VIP 
PS-1145 (MLN1145) 
2-[ ( aminocarbonyl)amino ]-5-( 4-fluorophenyl)-
3-tbiophenecarboxamides (TPCA-1) 
1'-Acetoxychavicol acetate (Languas galanga) 
17-Acetoxyjolkinolide B 
Acute alcohol exposure 
Anacardic acid (6-nonadecyl-salicylic acid) 
Apigenin (plant flavinoid) 
Asiatic acid 
Cardarnomin 
CD DO-Me (syntbetic triterpenoid) 
CHS 828 (anticancer drug) 
CNIL-1 
Compound 5 (Uredio-tbiophenecarboxamide derivative) 
CT20126 
Diaylpyridine derivative 
3,4-dihydroxybenzalacetone (from Chaga) 
Diosgenin 
E3-14. 7K (Adenovirus) 
E3-1 0.4K/14.5K (Adenovirus) 
E7 (human papillomavirus) 
Furonaphthoquinone 
3-Formylchromone 
Guggulsterone 
HB-EGF (Heparin-binding epidermal 
growtb factor-like growtb factor) 
Falcarindol 
Hammerhead ribozyme to IKKa!b 
Hepatocyte growtb factor 
Honokiol 
Humulone 
Hypoestoxide 
Indolecarboxarnide derivative 
Labdane diterpenoids 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity/IkE phosphorylation 
IKKb activity 
IKKb activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKKb activity 
IKK activity 
IKK activity 
IKKb activity (ATP analog) 
IKKb activity 
IKKb activity (ATP analog) 
IKK activity and RelA phosphor. 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity; DNA binding 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity 
IKKb activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity/NIK 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKKb activity/p65 DNA binding 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
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TABLE G-continued 
Examples of NFKB Inhibitors 
Any one or more of tbe following NFKB inhibitors 
LF15-0195 (analog of 15-deoxyspergnaline) 
gannna-mangostin (from Garcinia mangostana) 
Garcinone B 
(Amino )imidazolylcalboxaldehyde derivative 
Imidazolylquinoline-carboxaldehyde derivative 
Kahweol 
Kava (Piper metbysticum) derivatives 
Lead 
Marasmius oreades liquid extract 
Menatetrenone (vitamin K2 analogne) 
Metformin 
Mild hypothermia 
ML 120B 
Morin (3 ,5 ,7 ,2' ,4'-Pentahydroxyflavone) 
Morusin 
MX781 (retinoid antagonist) 
N-acetylcysteine 
Nitrosylcobalamin (vitamin B12 analog) 
NSA!Ds 
Hepatits C virus NS5B 
PAN! (aka NALP2 or PYPAF2) 
Pectin (citrus) 
Pinitol 
PMX464 
Pyrazolo[4,3-c ]quinoline derivative 
Pyridooxazinone derivative 
N-(4-hydroxyphenyl) retinamide 
Scytonemin 
Semecarpus anacardiu extract 
SPC-839 
Sulforaphane and phenylisotbiocyanate 
Survanta (Surfactant product) 
Torque Teno virus ORF2 
Piceatannol 
Plumbagin ( 5-hydroxy-2-metbyl-1 ,4-naphtboquinone) 
IKKb peptide to NEMO binding domain 
NEMO CC2-LZ peptide 
AGROlOO (G-quadraplex oligodeoxynucleotide) 
PTEN (tumor suppressor) 
Theaflavin (black tea component) 
Tilianin 
Witbanolides 
Zerumbone 
Silibinin 
Sulfasalazine 
Sulfasalazine analogs 
Quercetin 
Rosmarinic acid 
Staurosporine 
gamma-Tocotrienol 
Wedelolactone 
Betulinic acid 
Ursolic acid 
Thalidomide (and tbalidomideanalogs) 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK-NEMO interaction 
NEMO oligomerization 
NEMO binding 
Activation of IKK 
Activation of IKK 
Activation of IKK 
Activation of IKK 
Activation of IKK 
IKKa activity; nuclear translocation 
IKKa and IKKb kinase activity 
IKK kinase activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKK activity 
IKKa activity and p65 phosphorylation 
IKKa activity and p65 phosphorylation 
IKK activity 
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Han et al, 2003 
Calley et al, 2006 
Manna et al, 2007 
Lee et al, 2008 
Bayonet al, 2003 
Oka et al, 2000 
Chawla-Sarkar et al 2003 
Takada et al, 2004 
Choi et al, 2006 
Bruey et al, 2004 
Chen et al, 2006 
Setbi et al, 2008 
Callister et al, 2008 
Karin et al, 2004 
Karin et al, 2004 
Shishodia et al, 2005; 
Kuefer et al, 2007 
Stevenson et al, 2002 
Singh et al, 2006 
Palanki et al, 2002 
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Hayes et al, 2008 
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Islam et al, 2004 
Sandur et al, 2006 
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Agou et al, 2004 
Girvan et al, 2006 
Gustin et al, 2001 
Aneja et al, 2004; 
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Kalra et al, 2007 
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Ichikawa et al, 2006 
Takada et al, 2005 
Dhanalakahmi et al, 2002; 
Singh et al, 2004; 
Min et al, 2007 
Wahl et al, 1998: 
Weber et al, 2000 
Habens et al, 2005 
Peel & Li, 1999 
Lee et al, 2006 
Peel & Li, 1999 
Shah & Sylvester, 2005; 
Ahn et al, 2006 
Kobori et al, 2003 
Takada & Aggarwal, 2003; 
Rabi et al, 2008 
Shishodia et al, 2003; 
Manu & Kuttan, 2008 
Keifer et al, 2001; 
Ge et al, 2006; 
Carcache de-
Blanco et al, 2007 
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TABLE G-continued 
Examples of NFKB Inhibitors 
Any one or more of tbe following NFKB inhibitors 
Salubrinal 
Pas-associated factor-1 
Interleukin-10 
MC160 (molluscum contagiosum virus) 
Monochloramine and glycine chloramine (NH2C1) 
GS143 
Salmonella Secreted Factor L 
Anetbole 
Anti-tbrombin III 
Artemisia vestita 
Aspirin, sodiwn salicylate 
Azidothymidine (AZT) 
Baoganning 
BAY-11-7082 
(E3((4-metbylphenyl)-sulfonyl)-2-propenenitrile) 
Phosphorylation 
BAY-117083 
(E3((4-t-butylphenyl)-sulfonyl)-2-propenenitrile) 
Phosphorylation 
Benzyl isotbiocyanate 
Black raspberry extracts (cyanidin 3-0-glucoside, cyanidin 
3-0-(2(G)-xylosylrutinoside), cyanidin 
3-0-(2(G)-xylosylrutinoside), cyanidin 3-0-rutinoside) 
Buddlejasaponin IV 
Cacospongionolide B 
Calagualine 
Carbon monoxide 
Carboplatin 
Cardarnonin 
Chorionic gonadotropin 
Cordycepin 
Crassocephalum rabens galactolipid 
Cycloepoxydon; 1-hydroxy-2-
hydroxymetbyl-3-pent-1-enylbenzene 
Cytomegalovirus 
Deem-sin 
Delphinidin 
Dexanab ina 1 
Digitoxin 
Dihydrotestosterone 
Diterpenes (syntbetic) 
Docosahexaenoic acid 
Entamoeba histolytica 
Extensively oxidized low density lipoprotein 
(ox-LDL), 4-Hydroxynonenal (HNE) 
FBD 
FHIT (Fragile histidine triad protein) 
Fructus Ligustrum lucidi 
Gabexate mesilate 
[6]-gingerol; casparol 
Gleditsia sinensis thorns extract 
Gleevec (Imatanib) 
Glossogyne tenuifolia 
Guggulsterone 
4-hydroxy-3 ,6, 7, 8,3 ',4'-hexametboxyflavone 
Hydroquinone 
Ibuprofen 
Indirubin-3'-oxime 
Inonotus obliquus ethanol extract 
Interferon-alpha 
Inhaled isobutyl nitrite 
Kaempferol 
Kushen flavonoids and kurarinone 
Licorce extracts 
Melatonin 
IKK activity/ degradation 
IKK assembly 
Reduced IKKa and IKKb expression 
Reduced IKKa expression 
Oxidizes IkB 
Blocks IkB ubiquitylation 
Blocks IkB ubiquitylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation, IKKbeta 
Phosphorylation 
Phosphorylation 
Pierce et al, 1997 
Pierce et al, 1997 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
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Huang et al, 2011 
Park et al, 2007 
Tabary et al, 2003 
Nichols & Shisler, 2006 
Kim et al, 2005; 
Midwinter et al, 2006 
Naksjima et al, 2008; 
Hirose et al, 2008 
Le Negrate et al, 2008 
Chainy et al, 2000 
Oelschlager et al, 2002 
Sun et al, 2006 
Frantz & O'Neill, 1995; 
Kopp & Ghosh, 1994; 
Yin et al, 1998 
Ghosh et al, 2003; 
Kurokswa et al, 2005 
Tan et al, 2005 
Srivastava & Singh, 2004 
Huang et al, 2002; 
Hecht et al, 2006 
Won et al, 2006 
Posadas et al, 2003 
Manna et al, 2003 
Sarady et al, 2002 
Singh & Bhat, 2004 
Israf et al, 2006 
Manna et al, 2000 
Kim et al, 2006; 
Huang et al., 2007 
Hou et al., 2007 
Gehrt et al, 1998 
Jarvis et al, 2006 
Kim et al, 2006 
Syed et al, 2008 
Juttler et al, 2004 
Srivastava et al, 2004; 
Jagielska et al, 2009 
Xu et al, 2011 
Chao et al, 2005 
Chen et al, 2005; Zand et al, 2008 
Kanunanadiminti & Chadee, 2006 
Brand et al, 1997; Page et al, 1999 
Lin et al, 2008 
Naksgawa & Akao, 2006 
An et al, 2007 
Uchiba et al, 2003 
Kim et al, 2005; Aktan et al, 2006; 
Ishiguro et al, 2007 
Ha et al, 2008 
Wolf et al, 2005 
Wu et al, 2004; Ha et al, 2006 
Shishodia & Aggarwal, 2004 
Lai et al, 2007 
Kerzic et al, 2003 
Palayoor et al, 1998 
Mak et al, 2004 
Kim et al, 2007 
Manna et al, 2000 
Ponnappan et al, 2004 
Garcia-Mediavilla et al, 2006; 
Kim et al 2007 
Han et al, 2006 
Kim et al, 2006: Kwon et al, 2007 
Alonso et al, 2006; 
Tamura et al, 2009 
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TABLE G-continued 
Examples of NFKB Inhibitors 
Any one or more of the following NFKB inhibitors 
Marine natural products (several) 
Methotrexate 
Monochlorarnine 
Nafarnostat mesilate 
Obovatol 
Oleandrin 
Oleanolic acid (Aralia elata) 
Omega 3 fatty acids 
Panduratin A (from Kaempferia pandurata, Zingiberaceae) 
Petrosaspongiolide M 
Pinosylvin 
Plagius flosculosus extract polyacetylene spiroketal 
Phytic acid (inositol hexakisphosphate) 
Pomegranate fruit extract 
Prostaglandin Al 
Protocatechuic Aldehyde 
20(S)-Protopanaxatriol (ginsenoside metabolite) 
Rengyolone 
Rottlerin 
Saikosaponin-d 
Saline (low Na+istonic) 
Salvia miltiorrhizae water-soluble extract 
Sanguinarine (pseudochelerythrine, 
13-methyl-[1 ,3]-benzodioxolo- [5,6-c ]-
1 ,3-dioxolo-4,5phenanthridinium) 
Scoparone 
Sesarninol glucosides 
Shikonins 
Silymarin 
Snake venom toxin (Vipera lebetina turanica) 
SOCS1 
Spilanthol 
Statins (several) 
Sulindac 
THI 52 (1-naphthylethyl-6,7-dihydroxy-
1 ,2,3,4-tetrahydroisoquinoline) 
1 ,2,4-thiadiazolidine derivatives 
Tomatidine 
Vesnarinone 
Xanthoangelol D 
YC-1 
YopJ (encoded by Yersinia pseudotuberculosis) 
Osmotic stress 
Acetaminophen 
Activated Protein C (APC) 
Alachlor 
Allylpyrocatechol 
a-melanocyte-stimulating hormone (a-MSH) 
Arnentoflavone 
Angelica dahurica radix extract 
Apple extracts 
Artemisia capillaris Thunb extract (capillarisin) 
Artemisia iwayomogi extract 
L-ascorbic acid 
Antrodia camphorata 
Au cub in 
Baicalein 
N- (quina lin -8-y 1) benzenesulfonamindes 
beta-lapachone 
Blackberry extract 
IKKb/proteasome 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation/IKK 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation; 
Increased IkBLeung et al, 2005; 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
IKK/Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Deubiquintinase for Ililla; 
Acetylation of IKKbeta 
IkB ubiquitination 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation/proteasome 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
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Folmer et al, 2009 
Majumdar & Aggarwal, 2001; 
Yozai et al 2005 
Omori et al, 2002 
Noguchi et al, 2003 
Lee et al, 2008 
Manna et al, 2000; 
Sreeivasan et al, 2003 
Suh et al, 2007 
Novak et al, 2003 
Yun et al, 2003 
Posadas et al, 2003 
Lee et al, 2006 
Calzada et al, 2005 
Ferry et al, 2002 
Abmed et al, 2005 
Rossi et al, 1997, 2000 
Xu et al, 2011 
Oh et al, 2004; Lee et al, 2005 
Kim et al, 2006 
Kim et al, 2005; 
Torricelli et al, 2008 
Dang et al, 2007 
Tabary et al, 2003 
Kim et al, 2005 
Chaturvedi et al, 1997 
Jang et al, 2005 
Lee et al, 2006 
Nam et al, 2008 
Manna et al, 1999; 
Saliou et al, 1998 
Son et al, 2007 
Kinlyo et al, 2002; 
Nakagawa et al, 2002 
Wu et al, 2008 
Hilgendorff et al, 2003; 
Han et al, 2004; 
Planavila et al, 2005 
Yamamato et al, 1999 
Kang et al, 2003 
Manna et al, 2004 
Chiu & Lin, 2008 
Manna & Aggarwal, 2000; 
Harada et al 2005 
Sugii et al, 2005 
Huang et al, 2005 
Schesser et al, 1998; 
Zhou et al, 2005; 
Mittal et al, 2006; 
Mukherjee & Orth, 2008 
Huangfu et al, 2007 
Mancini et al, 2003 
Yuksel et al, 2002 
Shimomura-Shimizu 
et al, 2005 
Sarkar et al, 2008 
Manna & Aggarwal, 1998 
Banerjee et al, 2002; 
Guruvayoorappan & 
Kuttan, 2007 
Kang et al, 2006 
Yoon & Liu, 2007 
Hong et al, 2004; 
Kim et al, 2007; 
Lee et al, 2007 
Kim et al, 2005 
Han et al, 2004 
Hseu et al, 2005 
Jeong et al, 2002 
Ma et al, 2004 
Xie et al, 2007 
Manna et al, 1999 
Pergola et al, 2006 
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TABLE G-continued 
Examples of NFKB Inhibitors 
Any one or more of tbe following NFKB inhibitors 
1-Bromopropane 
Buchang-tang 
Capsaicin (8-metbyl-N-vanillyl-6-nonenamide) 
Catalposide 
Clerodendron trichotomum Tunberg Leaves 
Clomipramine/imipramine 
Coptidis rhizoma extract 
Cyclolinteinone (sponge sesterterpene) 
DA-9601 (Artemisia asiatica extract) 
Diamide (tyrosine phosphatase inhibitor) 
Dihydroarteanniun 
Dobutarnine 
Docosahexaenoic acid 
E-73 (cycloheximide analog) 
Ecabet sodium 
Electrical stimulation of vagus nerve 
Emodin (3-methyl-1 ,6,8-trihydroxyantbraquinone) 
Ephedrae herba (Mao) 
Equal 
Erbstatin (tyrosine kinase inhibitor) 
Estrogen (E2) 
Etbacrynic acid 
Fludarabine 
Fosfomycin 
Fungal gliotoxin 
Gabexate mesilate 
Gamisanghyulyunbueum 
Genistein (tyrosine kinase inhibitor) 
Genipin 
Glabridin 
Ginsenoside Re 
Glimepiride 
Glucosamine (sulfate or carboxybutyrylated) 
ganuna-glutamylcysteine synthetase 
Glutamine 
Glycochenodeoxycholate 
Guave leaf extract 
Gumiganghwaltang 
Gum mastic 
Heat shock protein-70 
Herbal mixture (Cinnarnomi ramulus, 
Anemarrheriae rhizoma, Officinari rhizoma) 
Hypochlorite 
Ibudilast 
IL-13 
Incensole acetate 
Intravenous immnnoglobulin 
Isomallotochromanol and isomallotochromene 
K1L (Vaccinia virus protein) 
Kochia scoparia fruit (metbanol extract) 
Kummerowia striata (Thunb.) Schindl (etbanol extract) 
Leflunomide metabolite (A77 1726) 
Lidocaine 
LipoxinA4 
Losartan 
Low level laser tberapy 
LY294002 (PI3-kinase inhibitor) 
[2-( 4-morpholinyl)-8-phenylchromone] 
MC159 (Molluscum contagiosum virus) 
Melatonin 
Meloxicarn 
5'-metbylthioadenosine 
Midazolam 
Momordin I 
Morinda officinalis extract 
Mosla dianthera extract 
Mume fructus extract 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation/and various other steps 
Degradation (and DNA binding) 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation; caspase cleavage of IkBa 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation/NF-kB expression 
Degradation 
Degradation 
Degradation of IkBb 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
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Yoshida et al, 2006 
Shin et al, 2005 
Singh et al, 1996; 
Mori et al, 2006; 
Kang et al, 2007 
Kim et al, 2004 
Park & Kim, 2007 
Hwang et al, 2008 
Kim et al, 2007 
D' Acquisto et al, 2000 
Choi et al, 2006 
Toledano & Leonard, 1991; 
Singh & Aggarwal, 1995 
Li et al, 2006 
Loop et al, 2004 
Weldon et al, 2006 
Sugimoto et al, 2000 
Kim et al, 2003 
Guarini et al, 2003 
Kumar et al, 1998; 
Huang et al, 2004 
Aoki et al, 2005 
Kang et al, 2005 
Natarajan et al, 1998 
Sun et al, 1998; 
Kalaitzidis & Gilmore, 2005; 
Steffan et al, 2006 
Han et al, 2004 
Nishioka et al, 2007 
Yoneshima et al, 2003 
Pahl et al, 1999 
Yuksel et al, 2003 
Shin et al, 2005 
Natarajan et al, 1998; 
Baxa & Yoshimura, 2003 
Koo et al, 2004 
Kang et al, 2004 
Zhang et al, 2007 
Schiekofer et al, 2003 
Largo et al, 2003; Rafi et al, 2007; 
Rajapakse et al, 2008 
Manna et al, 1999 
Singleton et al, 2005; 
Fillmann et al, 2007; 
Chen et al, 2008 
Bucher et al, 2006 
Choi et al, 2008 
Kim et al, 2005 
He et al, 2007 
Chan et al, 2004; Shi et al, 2006 
Jeong et al, 2008 
Mohri et al, 2002 
Kiebala & Maggirwar, 1998 
Manna & Aggarwal, 1998 
Moussaieff et al, 2007 
Ichiyama et al, 2004 
Ishii et al, 2003 
Shisler & Jin, 2004 
Shin et al, 2004 
Tao et al, 2008 
Manna & Aggarwal, 1999 
Feng et al, 2007; Lahat et al, 2008 
Zhang et al, 2007 
Chen et al, 2002; Zhu et al, 2007 
Rizzi et al, 2006 
Park et al 2002 
Murao & Shisler, 2005 
Zhang et al, 2004 
Liu et al, 2007 
Hevia et al, 2004 
Kim et al, 2006 
Hwang et al, 2005 
Kim et al, 2005 
Lee et al, 2006 
Choi et al, 2007 
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TABLE G-continued 
Examples of NFKB Inhibitors 
Any one or more of tbe following NFKB inhibitors 
Murrl gene product 
Neurofibromatosis-2 (NF-2; merlin) protein 
Opnntia ficus indica va saboten extract 
Ozone (aqueous) 
Paeony total glucosides 
Pectenotoxin-2 
Penetratin 
Pervanadate (tyrosine phosphatase inhibitor) 
Phenylarsine oxide (PAO, tyrosine phosphatase inhibitor) 
beta-Phenyletbyl (PEITC) and 8-methylsulphinyloctyl 
isotbiocyanates (MSO) (watercress) 
Phenytoin 
c-phycocyanin 
Platycodin saponins 
Polymeric formula 
Polymyxin B 
Poncirus trifoliata fruit extract 
Probiotics 
Pituitary adenylate cyclase-activating polypeptide (PACAP) 
Prostaglandin 15-deoxy-Delta(12,14)-PGJ(2) 
Prodigiosin (Hahella chejuensis) 
PS-341 
Radix asari extract 
Radix clematidis extract 
Resiniferatoxin 
Sabaeksan 
SAIF (Saccharomyces boulardii anti-inflammatory factor) 
Sanguis Draconis 
San-Huang-Xie-Xin-Tang 
Schisandra fructus extract 
Scutellarin 
Sesquiterpene lactones (partbenolide; ergolide; 
guaianolides; alpha-humulene; trans-caryophyllene) 
Sevoflurane/isoflurane 
Siegeskaurolic acid (from Siegesbeckia pubescens root) 
ST2 (IL-l-like receptor secreted form) 
Synadenium carinatum latex lectin 
Taiwanofnngus carnphoratus 
Taurene bromarnine 
Thiopental 
Tipifarnib 
Titaniwn 
TNP-470 (angiogenesis inhibitor) 
Stinging nettle (Urtica dioica) plant extracts 
Trichomomas vaginalis infection 
Triglyceride-rich lipoproteins 
Tussilagone (Farfarae fins) 
U0126 (MEK inhibitor) 
Ursodeoxycholic acid 
Xantbium strumarium L. (metbanol extract) 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation; phosphorylation of IkBa 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation/proteasome 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Degradation 
Yulda-Hanso-Tang Degradation 
Zinc Degradation 
Molluscum contagiosum virus MC159 protein IkBbeta degradation 
Vasoactive intestinal peptide Degradation (and CBP-RelA interaction) 
HIV-1 Vpu protein TrCP ubiquitin ligase inhibitor Bouret al, 2001 
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Ganesh et al, 2003 
Kim et al, 2002 
Lee et al, 2006 
Hutb et al, 2007 
Chen et al, 2007 
Kim et al, 2008 
Letoya et al, 2006 
Singh & Aggarwal, 1995; 
Singh et al, 1996 
Mahboubi et al, 1998; 
Singh & Aggarwal, 1995 
Rose et al, 2005 
Kato et al, 2005 
Cherng et al, 2007 
Aim et al, 2005; Lee et al, 2008 
de Jong et al, 2007 
Jiang et al, 2006 
Shin et al, 2006; Kim et al 2007 
Petrof et al, 2004 
Delgado & Ganea, 2001 
Cuzzocrea et al, 2003; 
Chatterjee et al, 2004 
Huh et al, 2007 
Hideshima et al, 2002 
Song et al, 2007 
Lee et al, 2009 
Singh et al, 1996 
Choi et al, 2005 
Sougioultzis et al 2006 
Choy et al, 2007 
Shih et al, 2007 
Kang et al, 2006; Guo et al, 2008 
Tan et al, 2007 
Behner et al, 1998; 
Whan Han et al, 2001; 
Schorr et al, 2002; 
Medeiros et al, 2007 
Boost et al, 2009 
Park et al, 2007 
Takezako et al, 2006 
Rogerio et al, 2007 
Liu et al, 2007 
Tokunaga et al, 2007 
Loop et al, 2002 
Xue et al, 2005 
Yang et al, 2003 
Mauriz et al, 2003 
Riehemann et al, 1999 
Chang et al, 2004 
Kumwenda et al, 2002 
Lim et al, 2008 
Takaya et al, 2003 
Joo et al, 2004 
Kim et al, 2005; Yoon et al, 2008 
Jeong et al, 2007 
Uzzo et al, 2006; Baa et al, 2006 
Murao & Shisler, 2005 
Delgado & Ganea, 2001; Delgado, 2002 
Epoxyquinone A monomer IKKb/DNA binding Liang et al, 2006 
Ro106-9920 (small molecule) IkBa ubiqutination inhibitor Swinney et al, 2002 
Furonaphtboquinone IKK activity Shin et al, 2006 
13-TrCP Degradation Kanarek et al, 2012 
Inhibitors from IMGENEX: NF-kB Patbway Inhibitory Peptides 
Cat.No 
IMG-2009-2 
IMG-2009-5 
IMG-2000 
Description 
Antennapedia Control Peptide 
Antennapedia Control Peptide 
IKKg NEMO Binding Domain 
(NBD) Inhibitory Peptide Set Functions as an 
IKKa/IKKb decoy by binding to IKKg NBD, 
tbereby preventing formation of tbe IKK 
complex. 
Species 
N!A 
N!A 
H,M,R 
IMG-2000-5 
IMG-2005-5 
IMG-2005-1 
IMG-2004 
IMG-2004-5 
IMG-2001 
IMG-2001-5 
IMG-2003 
IMG-2003-5 
IMG-2006-5 
IMG-2006-1 
IMG-2011 set 
IMG-2002 
IMG-2002-5 
NF kappa B Inhibitors 
9-Metbylstreptimidone 
Z-VRPR-FMK 
2-(1 ,8-naphtbyridin-2-y1 )-Phenol 
5-Aminosalicylic acid 
BAY 11-7082 
BAY 11-7085 
Caffeic acid phenetbyl ester 
Dietbylmaleate 
Etbyl 3,4-Dihydroxycinnamate 
Helenalin 
45 
NFicB Activation Inhibitor II, JSH-23 
NFicB Activation Inhibitor III 
PPM-18 
Pyrrolidinedithiocarbarnic acid arnmoniwn salt 
(R)-MG-132 
Rocaglamide 
Sodium Salicylate 
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TABLE G-continued 
Examples of NFKB Inhibitors 
Any one or more of tbe following NFKB inhibitors 
IKKg NEMO Binding Domain (NBD) 
Inhibitory Peptide Set Functions as an 
IKKa!IKKb decoy by binding to IKKg 
NBD, tbereby preventing formation of 
tbe IKK complex. 
MyD88 Homodimerization Inhibitory 
Peptide Set Functions as a decoy by binding to 
tbe MyD88 TIR domain 
MyD88 Homodimerization Inhibitory Peptide 
Set Functions as a decoy by binding to tbe 
MyD88 TIR domain 
NF-kB p50 (NLS) Inhibitory Peptide Set 
Functions as a p50 decoy by blocking tbe 
intracellular recognition mechanism of 
p50 NLS. 
NF-kB p50 (NLS) Inhibitory Peptide Set 
Functions as a p50 decoy by blocking tbe 
intracellular recognition mechanism of 
p50 NLS. 
NF-kB p65 (Ser276) Inhibitory Peptide Set 
Functions as a p65 decoy tbrough 
phosphorylation of tbe Ser276 site on 
tbe peptide. 
NF-kB p65 (Ser276) Inhibitory Peptide Set 
Functions as a p65 decoy tbrough 
phosphorylation of tbe Ser276 site on tbe 
peptide. 
NF-kB p65 (Ser529/536) Inhibitory Peptide 
Set Functions as a p65 decoy tbrough 
phosphorylation of tbe Ser529/536 sites on 
tbe peptide. 
NF-kB p65 (Ser529/536) Inhibitory Peptide 
Set Functions as a p65 decoy tbrough 
phosphorylation of tbe Ser529/536 sites on 
tbe peptide. 
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H,M,R 
H, M, R,X,Z 
H, M, R,X,Z 
B,C,C,D,H,M, 
R,X 
B,C,C,D,H,M, 
R,X 
C, D, H, M, M, R 
C, D, H, M, M, R 
C, D, H, M, M, R 
C, D, H, M, M, R 
TIRAP Inhibitory Peptide Set Functions as a H, M 
TIRAP decoy by binding to TIR interacting 
domains on specific TLR receptors. 
TIRAP Inhibitory Peptide Set Functions as a H, M 
TIRAP decoy by binding to TIR interacting 
domains on specific TLR receptors. 
TLR4 Peptide Inhibitor Set: VIPER H, M 
TRAF6 Inhibitory Peptide Set Functions as a H, M, R 
TRAF6 decoy by binding to tbe T6DP motif of 
RANK, tbereby preventing binding of 
RANK to TRAF6. 
TRAF6 Inhibitory Peptide Set Functions as a H, M, R 
TRAF6 decoy by binding to tbe T6DP motif of 
RANK, tbereby preventing binding of. 
RANK to TRAF6 
US 9,453,226 B2 
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The presently-disclosed subject matter further includes 
compositions useful for inhibiting NFKB. Such composi-
tions include an inhibitor. As noted above, such inhibitors 
can be, for example, a nucleotide, a polypeptide, a small 
(chemical) molecule, etc. In some embodiments, a compo-
sition can include an isolated RNA molecule. 
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numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±20%, in some embodiments 
The presently-disclosed subject matter further includes 
methods of screening candidate inhibitors to identifY NFKB 
inhibitors. In some embodiments, cell or cell line-based 
methods are used. 
Imaging Caspase in an Eye of a Subject 
In some embodiments, a diagnostic composition is pro-
vided for imaging activated Caspase in an eye of a subject, 
comprising a fluorescent molecule conjugated to a substrate 
±10%, in some embodiments ±5%, in some embodiments 
10 
±1 %, in some embodiments ±0.5%, and in some embodi-
ments ±0.1% from the specified amount, as such variations 
are appropriate to perform the disclosed method. 
of Caspase-1 or a molecule that fluoresces following cleav- 15 
age by Caspase-1. In some embodiments, a method is 
provided for imaging activated Caspase-1 in an eye of a 
subject, including administering (e.g., intraocularly or intra-
venously) to RPE cells of the subject the diagnostic com-
position, and optically monitoring the spatial clustering of 20 
fluorescence. 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 25 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 30 
understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
Some of the polynucleotide and polypeptide sequences 
disclosed herein are cross-referenced to GENBANK®/ 
GENPEPT® accession numbers. The sequences cross-ref- 35 
erenced in the GENBANK®/GENPEPT® database are 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
The presently-disclosed subject matter is further illus-
trated by the following specific but non-limiting examples. 
The following examples may include compilations of data 
that are representative of data gathered at various times 
during the course of development and experimentation 
related to the present invention. 
EXAMPLES 
Example 1 
Alu RNA accumulation due to DICER1 deficiency in the 
retinal pigmented epithelium (RPE) is implicated in geo-
graphic atrophy (GA), an advanced form of age-related 
macular degeneration that causes blindness in millions of 
individuals. The mechanism of Alu RNA-induced cytotox-
expressly incorporated by reference as are equivalent and 
related sequences present in GENBANK®/GENPEPT® or 
other public databases. Also expressly incorporated herein 
by reference are all annotations present in the GENBANK®/ 
GENPEPT® database associated with the sequences dis-
closed herein. Unless otherwise indicated or apparent, the 
references to the GENBANK®/GENPEPT® database are 
references to the most recent version of the database as of 
the filing date of this Application. 
40 icity is unknown. Here it is shown that DICER1 deficit or 
Alu RNA exposure activates the NLRP3 inflammasome and 
triggers TLR-independent MyD88 signaling via IL-18 in the 
RPE. Genetic or pharmacological inhibition of inflam-
masome components (NLRP3, Pycard, Caspase-1), MyD88, 
While the terms used herein are believed to be well 
understood by one of ordinary skill in the art, definitions are 
set forth to facilitate explanation of the presently-disclosed 
subject matter. 
45 or IL-18 prevents RPE degeneration induced by DICER1 
loss or Alu RNA exposure. These findings, coupled with the 
observation that human GA RPE contains elevated amounts 
ofNLRP3, PYCARD and IL-18, and evidence of increased 
Caspase-1 and MyD88 activation, provide a rationale for 
50 targeting this pathway in GA. The findings also reveal a 
novel function of the inflammasome outside the immune 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 55 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer- 60 
ence to "a cell" includes a plurality of such cells, and so 
forth. 
system and a surprising immunomodulatory action of 
mobile elements. 
Age-related macular degeneration (AMD) affects the 
vision of millions of individuals (Smith et a!., 2001 ). AMD 
is characterized by degeneration of the retinal pigmented 
epithelium (RPE), which is situated between the retinal 
photoreceptors and the choroidal capillaries (Ambati et a!., 
2003). RPE dysfunction disrupts both photoreceptors and 
choroidal vasculature (Blaauwgeers et a!., 1999; Lopez et 
a!., 1996; McLeod et a!., 2009; Vogt et a!., 2011). These 
tissue disruptions lead to atrophic or neovascular disease 
phenotypes. Although there are therapies for neovascular 
AMD, there is no effective treatment for the more common 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
65 atrophic form. GA, the advanced stage of atrophic AMD, is 
characterized by degeneration of the RPE, and is the leading 
cause of untreatable vision loss. 
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Recently it was shown that a dramatic and specific 
reduction of the RNase DICER1 leads to accumulation of 
Alu RNA transcripts in the RPE of human eyes with GA 
(Kaneko eta!., 2011). These repetitive element transcripts, 
which are non-coding RNAs expressed by the highly abun- 5 
dant Alu retrotransposon (Batzer and Deininger, 2002), 
induce human RPE cell death and RPE degeneration in 
mice. DICER1 deficit in GA RPE was not a generic cell 
death response because DICER1 expression was not dys-
regulated in other retinal diseases. Likewise, Alu RNA 10 
accumulation did not represent generalized retrotransposon 
activation due to a stress response in dying cells because 
other retrotransposons were not elevated in GA RPE. 
;;,:21-nucleotide fully complementary siRNAs activate TLR3 
on RPE cells (Kleinman et a!., 2011). Lack of TLR3 
activation by Alu RNA is likely due to its complex structure 
containing multiple hairpins and bulges that might preclude 
TLR3 binding. Neither 7SL RNA, the evolutionary precur-
sor of Alu RNA, nor p7SL induced RPE degeneration in WT 
mice (FIGS. SA and SB), suggesting that Alu RNA cyto-
toxicity might be due to as yet unclear structural features. 
pAlu induced RPE degeneration in Unc93b1 mice (FIG. 
lD), which lack TLR3, TLR7, and TLR9 signaling (Tabeta 
et a!., 2006), indicating that these nucleic acid sensors are 
not activated by Alu RNA redundantly. pAlu induced RPE 
degeneration in Tlr4_1_ mice (FIG. lE), and the TLR4 
antagonist Rhodobacter sphaeroides LPS (Qureshi et a!., 
1991) did not inhibit pAlu-induced RPE degeneration in WT 
mice (FIG. SC). Thus the observed RPE cell death is not due 
DICER1 is central to mature microRNA biogenesis (Ber-
nstein et a!., 2001). Yet following DICER1 deficit, the 15 
accumulation of Alu RNA and not the lack of mature 
microRNAs was the critical determinant ofRPE cell viabil-
ity (Kaneko et a!., 2011). Moreover, 7SL RNA, transfer 
RNA, and primary microRNAs do not induce RPE degen-
eration (Kaneko et a!., 2011), ruling out a nonspecific 20 
toxicity of excess, highly structured RNA. Still, the precise 
mechanisms of Alu RNA cytotoxicity are unknown. 
to lipopolysaccharide contamination. Further, two different 
in vitro transcribedAlu RNAs (Kaneko eta!., 2011) did not 
activate multiple TLRs (FIG. lF). 
Next it was tested whether other dsRNA sensors such as 
MDA5 (Kato et a!., 2006) or PKR (encoded by Prkr, (Yang 
et a!., 1995)) might mediate Alu RNA toxicity. However, 
pAlu induced RPE degeneration in Mdas-/- and Prkr_;_ 
mice (FIGS. SD and SE). It was tested whether the 
Although the retina is exceptional for its immune privi-
lege (Streilein, 2003), insults mediated by innate immune 
sensors can result in profound inflammation. The three 
major classes of innate immune receptors include the TLRs, 
RIG-1-like helicases, and NLR proteins (Akira eta!., 2006). 
Numerous innate immune receptors are expressed in the 
RPE (Kumar eta!., 2004 ), and several exogenous substances 
can induce retinal inflammation (Allensworth et a!., 2011; 
Kleiuman et a!., 2012). However, it is not known whether 
this surveillance machinery recognizes or responds to host 
endogenous RNAs. The concept was explored that innate 
immnne machinery, whose canonical function is the detec-
tion of pathogen associated molecular patterns and other 
moieties from foreign organisms, might also recognize Alu 
RNA. 
25 5'-triphosphate on in vitro transcribed Alu RNA, which 
could activate RIG-I or IFIT-1 that sense this moiety (Hor-
nung eta!., 2006; Pichlmair eta!., 2011 ), was responsible for 
RPE degeneration. Dephosphorylated Alu RNA induced 
RPE degeneration in WT mice just as well as Alu RNA not 
30 subjected to dephosphorylation (FIG. SF), indicating that 
this chemical group is not responsible for the observed cell 
death. Indeed a 5'-triphosphate ssRNA that activates RIG-I 
does not induce RPE degeneration in mice (Kleinman eta!., 
2011). Further, pAlu induced RPE degeneration in mice 
35 deficient in MAYS (FIG. SG), through which RIG-I and 
MDA-5 signal (Kumar et a!., 2006; Snn et a!., 2006). 
Collectively these data pointed to a novel mechanism of Alu 
RNA-induced RPE degeneration not mediated by a wide Indeed, it was shown that Alu transcripts can hijack innate 
immunity machinery to induce RPE cell death. Surprisingly, 
the data show that DICER1 deficit or Alu RNA activates the 40 
range of canonical RNA sensors. 
Alu RNA Cytotoxicity is Mediated Via MyD88 and IL-18 
The involvement ofTRIF (encoded by Ticam1), an adap-
tor for TLR3 and TLR4 (Hoebe eta!., 2003; Yamamoto et 
a!., 2003), and MyD88, an adaptor for all TLRs except TLR3 
(Akira et a!., 2006; Alexopoulou et a!., 2001; Suzuki et a!., 
NLRP3 inflammasome in a MyD88-dependent, but TLR-
independent manner. NLRP3 inflammasome activation in 
vivo has been largely restricted to immune cells, although 
the data open the possibility that NLRP3 activity may be 
more widespread, as reflected by examples in cell culture 
studies of keratinocytes (Feldmeyer et a!., 2007; Keller et 
a!., 2008). The data also broaden the scope of DICER1 
function beyond microRNA biogenesis, and identifY it as a 
guardian against aberrant accumulation of toxic retrotrans-
poson elements that comprise roughly 50% of the human 
genome (Lander eta!., 2001). In sum, the findings present a 
novel self-recognition immnne response, whereby endog-
enous non-coding RNA-induced NLRP3 inflammasome 
activation results from DICER1 deficiency in a non-immune 
cell. 
Results 
Alu RNA does not Activate a Variety of TLRs or RNA 
Sensors 
Alu RNA has single-stranded (ss) RNA and double-
stranded (ds) RNA motifs (Sinnett eta!., 1991). Thus it was 
tested whether Alu RNA induced RPE degeneration in mice 
deficient in toll-like receptor-3 (TLR3), a dsRNA sensor 
(Alexopoulou et a!., 2001), or TLR7, a ssRNA sensor 
(Diebold et a!., 2004; Heil et a!., 2004). Subretinal delivery 
of a plasmid coding for Alu RNA (pAlu) induced RPE 
degeneration in Tlr3_1_ and Tlr7_1_ mice just as in wild-type 
(WT) mice (FIGS. lA-C). It was previously shown that 
45 2003) were then tested. Alu RNA induced RPE degeneration 
in Ticam1_1_ mice (FIG. 9A), consistent with findings in 
Tlr3_1_ and Tlr4_1_ mice. Unexpectedly, neither Alu RNA 
nor two different pAlu plasmids induced RPE degeneration 
in Myd88_1_ mice (FIGS. 2A, 9B, and 9C). Intravitreous 
50 delivery of a peptide inhibitor of MyD88 homodimerization 
(Loiarro et a!., 2005) prevented RPE degeneration induced 
by Alu RNA in WT mice, whereas a control peptide did not 
do so (FIG. 2B). A MyD88-targeting short interfering RNA 
(siRNA), which was shorter than 21 nucleotides in length to 
55 prevent TLR3 activation and conjugated to cholesterol to 
enable cell permeation (Kleinman et a!., 2008), but not a 
control siRNA, inhibited RPE degeneration induced by pAlu 
in WT mice (FIGS. 2C-2E). Myd88+1- heterozygous mice 
were protected againstAlu RNA-induced RPE degeneration 
60 (FIGS. 2F and 9D), corroborating the siRNA studies that 
partial knockdown of MyD88 is therapeutically sufficient. 
MyD88-mediated signal transduction induced by inter-
leukins leads to recruitment and phosphorylation of IRAK1 
and IRAK4 (Cao eta!., 1996; Kanakaraj eta!., 1999; Suzuki 
65 et a!., 2003; Suzuki et a!., 2002). Alu RNA increased 
IRAK1/4 phosphorylation in human RPE cells (FIG. 2G), 
supporting the concept that Alu RNA triggers MyD88 sig-
US 9,453,226 B2 
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naling. The MyDSS inhibitory peptide reduced Alu RNA-
induced IRAKl/4 phosphorylation in human RPE cells 
(FIG. 9E), confirming its mode of action. 
Next it was assessed whether MyDSS activation mediates 
Alu RNA-induced cell death in human and mouse RPE cell 5 
52 
(FIGS. 3B and 3C). The Caspase-1-inhibitory peptide 
blockedA!u RNA-induced substrate cleavage in human RPE 
cells (FIG. lOC), confirming its mode of action. Similarly, 
Caspl_;_ mice treated withA!u RNA or pA!u did not exhibit 
RPE degeneration (FIGS. 3D and lOD). Also, pA!u did not 
induce cell death in Caspl_;_ mouse RPE cells (FIG. 3E). 
Caspase-1 can be activated within a multiprotein innate 
immune complex termed the inflammasome (Tschopp eta!., 
2003). The best-characterized inflammasome pathway is one 
culture systems. Consonant with the in vivo data, pA!u 
reduced cell viability in WT but not Mydss-/- mouse RPE 
cells (FIG. 2H). The MyDSS-inhibitory peptide, but not a 
control peptide, inhibited cell death in human RPE cells 
transfected with pA!u (FIG. 2I). Together, these data indicate 
that MyDSS is a critical mediator of Alu RNA-induced RPE 
degeneration. 
10 that is activated by binding of NLRP3 to the caspase-1 
adaptor ASC (encoded by PYCARD). One hallmark of 
inflammasome assembly is spatial clustering of PYCARD 
(Fernandes-Alnemri et a!., 2007). In human RPE cells 
transfected with fluorescent tagged PYCARD (GFP-PY-
MyDSS is generally considered an adaptor of immune 
cells (O'Neill and Bowie, 2007). However, Alu RNA 
induced cell death via MyDSS in RPE monoculture. Thus, it 
was tested whether Alu RNA-induced RPE degeneration in 
mice was also dependent solely on MyDSS activation in 
RPE cells. Conditional ablation of MyDSS in the RPE by 
subretinal injection of AAVl-BESTl-Cre in Mydsgftf mice 
protected against Alu RNA-induced RPE degeneration 20 
(FIGS. 2J and 9F). Consistent with this finding, Alu RNA 
induced RPE degeneration in WT mice receiving Mydss-/-
bone marrow but did not do so in Mydss-/- mice receiving 
WT bone marrow (FIG. 9G). Collectively, these results 
indicate that MyDSS expression in the RPE, and not in 25 
circulating immune cells, is critical for Alu RNA-induced 
RPE degeneration. These findings comport with histopatho-
logical studies of human GA tissue that show no infiltration 
15 CARD), Alu RNA induced the appearance of a brightly 
fluorescent cytoplasmic cluster similar to treatment with 
LPS and ATP, which activates the NLRP3 inflammasome 
(FIGS. 3F and lOE) (Mariathasan et a!., 2006). 
of immune cells in the area of pathology (personal commu-
nication, C. A. Curcio, H. E. Grossniklaus, G. S. Hageman, 30 
L. V. Johnson). 
Although MyDSS is critical in TLR signaling (O'Neill 
and Bowie, 2007), MyDSS activation by Alu RNA was 
independent of TLR activation. Thus, other mechanisms of 
MyDSS involvement were examined. MyDSS can regulate 35 
IFN-y signaling by interacting with IFN-y receptor 1 (en-
coded by Ifngrl) (Sun and Ding, 2006). However, pA!u 
induced RPE degeneration in both Ifng_;_ and Ifngrl_;_ 
Next the functional relevance ofNLRP3 and PYCARD to 
Alu RNA cytotoxicity was tested. Neither pA!u nor Alu 
RNA induced RPE degeneration in either Nlrp3_1_ or 
Pycard_;_ mice (FIGS. 3G, 3H, lOF and lOG), demonstrat-
ing the critical importance of the inflammasome inA!u RNA 
cytotoxicity. Also, pA!u did not induce cell death in Nlrp3 -l-
or Pycard_;_ mouse RPE cells (FIG. 31). Moreover, knock-
down of NLRP3 or PYCARD by siRNAs rescued pAin-
induced human RPE cell death (FIGS. 3J and lOH). These 
findings provide direct evidence that NLRP3 activation in 
response to Alu RNA occurs in RPE cells and does not 
require the presence of other immune cells. 
It was determined that IL-lS and MyDSS activation 
indeed were downstream of Caspase-1 activation by show-
ing (1) that whereas MyDSS inhibition reduced Alu RNA-
induced IRAKl/4 phosphorylation in human RPE cells 
(FIG. 9E), it did not reduce Alu RNA-induced Caspase-1 
cleavage or fluorescent substrate cleavage (FIGS. lOI and 
lOJ); (2) that IL-lS neutralization did not inhibit Alu RNA-
induced Caspase-1 cleavage (FIG. lOK); and (3) that Cas-
pase-1 inhibition reduced Alu RNA-induced phosphory-
lation of IRAKl/4 (FIG. lOL). 
Alu RNA Induces Mitochondrial ROS and NLRP3 Prim-
ing 
NLRP3 inflammasome function requires two signals, the 
first of which is termed priming. pA!u induced inflam-
mice (FIGS. 9H and 9I). MyDSS is also essential in inter-
leukin-1 signaling (Muzio eta!., 1997). Thus, it was tested 40 
whether IL-l~ and the related cytokine IL-lS, both of which 
activate MyDSS (Adachi eta!., 199S), mediated Alu RNA 
cytotoxicity. Interestingly, whereas Alu RNA overexpres-
sion in human RPE cells increased IL-lS secretion, IL-l~ 
secretion was barely detectable (FIG. 2K). 
Recombinant IL-lS induced RPE degeneration in WT but 
not Mydss-/- mice (FIG. 2L). IL-lS neutralization protected 
against pAin-induced RPE degeneration in WT mice, but 
IL-l~ did not (FIGS. 2M and 2N). Also, pA!u induced RPE 
degeneration in Illrl_;_ mice but not Il1Sr1_1_ mice (FIGS. 50 
91 and 9K). These data indicate that IL-lS is an effector of 
Alu RNA-induced cytotoxicity. 
45 masome priming as it upregulated both NLRP3 and ILlS 
mRNAs. This priming occurred equivalently in both WT 
and Mydss-/- mouse RPE cells (FIG. 4A), further corrobo-
rating that MyDSS functions downstream of NLRP3 in this 
Alu RNA Activates the NLRP3 Inflammasome 
It was explored whether Caspase-1 (encoded by Caspl), 
system. Akin to other inflammasome agonists that do not 
directly interact with NLRP3 (Tschopp and Schroder, 201 0), 
a physical interaction between Alu RNA and NLRP3 was 
not observed (FIG. llA). To determine how Alu RNA 
primed the inflammasome, it was studied whether it induced 
reactive oxygen species (ROS) production, a signal for 
55 priming (Bauernfeind et a!., 2011; Nakahira et a!., 2011 ). 
pA!u induced ROS generation in human RPE cells (FIG. 
4B), and the ROS inhibitor diphenyliodonium (DPI) blocked 
pAin-induced NLRP3 and ILlS mRNA upregulation and 
Alu RNA-induced RPE degeneration in WT mice (FIGS. 4C 
a protease that induces maturation of interleukins into bio-
logically active forms (Ghayur eta!., 1997; Gu eta!., 1997; 
Thornberry eta!., 1992), was involved inA!u RNA-induced 
RPE degeneration. Alu RNA treatment of human RPE cells 
led to Caspase-1 activation as measured by western blotting 
and by a fluorescent reporter of substrate cleavage (FIGS. 
3A and lOA). Indeed, Alu RNA induced Caspase-1 activa-
tion in other cell types such as HeLa and THP-1 monocytic 
cells (FIG. lOB), suggesting that Alu RNA cytotoxicity has 
potentially broad implications in many systems. Intravitre-
ous delivery of the Caspase-1-inhibitory peptide Z-WEHD- 65 
FMK, but not a control peptide Z-FA-FMK, blocked IL-lS 
maturation and pAin-induced RPE degeneration in WT mice 
60 and 4D). As DPI blocks mitochondrial ROS and phagosomal 
ROS (Li and Trush, 199S), it was tested which pathway was 
triggered because there is controversy surrounding the 
source of ROS contributing to NLRP3 responses (Latz, 
2010). 
MitoSOX Red was used, which labels ROS-generating 
mitochondria, in combination with MitoTracker Deep Red, 
which labels respiring mitochondria. To monitor phago-
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somal ROS generation, Fe OxyBURST Green was used, 
which measures activation of NADPH oxidase within the 
phagosome. A marked increase in ROS-generating mito-
chondria was observed in human RPE cells transfected with 
pA!u (FIG. 4E). In contrast, whereas phorbol myristate 5 
acetate (PMA) induced phagosomal ROS as expected 
(Savina et a!., 2006), pA!u did not do so (FIG. 4F). These 
data are consistent with the findings that NLRP3 responses 
are impaired by mitochondrial ROS inhibitors (Nakahira et 
a!., 2011; Zhou et a!., 2011) but are preserved in cells 10 
carrying genetic mutations that impair NADPH-oxidase-
dependent ROS production (Meissner et a!., 201 0; van 
Bruggen eta!., 2010). 
Consonant with these reports and the observation that the 
principal source of cellular ROS is mitochondria (Murphy, 15 
2009), it was found that the mitochondria-targeted antioxi-
dants Mito-TEMPO and MitoQ (Murphy and Smith, 2007; 
Nakahira eta!., 2011) both blockedA!u RNA-induced RPE 
degeneration in WT mice, whereas dTPP, a structural analog 
ofMitoQ that does not scavenge mitochondrial ROS, did not 20 
do so (FIG. 4G). In contrast, gp91ds-tat, a cell-permeable 
peptide that inhibits association of two essential NADPH 
oxidase subunits (gp9]Phox and p47phox) (Rey eta!., 2001), 
did not do so (FIG. 4H). Corroborating these data, Alu RNA 
induced RPE degeneration in mice deficient in Cybb (which 25 
encodes gp9]Phox) just as in WT mice (FIG. 4I). Next the 
voltage-dependent anion channels (VDAC) was studied 
because VDAC1 and VDAC2, but not VDAC3, are impor-
tant in mitochondrial ROS produced by NLRP3 activators in 
macrophages (Zhou et a!., 2011). Consistent with these 30 
observations, siRNA knockdown of VDAC1 and VDAC2, 
but not VDAC3, impaired pAin-induced mitochondrial ROS 
(FIGS. 4J and llB) and NLRP3 and ILlS mRNA induction 
in human RPE cells (FIG. 4K). Collectively, these data 
implicate mitochondrial ROS in Alu RNA-induced NLRP3 35 
inflammasome-mediated RPE degeneration. 
Alu RNA does not Induce RPE Degeneration Via Pyrop-
tosis 
Alu RNA activates Caspase-1, which can trigger pyrop-
tosis, a form of cell death characterized by formation of 40 
membrane pores and osmotic lysis (Fink and Cookson, 
2006). The cytoprotective agent glycine, which attenuates 
pyroptosis (Fink et a!., 200S; Fink and Cookson, 2006; 
Verhoef et a!., 2005), inhibited human RPE cells death 
induced by LPS+ATP but not by Alu RNA (FIGS. SA and 45 
SB). Pyroptosis requires Caspase-1 but can proceed inde-
pendent ofiL-1S (Miao eta!., 2010). Thus, the finding that 
IL-1S induced RPE degeneration in Casp1_1_ mice (FIG. 
SC), coupled with the lack of rescue by glycine, suggests 
that Alu RNA-induced RPE degeneration does not occur via 50 
pyroptosis. 
DICER1 Loss Induces Cell Death Via Inflammasome 
It was previously demonstrated that the key role of 
DICER1 in maintaining RPE cell health (Kaneko et a!., 
2011): DICER1-cleaved Alu RNA did not induce RPE 55 
degeneration in vivo; DICER1 overexpression protected 
against Alu RNA-induced RPE degeneration; and DICER1 
loss-induced RPE degeneration was blocked by antagoniz-
ingA!u RNA (Kaneko eta!., 2011). Also, rescue ofDICER1 
knockdown-induced RPE degeneration by Alu RNA inhibi- 60 
tion was not accompanied by restoration of microRNA 
deficits (Kaneko et a!., 2011). Therefore, it was tested 
whether DICER1 also prevented NLRP3 inflammasome 
activation by Alu RNA. Alu RNA-induced Caspase-1 acti-
vation in human RPE cells was inhibited by DICER1 65 
overexpression (FIGS. 6A and 6B). Conversely, Caspase-1 
cleavage induced by DICER1 knockdown in human RPE 
54 
cells was inhibited by simultaneous antisense knockdown of 
Alu RNA (FIGS. 12A and 12B). 
Next the relevance of these pathways was tested in the 
context of DICER1 loss in vivo. Caspase-1 cleavage was 
increased in the RPE of BEST! Cre; Dicer]flf mice (FIG. 
6C), which lose DICER1 expression in the RPE during 
development and exhibit RPE degeneration (Kaneko et a!., 
2011 ). Subretinal delivery of AAV1-BEST1-Cre in Dicer]flf 
mice induced Caspase-1 activation and IL-1S maturation in 
the RPE (FIG. 6D). This treatment also induced RPE degen-
eration, which was blocked by intravitreous delivery of the 
Caspase-1-inhibitory peptide but not the control peptide 
(FIG. 6E). AAV1-BEST1-Cre-induced RPE degeneration in 
Dicer]flf mice was also blocked by intravitreous delivery of 
the MyDSS-inhibitory peptide but not a control peptide 
(FIG. 6F). In addition, MyDSS inhibition prevented cell 
death in human RPE cells treated with antisense oligonucle-
otides targeting DICER1 (FIG. 6G). DICER1 knockdown in 
human RPE cells increased IRAK1/4 phosphorylation, pro-
viding further evidence of MyDSS activation upon loss of 
DICER1 (FIG. 6H). MyDSS inhibition also prevented cell 
death in Dicer1flf mouse RPE cells treated with an adenoviral 
vector coding for Cre recombinase (FIG. 6I). MyDSS inhi-
bition blocked RPE cell death without restoring the micro-
RNA expression deficits induced by Dicerl knockdown 
(FIG. 61). These findings demonstrate that DICER1 is an 
essential endogenous negative regulator of NLRP3 inflam-
masome activation, and that DICER1 deficiency leads to Alu 
RNA-mediated, MyDSS-dependent, microRNA-indepen-
dent RPE degeneration. 
Inflammasome and MyDSS Activation in Human GA 
Next it was tested whether human eyes with GA, which 
exhibit loss of DICER1 and accumulation of Alu RNA in 
their RPE (Kaneko et a!., 2011 ), also display evidence of 
inflammasome activation. The abundance ofNLRP3 mRNA 
in the RPE of human eyes with GA was markedly increased 
compared to control eyes (FIG. 7A). ILlS and ILlB mRNA 
abundance also was increased in GA RPE; however, only the 
disparity in ILlS levels reached statistical significance (FIG. 
7A) Immnnolocalization studies showed that the expression 
of NLRP3, PYCARD, and Caspase-1 proteins was also 
increased in GA RPE (FIGS. 7B-D). Western blot analyses 
corroborated the increased abundance of NLRP3 and 
PYCARD in GA RPE, and revealed greatly increased levels 
of the enzymatically active cleaved Caspase-1 p20 subunit 
in GA RPE (FIG. 7E). There was also an increase in the 
abundance of phosphorylated IRAK1 and IRAK4 in GA 
RPE, indicative of increased MyDSS signal transduction 
(FIG. 7E). Collectively, these data provide evidence of 
NLRP3 inflammasome and MyDSS activation in situ in 
human GA, mirroring the functional data in human RPE cell 
culture and mice in vivo. 
Discussion 
The data establish a functional role for the subversion of 
innate immune sensing pathways by Alu RNA in the patho-
genesis of GA. Collectively, the findings demonstrate that 
the NLRP3 inflammasome senses GA-associated Alu RNA 
danger signals, contributes to RPE degeneration, and poten-
tially vision loss in AMD (FIG. 13). To date, the function of 
the NLRP3 inflammasome has been largely restricted to 
immnne cells in vivo. The finding that it plays a critical 
function in RPE cell survival broadens the cellular scope of 
this inflammasome and raises the possibility that other 
non-immune cells could employ this platform. 
The NLRP3 inflannnasome was originally recognized as 
a sensor of external danger signals such as microbial toxins 
(Kanneganti eta!., 2006; Mariathasan eta!., 2006; Muruve 
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et a!., 2008). Subsequently, endogenous crystals, polypep-
tides, and lipids were reported to activate it in diseases such 
56 
enticing therapeutic target. A potential concern is its impor-
tant anti-microbial function in mice (O'Neill and Bowie, 
2007). However, in contrast to Myd88_1_ mice, adult 
humans with MyD88 deficiency are described to be gener-
ally healthy and resistant to a wide variety of microbial 
pathogens (von Bernuth et a!., 2008). MyD88-deficient 
humans have a narrow susceptibility range to pyogenic 
bacterial infections, and that too only in early childhood and 
not adult life (Picard eta!., 201 0). Moreover, as evident from 
as gout, atherogenesis, Alzheimer disease, and Type 2 dia-
betes (Halle eta!., 2008; Masters eta!., 2010; Muruve eta!., 
2008; Wen eta!., 2011). To the knowledge, Alu RNA is the 5 
first endogenous nucleic acid known to activate this immune 
platform. The findings expand the diversity of endogenous 
danger signals in chronic human diseases, and comport with 
the concept that this inflammasome is a sensor of metabolic 
danger (Schroder eta!., 2010). 
Dampening inflammasome activation can be essential to 
limiting the inflammatory response. Pathogens have evolved 
many strategies to inhibit inflammasome activation (Marti-
non et a!., 2009). Likewise, host autophagy proteins (Naka-
hira eta!., 2011), Type I interferon (Guarda eta!., 2011), and 15 
T cell contact with macrophages can inhibit this process 
(Guarda eta!., 2009). The finding that DICERl, through its 
cleavage of Alu RNA, prevents activation ofNLRP3 adds to 
the repertoire of host inflammasome modulation capabilities 
and reveals a new facet of how dysregulation of homeostatic 20 
anti-inflammatory mechanisms can promote AMD (Ambati 
10 the siRNA and Myd88+1- studies, partial inhibition of 
MyD88 is sufficient to protect against Alu RNA. Localized 
intraocular therapy, the current standard of care in most 
retinal diseases, would further limit the likelihood of adverse 
et a!., 2003; Takeda et a!., 2009). 
Added to its recently described anti-apoptotic and tumor-
related functions, DICERl emerges as a multifaceted pro-
tein. It remains to be determined how this functional versa- 25 
tility is channeled in various states. As DICERl 
dysregulation is increasingly recognized in several human 
diseases, it is reasonable to imagine that Alu RNA might be 
an inflammasome activating danger signal in those condi-
tions too. It is also interesting that, at least in adult mice and 30 
in a variety of mouse and human cells, the microRNA 
biogenesis function of DICERl is not critical for cell 
survival, at least in a MyD88-deficient environment (data 
not shown). 
The data that mitochondrial ROS production is involved 35 
in Alu RNA-induced RPE degeneration comport with obser-
vations of mitochondrial DNA damage (Lin et a!., 2011 ), 
downregulation of proteins involved in mitochondrial 
energy production and trafficking (Nordgaard et a!., 2008), 
and reduction in the number and size of mitochondria (Feher 40 
et a!., 2006) in the RPE of human eyes with AMD. Jointly, 
these findings suggest a potential therapeutic benefit to 
interfering with mitochondrial ROS generation. 
Current clinical programs targeting the inflammasome 
largely focus on IL-l~; presently there are no IL-18 inhibi- 45 
tors in registered clinical trials. However, the data indicate 
that IL-18 is more important than IL-l~ in mediating RPE 
cell death in GA (similar to selective IL-18 involvement in 
a colitis model (Zaki eta!., 2010)), pointing to the existence 
infectious outcomes. It is reasonable to foresee development 
of MyD88 inhibitors for prevention or treatment of GA. 
Experimental Procedures 
Subretinal injection and imaging. Subretinal injections (1 
f.LL) were performed using a Pi co-Injector (PLI -100, Harvard 
Apparatus). Plasmids were transfected in vivo using 10% 
Neuroporter (Genlantis). Fundus imaging was performed on 
a TRC-50 IX camera (Topcon) linked to a digital imaging 
system (Sony). RPE flat mounts were immunolabeled using 
antibodies against zonula occludens-1 (Invitrogen). 
mRNA Abundance. 
Transcript abundance was quantified by real-time RT-
PCR using an Applied Biosystems 7900 HT Fast Real-Time 
PCR system by the 2-Mct method. 
Protein Abundance and Activity. 
Protein abundance was assessed by Western blot analysis 
using antibodies against Caspase-1 (1:500; Invitrogen), 
piRAKl (1:500; Thermo Scientific), piRAK4 (1:500, Abb-
omax), PYCARD (1:200, Santa Cruz Biotechnology), 
NLRP3 (1:500, Enzo Life Sciences) and Vinculin (1:1,000; 
Sigma-Aldrich). Caspase-1 activity was visualized using 
Caspaluxl ElD2 (Oncolmmnnin) according to manufactur-
er's instructions. 
Mice. 
All animal experiments were approved by institutional 
review committees and in accordance with the Association 
for Research in Vision and Ophthalmology Statement for the 
Use of Animals in Ophthalmic and Visual Research. Wild-
type C57BL/6J, Cybb-1-, Tlr3_ 1_, Tlr4_1_ (C57BL/10ScNJ), 
Trir1- (Ticaml Lps2 ) Ifng_;_ Ifngrl_;_ Illrl_ 1_ Il18rl_ 1 _ 
Myd8sft--'; and Dic~r]flf mi~e were ;urchased' from Th~ 
Jackson Laboratory. Caspl- 1-, Nbp3_1_, and Pycard_;_ mice 
have been previously described (Kanneganti et a!., 2006). 
Unc93bl mutant mice were generously provided by B. A. 
Beutler via K. Fitzgerald. Myd88_1_ and Tlr7_1_ mice were 
generously provided by S. Akira via T. Hawn and D. T. 
Golenbock. Mda5_1_ mice were generously provided by M. 
Colonna. mice were generously provided by B. R. Williams 
and R. L. Silverman. Mavs_;_ mice were generously pro-
vided by Z. Chen via K. Fitzgerald. For all procedures, 
anesthesia was achieved by intraperitoneal injection of 100 
of regulatory mechanisms by which inflammasome activa- 50 
tion bifurcates at the level of or just preceding the interleukin 
effectors. Although Caspase-1 inhibition could be an attrac-
tive local therapeutic strategy, caspase inhibitors can pro-
mote alternative cell death pathways, possibly limiting their 
utility (Vandenabeele et a!., 2006). 55 mg/kg ketamine hydrochloride (Ft. Dodge Animal Health) 
and 10 mg/kg xylazine (Phoenix Scientific), and pupils were 
dilated with topical 1% tropicamide (Alcon Laboratories). 
MyD88 is best known for transducing TLR signaling 
initiated by pathogen associated molecular patterns (O'Neill 
and Bowie, 2007), although recently it has been implicated 
in human cancers (Ngo eta!., 2011; Puente eta!., 2011 ). The 
findings introduce an unexpected new function for MyD88 60 
in effecting death signals from mobile element transcripts 
that can lead to retinal degeneration and blindness, and raise 
the possibility that MyD88 could be a central integrator of 
signals from other non-NLRP3 inflammasomes that also 
employ Caspase-1 (Schroder and Tschopp, 2010). Since 65 
non-canonical activation of MyD88 is a critical checkpoint 
in RPE degeneration in GA (FIG. 13), it represents an 
Fundus Photography. 
Retinal photographs of dilated mouse eyes were taken 
with a TRC-50 IX camera (Topcon) linked to a digital 
imaging system (Sony). 
Human Tissue. 
Donor eyes or ocular tissues from patients with geo-
graphic atrophy due to AMD or age-matched patients with-
out AMD were obtained from various eye banks. These 
diagnoses were confirmed by dilated ophthalmic examina-
tion prior to acquisition of the tissues or eyes or upon 
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f.LL with a 33-gauge Exmire microsyringe (Ito Corporation). 
To assess the effect of MyDSS blockade on pAin-induced 
RPE degeneration, 1 f.LL of cholesterol ( chol) conjugated 
MyDSS siRNA (17+2 nt; 2 flg/flL) was intravitreously 
examination of the eye globes post mortem. The study 
followed the guidelines of the Declaration of Helsinki. 
Institutional review boards granted approval for allocation 
and histological analysis of specimens. 
Immunolabeling. 
Human eyes fixed in 2-4% paraformaldehyde were pre-
pared as eyecups, cryoprotected in 30% sucrose, embedded 
5 injected 1 day after pA!u injection. As a control, Luc 
siRNA-chol (17 +2 nt) was used with identical dosages. 
in optimal cutting temperature compound (Tissue-Tek OCT; 
Sakura Finetek), and cryosectioned into 10 f.Ull sections. 
Depigmentation was achieved using 0.25% potassium per- 10 
manganate and 0.1% oxalic acid. Immunohistochemical 
staining was performed with the rabbit antibody against 
NLRP3 (1:100, Sigma Aldrich) or rabbit antibody against 
Caspase-1 (prediluted, AbCam). Isotype IgG was substituted 
for the primary antibody to assess the specificity of the 15 
staining. Bound antibody was detected with biotin-conju-
gated secondary antibodies, followed by incubation with 
ABC reagent and visualized by Vector Blue (Vector Labo-
ratories). Levamisole (Vector Laboratories) was used to 
block endogenous alkaline phosphatase activity. Slides were 20 
washed in PBS, counterstained with neutral red (Fisher 
Scientific), rinsed with deionized water, air dried, and then 
mounted in Vectamount (Vector Laboratories). Fluorescent 
labeling of human tissue was performed with the rabbit 
antibody against PYCARD (1:50, Clone N-15, Santa Cruz 25 
Biotechnology) Immunolabeling was visualized by fluores-
cently conjugated anti-rabbit secondary antibody (Invitro-
gen). Tissue autofluorescence was quenched by incubating 
the sections in 0.3% Sudan black (Fisher Scientific). Sec-
tions were mounted in Vectashield with DAPI (Vector Labo- 30 
ratories). Mouse RPE/choroid flat mounts were fixed with 
4% paraformaldehyde or 100% methanol, stained with rab-
bit antibodies against human zonula occludens-1 (1: 100, 
Invitrogen) and visualized with Alexa594 (Invitrogen). All 
images were obtained using the Leica SP-5 or Zeiss Axio 35 
Observer Zl microscopes. 
Subretinal Injection. 
Subretinal injections (1 f.LL) in mice were performed using 
a Pica-Injector (PLI-100, Harvard Apparatus). In vivo trans-
fection of plasmids coding for two different Alu sequences 40 
(pA!u) or empty control vector (pNull) (Bennett eta!., 200S; 
Kaneko eta!., 2011; Shaikh eta!., 1997) was achieved using 
10% Neuroporter (Genlantis). AAVl-BESTl-Cre (Alexan-
der and Hauswirth, 200S) or AAVl-BESTl-GFP were 
injected at l.Oxl011 pfu/mL and in vitro transcribed Alu 45 
RNA was injected at 0.3 mg/mL. 
Drug Treatments. 
siRNAs formulated in siRNA buffer (20 mM KCL, 0.2 
mM MgCI2 in HEPES buffer at pH 7.5; Dharmacon) or 
phosphate buffered saline (PBS; Sigma-Aldrich); the TLR4 50 
antagonist Ultra Pure Rhodobacter sphaeroides LPS (LPS-
RS, InvivoGen), a peptide inhibitor of MyDSS homodi-
merization IMG-2005 (IMGENEX), control inhibitor (IM-
GENEX), recombinant IL-lS (Medical & Biological 
Laboratories), neutralizing rat antibodies against mouse 55 
IL-l~ (IMGENEX), neutralizing rat antibodies against 
mouse IL-lS (Medical & Biological Laboratories), isotype 
control IgGs (R&D Systems or eBioscience as appropriate), 
Caspase-1 inhibitor Z-WEHD-FMK (R&D Systems), Cas-
pase control inhibitor Z-FA-FMK (R&D Systems), DPI 60 
(Enzo Life Sciences), Mito-TEMPO (Enzo Life Sciences), 
MitoQ and dTPP (both adsorbed to cyclodextrin and pro-
vided by M.P. Murphy, MRC Mitochondrial Biology Unit), 
and gp91ds-tat and scrambled gp91 ds-tat (both Anaspec), 
were dissolved in phosphate buffered saline (PBS; Sigma- 65 
Aldrich) or dimethyl sulfoxide (DMSO; Sigma-Aldrich), 
and injected into the vitreous humor in a total volume of 1 
Bone Marrow Chimeras. 
Bone marrow transplantation was used to create 
Mydss-/- chimera mice wherein the genetic deficiency of 
MydSS was confined to either circulating cells 
(Mydss-/- ~WT) or nonhematopoietic tissue 
(WT ~Mydss-1-). Briefly, bone marrows were collected 
from femur and tibia of congenic WT or Mydss-/- donor 
mice by flushing with RPMI1640. After two washing steps, 
cells were resuspended in RPMI1640. lxl07 cells in 150 flL 
of RPMI1640 were injected into the tail vein of irradiated 
donor mice. Two chimera groups were generated: 
WT ~ Mydss-/- (WT cells into Mydss-/- mice) and 
Mydss~wT (MydSS cells into WT mice). 2 months after 
bone marrow transfer, mice were injected subretinally with 
Alu RNA, vehicle, pA!u, or pNull, and monitored for RPE 
degeneration 7 days later. 
Real-Time PCR. 
Total RNA was extracted from tissues or cells using Trizol 
reagent (Invitrogen) according to manufacturer's recom-
mendations, DNase treated and reverse transcribed (Quan-
tiTect, Qiagen). The RT products (eDNA) were amplified by 
real-time quantitative PCR (Applied Biosystems 7900 HT 
Fast Real-Time PCR system) with Power SYBR green 
Master Mix. Oligonucleotide primers specific for human 
ILlB (forward 5'-TTAAAGCCCGCCTGACAGA-3' and 
reverse 5'-GCGAATGACAGAGGGTTTCTTAG-3'), 
human ILlS (forward 5'-ATCACTTGCACTCCGGAG-
GTA-3' and reverse 5'-AGAGCGCAATGGTGCAATC-3'), 
human NLRP3 (forward 5'-GCACCTGTTGTGCAATCT-
GAA-3' and reverse 5'-TCCTGACAACATGCTGAT-
GTGA-3'), human PYCARD (forward 5'-GCCAGGCCTG-
CACTTTATAGA-3' and reverse 
5'-GTTTGTGACCCTCGCGATAAG-3'), human VDACl 
(forward 5'-ACTGCAAAATCCCGAGTGAC-3' and 
reverse 5'-CTGTCCAGGCAAGATTGACA-3'), human 
VDAC2 (forward 5'-CAGTGCCAAATCAAAGCTGA-3' 
and reverse 5'-CCTGATGTCCAAGCAAGGTT-3'), human 
VDAC3 (forward 5'-TTGACACAGCCAAATCCAAA-3' 
and reverse 5'-GCCAAAACGGGTGTTGTTAC-3'), human 
ISS rRNA (forward 5'-CGCAGCTAGGAATAATG-
GAATAGG-3' and reverse 5'-GCCTCAGTTCCGAAAAC-
CAA-3'), mouse MydSS (forward 5'-CACCTGTGTCTG-
GTCCATTG-3' and reverse 
5'-AGGCTGAGTGCAAACTTGGT-3'), mouse Nlrp3 (for-
ward 5'-ATGCTGCTTCGACATCTCCT-3' and reverse 
5'-AACCAATGCGAGATCCTGAC-3'), mouse IllS (for-
ward 5'-GACAGCCTGTGTTCGAGGAT-3' and reverse 
5'-TGGATCCATTTCCTCAAAGG-3'), and mouse ISS 
rRNA (forward 5'-TTCGTATTGCGCCGCTAGA-3' and 
reverse 5'-CTTTCGCTCTGGTCCGTCTT-3') were used. 
The QPCR cycling conditions were 50° C. for 2 min, 95° C. 
for 10 min followed by 40 cycles of a two-step amplification 
program (95° C. for 15 s and 5S° C. for 1 min). At the end 
of the amplification, melting curve analysis was applied 
using the dissociation protocol from the Sequence Detection 
system to exclude contamination with unspecific PCR prod-
ucts. The PCR products were also confirmed by agarose gel 
and showed only one specific band of the predicted size. For 
negative controls, no RT products were used as templates in 
the QPCR and verified by the absence of gel-detected bands. 
Relative expressions of target genes were determined by the 
2-M.ct method. 
US 9,453,226 B2 
59 
miRNA Quantification. 
Total RNA containing miRNAs was polyadenylated and 
reverse transcribed using universal primer using the All-In-
One miRNA q-RT-PCR Detection Kit (GeneCopoeia) 
according to the manufacturer's specifications using a uni- 5 
versa! reverse primer in combination with the following 
forward primers: mouse miR-184 (5'-TGGACGGA-
GAACTGATAAGGGT-3'); mouse miR-221/222 (5'-AGC-
TACATCTGGCTACTGGGT-3'); mouse miR-320a (5'-
AAAAGCTGGGTTGAGAGGGCGA-3'), and mouse miR- 10 
484 (5'-TCAGGCTCAGTCCCCTCCCGAT-3'). miRNA 
levels were normalized to levels of U6 snRNA (5'-AAAT-
TCGTGAAGCGTTCC-3') using the 2-Mct method. Detec-
tion was achieved by SYBR green qPCR with the following 
conditions: 95° C. for 10 min followed by 40 cycles of 95° 15 
C. for 10 s, 60° C. for 20 sand 72o C. for 20 s. Amplicon 
specificity was assessed by melt curve analysis and unique 
bands by agarose gel electrophoresis. 
Western Blotting. 
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yields single stranded RNAs that fold into a defined sec-
ondary structure identical to Pol III derived transcripts. 
Where indicated, transcribed RNA was dephosphorylated 
using calf intestine alkaline phosphatase (Invitrogen) and 
repurified by Phenol:Chloroform:Isoamyl alcohol precipita-
tion. 
Transient Transfection. 
Human or mouse RPE cells were transfected with pUC19, 
pA!u, pcDNA3.1/Dicer-FLAG, pcDNA3.1, Alu RNA, 
NLRP3 siRNA sense (5'-GUUUGACUAUCU-
GUUCUdTdT-3'), PYCARD siRNA sense (5'-GAAGCUC-
UUCAGUUUCAdTdT-3'), MyD88 siRNA sense (sense: 
5'-CAGAGCAAGGAAUGUGAdTdT-3'), VDAC1 siRNA 
sense (5'-CGGAAUAGCAGCCAAGUdTdT-3'), VDAC2 
siRNA sense (5'-CCCUGGAGUUGGAGGCUdTdT-3'), 
VDAC3 siRNA sense (5'-GCUUUAAUC-
GAUGGGAAdTdT-3'), DICER1 antisense oligonucleotide 
(AS) (5'-GCUGACCTTTTTGCTUCUCA-3'), control (for 
DICER1) AS (5'-TTGGTACGCATACGTGTTGACT-
GTGA-3'), Alu AS (5'-CCCGGG-
TTCACGCCATTCTCCTGCCTCAGCCTCACGAGTAG-
CTGGGACTACAGGCGCCCGACACCACTCCCG-
GCTAATTTTTTGTATTTTT-3'), control (for Alu) AS (5'-
GCATGGCCAGTCCATTGATCTTGCACGCTTGCCTA-
GTACGCTCCTCAACCTATCCTCCTAGCCCGTTAC~ 
TGGTGCCACCGGCG-3') using Lipofectamine 2000 (In-
vitrogen) according to the manufacturer's instructions. 
Adenoviral Infection. 
Cells were plated at density of 15x103/cm2 and after 16 h, 
at approximately 50% confluence, were infected withAdCre 
or AdNull (Vector Laboratories) with a multiplicity of 
infection of 1 ,000. 
Cell Viability. 
MTS assays were performed using the Cell Titer 96 AQue-
ous One Solution Cell Proliferation Assay (Promega) 
according to the manufacturer's instructions. For examining 
Tissues or cells were homogenized in lysis buffer (1 0 mM 20 
Tris base, pH 7.4, 150 mM NaCI, 1 mM EDTA, 1 mM 
EGTA, 1% Triton X-100, 0.5% NP-40, protease and phos-
phatase inhibitor cocktail (Roche)). Protein concentrations 
were determined using a Bradford assay kit (Bio-Rad) with 
bovine serum albumin as a standard. Proteins ( 40-1 00 flg) 25 
were run on NuPAGE Bis-Tris gels (Invitrogen) and trans-
ferred to Immun-Blot PVDF membranes (Bio-Rad). Cells 
were scraped in hot Laemmli buffer (62.5 mM Tris base, pH 
6.8, 2% SDS, 5% 2-Mercaptoethanol, 10% Glycerol, 0.01% 
Bromophenol Blue). Samples were boiled and run on 4-20% 30 
NuPAGE Tris-Glycine gels (Invitrogen). The transferred 
membranes were blocked for 1 h at RT and incubated with 
antibodies against human Caspase-1 (1:500; Invitrogen), 
mouse Caspase 1 (1:500; MBL), NLRP3 (1: 1000; Enzo Life 
Sciences), PYCARD (1:1000, RayBiotech), phospho-
IRAK1 (S376) (1:500, Thermo Scientific), phospho-IRAK4 
(T345) (1:500, AbboMax), DICER1 (1:2,000; Bethyl), 
MyD88 (1:1,000; Cell Signaling), and mouse IL-18 (1:200; 
MBL) at 4° C. overnight. Protein loading was assessed by 
immunoblotting using an anti-Vinculin antibody (1:1,000; 
Sigma-Aldrich). The secondary antibodies were used (1 :5, 
000) for 1 h at RT. The signal was visualized by enhanced 
chemiluminescence (ECL plus) and captured by Vision-
WorksLS Image Acquisition and Analysis software (Version 
6.7.2, UVP, LLC). 
35 the cytoprotective effect of glycine in Alu RNA induced cell 
death, human RPE cells were transfected with pNull/pA!u. 
At 6 h post-transfection the cells were incubated with 
complete media containing glycine (5 mM) or vehicle, and 
cell viability was assessed after 24 h. Similarly, human RPE 
Cell Culture. 
All cell cultures were maintained at 37° C. and 5% C02 . 
40 cells primed with LPS (5 flg/ml for 6 h) were treated with 
ATP (25 f.LM) in the presence of glycine containing media (5 
mM). 30 min post ATP cell viability was assessed as 
described above. 
Caspase-1 activity. Caspase-1 activity was visualized by 
45 incubating cells with Caspalux1E1D2 reagent (Oncolm-
munin) according to the manufacturer's instructions. 
Caspalux1E1D2 signal was quantified reading the fluores-
cence (excitation 552 nm, emission 580 nm) using a Synergy 
4 reader (Biotek). Quantification of fluorescence from 
Primary mouse RPE cells were isolated as previously 
described (Yang eta!., 2009) and grown in Dulbecco Modi-
fied Eagle Medium (DMEM) supplemented with 20% FBS 
and standard antibiotics concentrations. Primary human 
RPE cells were isolated as previously described (Yang et a!., 
2008) and maintained in DMEM supplemented with 10% 
FBS and antibiotics. HeLa cells were maintained in DMEM 
supplemented with 20% FBS and standard antibiotics con- 55 
centrations. THP-1 cells were cultured in RPMI 1640 
50 images was performed by converting images into grayscale 
in Adobe Photoshop CSS, and measuring the integrated 
density of black and white images using ImageJ software 
(NIH) (Bogdanovich et a!., 2008). 
ROS Production. 
Cellular ROS production was assessed using the ROS-
specific probe 2'7'-dichlorodihydrofluorescin diacetate 
(H2 DCFDA, BioChemica, Fluka). Mitochondrial ROS pro-
duction was assessed using MitoSOX™ Red (Invitrogen). 
Sub-confluent human RPE cells were transfected with pNull 
medium supplemented with 10% FBS and antibiotics. 
In vitro transcription of Alu RNAs. Two Alu RNAs were 
synthesized: a 281 nt Alu sequence originating from the 
eDNA clone TS 103 (Shaikh eta!., 1997) and a 302 nt Alu 
sequence isolated from the RPE of a human eye with 
geographic atrophy. Linearized plasmids containing these 
Alu sequences with an adjacent 5' T7 promoter were sub-
jected to AmpliScribe™ T7 -Flash™ Transcription Kit (Epi-
centre) according to the manufacturer's instructions. DN ase-
treated RNA was purified using MEGAclear™ (Ambion), 
and integrity was monitored by gel electrophoresis. This 
60 or pA!u. After 24 h cells were loaded for 10 min at 37° C. 
with 10 f.LM H2 DCFDA or MitoSOX™ Red (Invitrogen) 
mitochondrial superoxide indicator for live-cell imaging and 
washed twice with PBS. For H2 DCFDA, fluorescence was 
recorded in 96-well plate using with a Synergy 4 reader 
65 (Biotek) using a FITC filter (excitation 485 nm, emission 
538 nm). To visualize respiring mitochondria for colocal-
ization with the mitochondrial ROS signal, after PBS wash 
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cells were incubated with MitoTracker Deep Red™ (Invit-
rogen) for 30 min at 37° C. and then washed twice with PBS. 
The fluorescent signals were detected using Leica SP-5 or 
Zeiss Axio Observer Zl microscopes. Phagosomal ROS 
production was assessed using the Fc-OXYBURST Green™ 5 
assay (Invitrogen). Sub-confluent human RPE cells were 
transfected with pNull or pA!u, or treated with PMA (0.5 
flg/ml; Sigma-Aldrich). The cells were incubated with 
Krebs-Ringer's PBS (KRP) at 37° C. for 20 min before 
adding Fc-OXYBURST Green™. The total fluorescence 10 
from the cells was measured immediately after adding 
Fc-OXYBURST Green™ with a Synergy 4 reader (Biotek) 
using FITC filter (excitation 485 nm, emission 538 nm). 
RNA-Binding Protein Immunoprecipitation (RIP): 
The physical interaction between NLRP3 and Alu RNA 15 
was examined using RNA ChiP-IT kit following the manu-
facturer's instructions (Active Motif). Briefly, human RPE 
cells were transfected with pA!u and pNLRP3-FLAG (pro-
vided by G. NUiiez) and the protein-RNA complexes were 
immunoprecipitated with antibodies against NLRP3 (Enzo 20 
Life Sciences), FLAG (Sigma-Aldrich) or control IgG 
(Sigma-Aldrich). RNA isolated from these immunoprecipi-
tates was analyzed by real-time RT-PCR using Alu-specific 
62 
of Fas (encoded by CD95) or FasL (encoded by Fasig) 
would inhibit RPE cell death or degeneration induced by Alu 
RNA, pA!u, or IL-18. It was found that neither pA!u (FIG. 
18) nor Alu RNA (FIG. 19) induced RPE degeneration in 
CD95-/- (Fas1P') mice. In addition, recombinant IL-18 also 
did not induce RPE degeneration in CD95-/- (Fas1P) mice 
(FIG. 20). Likewise, pA!u (FIG. 21), Alu RNA (FIG. 22), 
and IL-18 (FIG. 23) did not induce RPE degeneration in 
Fasig-/- (Faslg1d) mice. 
It has been shown that Alu RNA induces RPE degenera-
tion via the NLRP3 inflammasome. Because NF-KB activa-
tion is required for NLRP3 activation (Bauernfeind et a!. 
2009; Qiao et a!. 2012), it was tested whether Alu RNA 
required NF-KB to induce RPE degeneration. Indeed, it was 
found that Alu RNA did not induce RPE degeneration in 
Nfkbl-/- mice, confirming that NF-KB activation is a 
critical step in this cell death pathway. 
Experimental Procedures 
Mice. 
All animal experiments were approved by institutional 
review committees and in accordance with the Association 
for Research in Vision and Ophthalmology Statement for the 
Use of Animals in Ophthalmic and Visual Research. Wild-
type C57BL/6J, Fas_;_ (a.k.a CD95 or Fas1P) Fasig_;_ (a.k.a. primers. 
ELISA. 
Secreted cytokine content in conditioned cell culture 
media was analyzed using the Human IL-l~ and IL-18 
ELISA Kits (R&D) according to the manufacturer's instruc-
tions. 
25 Fasg1d) and Nfkbl_;_ mice were purchased from The Jackson 
Laboratory. For all procedures, anesthesia was achieved by 
intraperitoneal injection of 100 mg/kg ketamine hydrochlo-
ride (Ft. Dodge Animal Health) and 10 mg/kg xylazine 
(Phoenix Scientific), and pupils were dilated with topical!% 
TLR Screen. 30 tropicamide (Alcon Laboratories). 
A custom TLR ligand screen was performed by Invivo-
Gen using HEK293 cells over-expressing individual TLR 
family members coupled with an AP-1/NF-KB reporter 
system. Cells were stimulated with each of two Alu RNAs 
synthesized by in vitro transcription, or a TLR-specific 35 
positive control ligand. 
Statistics. 
Fundus Photography. 
Retinal photographs of dilated mouse eyes were taken 
with a TRC-50 IX camera (Topcon) linked to a digital 
imaging system (Sony). 
Subretinal Injection. 
Subretinal injections (1 f.LL) in mice were performed using 
a Pica-Injector (PLI-100, Harvard Apparatus). In vivo trans-
fection of plasmids coding for two different Alu sequences 
(pA!u) or empty control vector (pNull) (Bennett eta!., 2008; 
Results are expressed as mean±SEM, with p<0.05 con-
sidered statistically significant. Differences between groups 
were compared by using Mann-Whitney U test or Student 
t-test, as appropriate, and 2-tailed p values are reported. 
40 Kaneko eta!., 2011; Shaikh eta!., 1997) was achieved using 
10% Neuroporter (Genlantis). In vitro transcribedA!u RNA 
was injected at 0.3 mg/mL. 
Example 2 Drug Treatments. 
Recombinant IL-18 (Medical & Biological Laboratories), 
It was shown that both in vitro transcribed Alu RNA and 
a plasmid encoding Alu (pA!u) both induce RPE cell death 
by inducing IL-18 secretion, which triggers MyD88-depen-
dent signaling that leads to Caspase-3 activation. Determine 
the intervening mechanistic steps in this cell death pathway 
were sought. 
45 Caspase-8 inhibitor Z-IETD-FMK (R&D Systems), Caspase 
control inhibitor Z-FA-FMK (R&D Systems), IRAKl/4 
inhibitor (Calbiochem), were dissolved in phosphate buff-
ered saline (PBS; Sigma-Aldrich) or dimethyl sulfoxide 
(DMSO; Sigma-Aldrich), and injected into the vitreous 
Caspase-8 is known to activate Caspase-3 (Stennicke et 
a!. 1998). Therefore, it was tested whether Caspase-8 inhi-
bition would inhibit RPE cell death or degeneration induced 
50 humor in a total volume of 1 f.LL with a 33-gauge Exmire 
microsyringe (Ito Corporation). 
by Alu RNA or pA!u. It was found that the Caspase-8 
inhibitory peptide Z-IETD-FMK, but not the control peptide 55 
Z-FA-FMK, blocked RPE degeneration induced by pA!u in 
wild-type mice (FIG. 14). Z-IETD-FMK also inhibited 
human RPE cell death induced by Alu RNA (FIG. 15) or 
pA!u (FIG. 16). It was also found that subretinal injection of 
recombinant IL-18 induced activation of Caspase-8, as 60 
monitored by a fluorometric assay, in the RPE of wild-type 
mice (FIG. 17). These data indicate that Alu RNA- or 
pAin-induced IL-18 leads to Caspase-8 activation upstream 
of Caspase-3 activation. 
MyD88 is known to bind Pas-associated death domain 65 
protein (FADD) and induce apoptosis via Caspase 8 (Alip-
rantis et a!. 2000). Therefore, it was tested whether ablation 
Cell Culture. 
All cell cultures were maintained at 37° C. and 5% C02 . 
Primary mouse RPE cells were isolated as previously 
described (Yang eta!., 2009) and grown in Dulbecco Modi-
fied Eagle Medium (DMEM) supplemented with 20% FBS 
and standard antibiotics concentrations. Primary human 
RPE cells were isolated as previously described (Yang eta!., 
2008) and maintained in DMEM supplemented with 10% 
FBS and antibiotics. HeLa cells were maintained in DMEM 
supplemented with 20% FBS and standard antibiotics con-
centrations. THP-1 cells were cultured in RPMI 1640 
medium supplemented with 10% FBS and antibiotics. 
In Vitro Transcription of Alu RNAs. 
We synthesized a 302 nt Alu sequence isolated from the 
RPE of a human eye with geographic atrophy. A linearized 
plasmid containing this Alu sequence with an adjacent 5' T7 
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promoter were subjected to AmpliScribe™ T7-Flash™ 
Transcription Kit (Epicentre) according to the manufactur-
er's instructions. DNase-treated RNA was purified using 
MEGAclear™ (Ambion), and integrity was monitored by 
gel electrophoresis. This yields single stranded RNAs that 5 
fold into a defined secondary structure identical to Pol III 
derived transcripts. Where indicated, transcribed RNA was 
dephosphorylated using calf intestine alkaline phosphatase 
(Invitrogen) and repurified by Phenol:Chloroform:Isoamyl 
alcohol precipitation. 10 
Transient Transfection. 
Human RPE cells were transfected with pUC19, pA!u, 
Alu RNA, VDACl siRNA sense (5'-CGGAAUAGCAGC-
CAAGUdTdT-3'), VDAC2 siRNA sense (5'-CCCUG- 15 
GAGUUGGAGGCUdTdT-3'), VDAC3 siRNA sense (5'-
GCUUUAAUCGAUGGGAAdTdT-3'), using 
Lipofectamine 2000 (Invitrogen) according to the manufac-
turer's instructions. 
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(1998). Targeted disruption of the MyD88 gene results in 
loss of IL-l- and IL-lS-mediated function. Immunity 9, 
143-150. 
3) Aeffner, F., Z. P. Traylor, eta!. (2011). "Double-stranded 
RNA induces similar pulmonary dysfunction to respira-
tory syncytial virus in BALB/c mice." Am J Physiol Lung 
Cell Mol Physiol 301(1): L99-Ll09. 
4)Akira, S., Uematsu, S., and Takeuchi, 0. (2006). Pathogen 
recognition and innate immunity. Celll24, 783-801. 
5) Alegre, M. L., J. Leemans, et a!. (2008). "The multiple 
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activation of NF-kappaB by Toll-like receptor 3. Nature 
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Cell Viability. 20 8) Aliprantis, A. 0., Yang, R. B., Weiss, D. S., et a!. (2000). 
MTS assays were performed using the Cell Titer 96 AQue-
ous One Solution Cell Proliferation Assay (Promega) 
according to the manufacturer's instructions. 
Caspase-8 Activity. 
RPE tissues were homogenized in lysis buffer (10 mM 25 
Tris base, pH 7.4, 150 mM NaCI, 1 mM EDTA, 1 mM 
EGTA, 1% Triton X-100, 0.5% NP-40, protease and phos-
phatase inhibitor cocktail (Roche)). Protein concentrations 
were determined using a Bradford assay kit (Bio-Rad) with 
bovine serum albumin as a standard. The caspase-3 activity 30 
was measured using Caspase-8 Fluorimetric Assay (R&D) 
in according to the manufacturer's instructions. 
Statistics. 
Results are expressed as mean±SEM, with p<0.05 con-
sidered statistically significant. Differences between groups 35 
were compared by using Mann-Whitney U test or Student 
t-test, as appropriate, and 2-tailed p values are reported. 
Methods for Caspase Imaging 
Alu RNA or recombinant IL-18 was injected into the 
subretinal space of wild-type mice on day 0. DyeLight782- 40 
VAD-FMK3 (ThermoScientific), a probe that fluoresces in 
the presence of bioactive caspases, was injected into the 
vitreous humor of wild-type mice on day 2 or day 3 after 
injection. 
Flat Mount Imaging. 
At 24 hours after injection ofDyeLight782-VAD-FMK3, 
the eyecup was dissected out of mice, the neural retina was 
removed, and a flat mount of the RPE was prepared, and 
viewed under a fluorescent microscope. 
45 
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In Vivo Bioimaging in the Living Eye. 
At intervals from 0-24 hours after injection of Dye-
Light782-VAD-FMK3, fundus photographs were taken with 
the Topcon 50IX camera using the ICG filter. 
50 17) Batzer, M. A., and Deininger, P. L. (2002). Alu repeats 
and human genomic diversity. Nat Rev Genet. 3, 370-379. 
Throughout this document, various references are men-
tioned. All such references are incorporated herein by ref- 55 
erence to the same extent as if each individual reference was 
specifically and individually indicated to be incorporated by 
reference, including the references set forth in the following 
list: 
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<160> NUMBER OF SEQ ID NOS, 61 
<210> SEQ ID NO 1 
<211> LENGTH, 24 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic polypeptide 
<400> SEQUENCE, 1 
Furthermore, the foregoing description is for the purpose of 
illustration only, and not for the purpose of limitation. 
Asp Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys 
1 5 10 15 
Lys Arg Asp Val Leu Pro Gly Thr 
20 
<210> SEQ ID NO 2 
<211> LENGTH, 17 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic polypeptide 
<400> SEQUENCE, 2 
Asp Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys 
1 5 10 15 
Lys 
<210> SEQ ID NO 3 
<211> LENGTH, 19 
<212> TYPE, DNA 
77 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<220> 
<221> 
<222> 
<220> 
<221> 
<222> 
FEATURE, 
NAME/KEY, 
LOCATION, 
FEATURE, 
NAME/KEY, 
LOCATION, 
dT 
(18) 
dT 
(19) 
<400> SEQUENCE, 3 
gagaagccuu uacaggutt 
<210> SEQ ID NO 4 
<211> LENGTH, 19 
<212> TYPE, DNA 
.. (18) 
.. (19) 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<220> 
<221> 
<222> 
<220> 
<221> 
<222> 
FEATURE, 
NAME/KEY, 
LOCATION, 
FEATURE, 
NAME/KEY, 
LOCATION, 
dT 
(18) 
dT 
(19) 
<400> SEQUENCE, 4 
accuguaaag gcuucuctt 
<210> SEQ ID NO 5 
<211> LENGTH, 19 
<212> TYPE, DNA 
.. (18) 
.. (19) 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<220> 
<221> 
<222> 
<220> 
<221> 
<222> 
FEATURE, 
NAME/KEY, 
LOCATION, 
FEATURE, 
NAME/KEY, 
LOCATION, 
dT 
(18) 
dT 
(19) 
<400> SEQUENCE, 5 
cagagcaagg aaugugatt 
<210> SEQ ID NO 6 
<211> LENGTH, 19 
<212> TYPE, DNA 
.. (18) 
.. (19) 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<220> 
<221> 
<222> 
<220> 
<221> 
<222> 
FEATURE, 
NAME/KEY, 
LOCATION, 
FEATURE, 
NAME/KEY, 
LOCATION, 
<400> SEQUENCE, 
dT 
(18) 
dT 
(19) 
ucacauuccu ugcucugtt 
<210> SEQ ID NO 7 
<211> LENGTH, 19 
<212> TYPE, DNA 
.. (18) 
.. (19) 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
78 
19 
19 
19 
19 
79 
<223> OTHER INFORMATION, Synthetic 
<220> FEATURE, 
<221> NAME/KEY, dT 
<222> LOCATION, (18) 
<220> FEATURE, 
<221> NAME/KEY, dT 
<222> LOCATION, (19) 
<400> SEQUENCE, 7 
guuugacuau cuguucutt 
<210> SEQ ID NO 8 
<211> LENGTH, 19 
<212> TYPE, RNA 
.. (18) 
.. (19) 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
oligonucleotide 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 8 
ggaucaaacu acucuguga 
<210> SEQ ID NO 9 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 9 
ugcaagaucu cucagcaaa 
<210> SEQ ID NO 10 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 10 
gaaguggggu ucagauaau 
<210> SEQ ID NO 11 
<211> LENGTH, 19 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 11 
gcaagaccaa gacguguga 
<210> SEQ ID NO 12 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<220> 
<221> 
<222> 
<220> 
<221> 
<222> 
FEATURE, 
NAME/KEY, 
LOCATION, 
FEATURE, 
NAME/KEY, 
LOCATION, 
dT 
(18) 
dT 
(19) 
<400> SEQUENCE, 12 
gaagcucuuc aguuucatt 
.. (18) 
.. (19) 
80 
19 
19 
19 
19 
19 
19 
<210> SEQ ID NO 13 
<211> LENGTH, 25 
<212> TYPE, RNA 
81 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 13 
ggcugcugga ugcucuguac gggaa 
<210> SEQ ID NO 14 
<211> LENGTH, 25 
<212> TYPE, RNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 14 
uucccguaca gagcauccag cagcc 
<210> SEQ ID NO 15 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 15 
gctggagcag gtgtactact tc 
<210> SEQ ID NO 16 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 16 
caggtttgac tatctgttct 
<210> SEQ ID NO 17 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 17 
gtgaagagat ccttctgta 
<210> SEQ ID NO 18 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 18 
ttaaagcccg cctgacaga 
<210> SEQ ID NO 19 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
82 
25 
25 
22 
20 
19 
19 
83 
<400> SEQUENCE, 19 
gcgaatgaca gagggtttct tag 
<210> SEQ ID NO 20 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 20 
atcacttgca ctccggaggt a 
<210> SEQ ID NO 21 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 21 
agagcgcaat ggtgcaatc 
<210> SEQ ID NO 22 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 22 
gcacctgttg tgcaatctga a 
<210> SEQ ID NO 23 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 23 
tcctgacaac atgctgatgt ga 
<210> SEQ ID NO 24 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 24 
gccaggcctg cactttatag a 
<210> SEQ ID NO 25 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 25 
gtttgtgacc ctcgcgataa g 
<210> SEQ ID NO 26 
<211> LENGTH, 20 
84 
23 
21 
19 
21 
22 
21 
21 
85 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
US 9,453,226 B2 
-continued 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 26 
actgcaaaat cccgagtgac 
<210> SEQ ID NO 27 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 27 
ctgtccaggc aagattgaca 
<210> SEQ ID NO 28 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 28 
cagtgccaaa tcaaagctga 
<210> SEQ ID NO 29 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 29 
cctgatgtcc aagcaaggtt 
<210> SEQ ID NO 30 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 30 
ttgacacagc caaatccaaa 
<210> SEQ ID NO 31 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 31 
gccaaaacgg gtgttgttac 
<210> SEQ ID NO 32 
<211> LENGTH, 24 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 32 
86 
20 
20 
20 
20 
20 
20 
87 
cgcagctagg aataatggaa tagg 
<210> SEQ ID NO 33 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 33 
gcctcagttc cgaaaaccaa 
<210> SEQ ID NO 34 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 34 
cacctgtgtc tggtccattg 
<210> SEQ ID NO 35 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 35 
aggctgagtg caaacttggt 
<210> SEQ ID NO 36 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 36 
atgctgcttc gacatctcct 
<210> SEQ ID NO 37 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 37 
aaccaatgcg agatcctgac 
<210> SEQ ID NO 38 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 38 
gacagcctgt gttcgaggat 
<210> SEQ ID NO 39 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
88 
24 
20 
20 
20 
20 
20 
20 
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<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 39 
tggatccatt tcctcaaagg 
<210> SEQ ID NO 40 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 40 
ttcgtattgc gccgctaga 
<210> SEQ ID NO 41 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 41 
ctttcgctct ggtccgtctt 
<210> SEQ ID NO 42 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 42 
tggacggaga actgataagg gt 
<210> SEQ ID NO 43 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 43 
agctacatct ggctactggg t 
<210> SEQ ID NO 44 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 44 
aaaagctggg ttgagagggc ga 
<210> SEQ ID NO 45 
<211> LENGTH, 22 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 45 
tcaggctcag tcccctcccg at 
90 
20 
19 
20 
22 
21 
22 
22 
<210> SEQ ID NO 46 
<211> LENGTH, 18 
<212> TYPE, DNA 
91 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 46 
aaattcgtga agcgttcc 
<210> SEQ ID NO 47 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<220> 
<221> 
<222> 
<220> 
<221> 
<222> 
FEATURE, 
NAME/KEY, 
LOCATION, 
FEATURE, 
NAME/KEY, 
LOCATION, 
dT 
(18) 
dT 
(19) 
<400> SEQUENCE, 47 
cggaauagca gccaagutt 
<210> SEQ ID NO 48 
<211> LENGTH, 19 
<212> TYPE, DNA 
.. (18) 
.. (19) 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<220> 
<221> 
<222> 
<220> 
<221> 
<222> 
FEATURE, 
NAME/KEY, 
LOCATION, 
FEATURE, 
NAME/KEY, 
LOCATION, 
dT 
(18) 
dT 
(19) 
<400> SEQUENCE, 48 
cccuggaguu ggaggcutt 
<210> SEQ ID NO 49 
<211> LENGTH, 19 
<212> TYPE, DNA 
.. (18) 
.. (19) 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<220> 
<221> 
<222> 
<220> 
<221> 
<222> 
FEATURE, 
NAME/KEY, 
LOCATION, 
FEATURE, 
NAME/KEY, 
LOCATION, 
dT 
(18) 
dT 
(19) 
<400> SEQUENCE, 49 
cccuggaguu ggaggcutt 
<210> SEQ ID NO 50 
<211> LENGTH, 20 
<212> TYPE, DNA 
.. (18) 
.. (19) 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 50 
gcugaccttt ttgctucuca 
92 
18 
19 
19 
19 
20 
<210> SEQ ID NO 51 
<211> LENGTH, 26 
<212> TYPE, DNA 
93 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 51 
ttggtacgca tacgtgttga ctgtga 
<210> SEQ ID NO 52 
<211> LENGTH, 91 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 52 
26 
cccgggttca cgccattctc ctgcctcagc ctcacgagta gctgggacta caggcgcccg 60 
acaccactcc cggctaattt tttgtatttt t 91 
<210> SEQ ID NO 53 
<211> LENGTH, 84 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<400> SEQUENCE, 53 
gcatggccag tccattgatc ttgcacgctt gcctagtacg ctcctcaacc tatcctccta 60 
gcccgttact tggtgccacc ggcg 84 
<210> SEQ ID NO 54 
<211> LENGTH, 7 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic polypeptide 
<400> SEQUENCE, 54 
Arg Asp Val Leu Pro Gly Thr 
1 5 
<210> SEQ ID NO 55 
<211> LENGTH, 7 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic polypeptide 
<400> SEQUENCE, 55 
Arg Asp Val Val Pro Gly Gly 
1 5 
<210> SEQ ID NO 56 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<220> 
<221> 
<222> 
<220> 
<221> 
<222> 
FEATURE, 
NAME/KEY, 
LOCATION, 
FEATURE, 
NAME/KEY, 
LOCATION, 
dT 
(18) .. (18) 
dT 
(19) .. (19) 
94 
<400> SEQUENCE, 56 
uauuuccuaa uuggguctt 
<210> SEQ ID NO 57 
<211> LENGTH, 19 
<212> TYPE, DNA 
95 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<223> OTHER INFORMATION, Synthetic oligonucleotide 
<220> 
<221> 
<222> 
<220> 
<221> 
<222> 
FEATURE, 
NAME/KEY, 
LOCATION, 
FEATURE, 
NAME/KEY, 
LOCATION, 
dT 
(18) 
dT 
(19) 
<400> SEQUENCE, 57 
cggaauagca gccaagutt 
<210> SEQ ID NO 58 
<211> LENGTH, 19 
<212> TYPE, DNA 
.. (18) 
.. (19) 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<220> 
<221> 
<222> 
<220> 
<221> 
<222> 
FEATURE, 
NAME/KEY, 
LOCATION, 
FEATURE, 
NAME/KEY, 
LOCATION, 
dT 
(18) 
dT 
(19) 
<400> SEQUENCE, 58 
cccuggaguu ggaggcutt 
<210> SEQ ID NO 59 
<211> LENGTH, 19 
<212> TYPE, DNA 
.. (18) 
.. (19) 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic oligonucleotide 
<220> 
<221> 
<222> 
<220> 
<221> 
<222> 
FEATURE, 
NAME/KEY, 
LOCATION, 
FEATURE, 
NAME/KEY, 
LOCATION, 
dT 
(18) 
dT 
(19) 
<400> SEQUENCE, 59 
gcuuuaaucg augggaatt 
<210> SEQ ID NO 60 
<211> LENGTH, 32 
<212> TYPE, PRT 
.. (18) 
.. (19) 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthesized polypeptide 
<400> SEQUENCE, 60 
Asp Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys 
1 5 10 15 
Lys Arg Asp Val Leu Pro Gly Thr Cys Val Trp Ser Ile Ala Ser Glu 
20 25 30 
96 
19 
19 
19 
19 
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<210> SEQ ID NO 61 
<211> LENGTH, 15 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Synthetic Polypeptide 
<400> SEQUENCE, 61 
Arg Asp Val Leu Pro Gly Thr Cys Val Trp Ser Ile Ala Ser Glu 
1 5 10 15 
What is claimed is: a polypeptide sequence selected from the sequences of SEQ 
1. A method of protecting an retinal pigment epithelium 
(RPE) cell, a retinal photoreceptor cell, or a choroidal cell, 
comprising: 
inhibiting one or more of an inflammasome of the cell; 
MyD88 of the cell; IL-18 of the cell; VDACl of the 
15 ID NO: 1, 54, 55, 60, and 61; and a MyD88 inhibitor 
comprising a double-stranded RNA molecule, at least one 
strand of which includes a sequence selected from SEQ ID 
NOS: 3, 4, 5, 6, and 56. 
20 
cell; VDAC2 of the cell; caspase-8 of the cell; and 
NFKB of the cell; 
wherein the cell is protected against Alu-RNA-induced 
degeneration; 
wherein inhibiting the inflmasome consists essentially 25 
of administering an inflammasome inhibitor selected 
from the group consisting of an NLRP3 inhibitor, a 
PYCARD inhibitor, an inflammosome inhibitor com-
prising a sequence selected from the sequences of SEQ 
4. The method of claim 2, wherein the My D88 inhibitor 
is selected from the group consisting of a MyD88 homodi-
merization inhibitor; Pepinh-MYD; a dominant negative or 
splice variant of MyD88; a MyD88 splice variants that lack 
exon 2; and MyD88 inhibitors as set forth in Table C. 
5. The method of claim 4, wherein the inhibitor is 
administered by intravitreous injection; subretinal injection; 
episcleral injection; sub-Tenon's injection; retrobulbar 
injection; peribulbar injection; topical eye drop application; 
release from a sustained release implant device that is 
sutured to or attached to or placed on the sclera, or injected 
into the vitreous humor, or injected into the anterior cham-
ber, or implanted in the lens bag or capsule; oral adminis-
tration; or intravenous administration. 
6. A method of protecting an RPE cell, a retinal photo-
35 receptor cell, or a choroidal cell, comprising: 
ID NOS: 7-16, an inhibitor of Caspase-1, a peptide 30 
inhibitor of Caspase-1, a Caspase-1 inhibitor compris-
ing the sequence of SEQ ID NO: 17, and the inflam-
mosome inhibitors selected from: ion channel inhibi-
tors; Il<B-a inhibitors; antibodies selected from: Anti-
ASC, Anti-NALPl, antibodies based on protein 
sequences selected from: ASC: ALR QTQ PYL VTD 
LEQ S; NALPl: MEE SQS KEE SNT EG-cys; Anti-
NALPl, anti-IL-l~, anti-IL-18, anti-caspase-1, and 
anti-caspase-11; direct inhibitors of Caspase-1 and/or 
NLRP3; parthenolide; estrogen binding B-box pro- 40 
teins, COP, ICEBERG, and Z-WEHD-FMK; Caspase 1 
and/or 4 inhibitors; Caspase-12 inhibitors; host-derived 
inhibitors of caspase-1; inhibitors of Nlrpl b inflam-
masome; virus expressed inhibitors of the inflam-
masome; potassium chloride; Cathepsin-B-inhibitors; 45 
Cytochalsin D; ROS inhibitors; ASC-1 inhibitors; 
NLRP3 inflmasome pan-caspase inhibitors; Micro-
tubules; an isolated double-stranded RNA molecule 
that inhibits expression of NLRP3, and which can be 
conjugated to cholesterol or not, and at least one strand 50 
including the sequence: GUUUGACUAUCU-
GUUCUdTdT (SEQ ID NO: 7); an isolated double-
stranded RNA molecule that inhibits expression of 
PYCARD, at least one strand of which includes the 
sequence of: 5'-GAAGCUCUUCAGUUUCAdTdT-3' 55 
(SEQ ID NO: 12); and an isolated double-stranded 
RNA molecule that inhibits expression of PYCARD, at 
least one strand of which includes a sequence selected 
from: 5'-GAAGCUCUUCAGUUUCAdTdT-3' (SEQ 
ID NO: 12); 5'-GGCUGCUGGAUGCUCU- 60 
GUACGGGAA-3' (SEQ ID NO: 13); and 5'-UUC-
CCGUACAGAGCAUCCAGCAGCC-3' (SEQ ID NO: 
14). 
2. The method of claim 1, wherein the inhibiting MyD88 
comprises administering a MyD88 inhibitor. 
3. The method of claim 2, wherein the inhibitor is selected 
from the group consisting of a MyD88 inhibitor comprising 
65 
inhibiting one or more of an inflmasome of the cell; 
MyD88 of the cell; IL-18 of the cell; VDACl of the 
cell; VDAC2 of the cell; caspase-8 of the cell; and 
NFKB of the cell; 
wherein the cell is protected against Alu-RNA-induced 
degeneration; 
wherein inhibiting the inflmasome comprises admin-
istering an inflammasome inhibitor selected from the 
group consisting of an NLRP3 inhibitor, a PYCARD 
inhibitor, an inflmosome inhibitor comprising a 
sequence selected from the sequences of SEQ ID NOS: 
7-16, an inhibitor of Caspase-1, a peptide inhibitor of 
Caspase-1, a Caspase-1 inhibitor comprising the 
sequence of SEQ ID NO: 17, and the inflmosome 
inhibitors selected from: ion channel inhibitors; IkB-a 
inhibitors; antibodies selected from: Anti-ASC, Anti-
NALPl, antibodies based on protein sequences 
selected from: ASC: ALR QTQ PYL VTD LEQ S; 
NALPl: MEE SQS KEE SNT EG-cys; Anti-NALPl, 
anti-IL-l~' anti-IL-18, anti-caspase-1, and anti-cas-
pase-11; direct inhibitors of Caspase-1 and/or NLRP3; 
parthenolide; estrogen binding B-box proteins, COP, 
ICEBERG, and Z-WEHD-FMK; Caspase 1 and/or 4 
inhibitors; Caspase-12 inhibitors; host-derived inhibi-
tors of caspase-1; inhibitors of Nlrp 1 b inflammasome; 
virus expressed inhibitors of the inflammasome; potas-
sium chloride; Cathepsin-B-inhibitors; Cytochalsin D; 
ROS inhibitors; ASC-1 inhibitors; NLRP3 inflam-
masome pan-caspase inhibitors; Microtubules; an iso-
lated double-stranded RNA molecule that inhibits 
expression ofNLRP3, and which can be conjugated to 
cholesterol or not, and at least one strand including the 
US 9,453,226 B2 
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sequence: GUUUGACUAUCUGUUCUdTdT (SEQ 
ID NO: 7); an isolated double-stranded RNA molecule 
that inhibits expression ofPYCARD, at least one strand 
of which includes the sequence of: 5'-GAAGCUC-
UUCAGUUUCAdTdT-3' (SEQ ID NO: 12); and an s 
isolated double-stranded RNA molecule that inhibits 
injection; peribulbar injection; topical eye drop application; 
release from a sustained release implant device that is 
sutured to or attached to or placed on the sclera, or injected 
into the vitreous humor, or injected into the anterior cham-
ber, or implanted in the lens bag or capsule; oral adminis-
tration; or intravenous administration. 
expression of PYCARD, at least one strand of which 
includes a sequence selected from: 5'-GAAGCUC-
UUCAGUUUCAdTdT-3' (SEQ ID NO: 12); 
5'-GGCUGCUGGAUGCUCUGUACGGGAA-3' 
(SEQ ID NO: 13); and 5'-UUCCCGUACAGAG-
CAUCCAGCAGCC-3' (SEQ ID NO: 14), wherein the 
inflammasome includes a protein encoded by 
PYCARD. 
7. The method of claim 6, wherein the inflammasome is 
selected from NLRP3 inflammasome, NLRPl inflam-
masome, NLRC4 inflammasome, AIM2 inflammasome, and 
IFI16 inflammasome. 
8. The method of claim 7, wherein the inflammasome is 
the NLRP3 inflammasome. 
9. The method of claim 1, wherein the inflammasome 
inhibitor is selected from glybenclamide/glyburide; BAYll-
7082 (CAS Number: 195462-67-7; also known as (E)-3-(4-
Methy lpheny !sulfonyl)-2-propenenitrile ); Anti-ASC and 
Anti-NALPl and antibodies based on protein sequences 
selected from: ASC: ALR QTQ PYL VTD LEQ S; NALPl: 
12. The method of claim 1, wherein the inhibiting IL-18 
comprises administering an IL-18 inhibitor. 
13. The method of claim 12, wherein the IL-18 inhibitor 
10 is selected from the group consisting of a neutralizing 
antibody against IL-18; an antibody that blocks IL-18 bind-
ing to the IL-18 receptor, IL-18 neutralizing antibodies; 
IL-18 binding protein; and IL18BP. 
14. The method of claim 13, wherein the inhibitor is 
15 administered by intravitreous injection; subretinal injection; 
episcleral injection; sub-Tenon's injection; retrobulbar 
injection; peribulbar injection; topical eye drop application; 
release from a sustained release implant device that is 
sutured to or attached to or placed on the sclera, or injected 
20 into the vitreous humor, or injected into the anterior cham-
ber, or implanted in the lens bag or capsule; oral adminis-
tration; or intravenous administration. 
15. The method of claim 1, wherein the inhibiting 
VDACl comprises administering a VDACl inhibitor and 
25 inhibiting VDAC2 comprises administering a VDAC2 
inhibitor. 
16. The method of claim 15, wherein the VDACl inhibi-
tor is selected from the group consisting of a VDACl 
inhibitor comprising the sequence of SEQ ID NO: 47; a 
30 VDAC2 inhibitor comprising the sequence of SEQ ID NO: 
48; phosphorothioate oligonucleotide randomer (Trilink 
Industries) that inhibits VDAC; cyclosporin A; superoxide 
dismutase 1; 4,4'-diisothiocyanatostilbene-2,2'-disulfonic 
MEE SQS KEE SNT EG-cys; Anti-NALPl, anti-IL-l~, 
anti-IL-18, anti-caspase-1, and anti-caspase-11; partheno-
lide; estrogen binding B-box proteins, COP, ICEBERG, and 
Z-WEHD-FMK; Ac-Tyr-Val-Ala-Asp-CHO (Ac-YVAD-
CHO) or N-acetyl-L-tyrosyl-L-valyl-N-[(1 S)-1-( carboxym-
ethy 1)-3 -chloro-2-oxo-propy 1]-L-alaninamide ( Ac-YV AD-
CMK); Caspase-12 inhibitors; cellular PYRIN domain 
(PYD)-ony proteins (POP) family: cPOPl and cPOP2; ser-
pin proteinase inhibitor 9 (PI-9); BCL-2 and BCL-xL; 35 
auranofin; PYD homologs M13L-PYD, S013L, SPI-2 
homologs CrmA, Serp2, SPI-2, NSl, Kaposi Sarcoma-
associated Herpesvirus Orf63; potassium chloride; L-3-
trans-(Propylcarbamoyl)oxirane-2-Carbonyl)-L-Isoleucyl-
L-Proline Methyl Ester ("CA-074 Me"); Cytochalsin D; 
N-acetyl-L-cysteine (NAC), (2R,4R)-4-aminopyrrolidine-2, 
4-dicarboxylate (APDC); cellular pyrin domain (PYD) 
superfamily proteins, also known as M013; Z-VAD-FMK; 
colchicine; an isolated double-stranded RNA molecule that 
inhibits expression ofNLRP3, and which can be conjugated 
acid (DIDS); Bcl-x(L) BH4(4-23); and TR019622. 
17. The method of claim 15, wherein the inhibitor is 
administered by intravitreous injection; subretinal injection; 
episcleral injection; sub-Tenon's injection; retrobulbar 
injection; peribulbar injection; topical eye drop application; 
release from a sustained release implant device that is 
40 sutured to or attached to or placed on the sclera, or injected 
into the vitreous humor, or injected into the anterior cham-
ber, or implanted in the lens bag or capsule; oral adminis-
tration; or intravenous administration. 
18. The method of claim 1, wherein the inhibiting Cas-
45 pase-8 comprises administering a Caspase-8 inhibitor. 
to cholesterol or not, and at least one strand including the 
sequence: GUUUGACUAUCUGUUCUdTdT (SEQ ID 
NO: 7); an isolated double-stranded RNA molecule that 
inhibits expression ofPYCARD, at least one strand of which 
includes the sequence of: 5'-GAAGCUCUUCAGUUU-
CAdTdT-3' (SEQ ID NO: 12); and an isolated double-
stranded RNA molecule that inhibits expression of 
PYCARD, at least one strand of which includes a sequence 
selected from: 5'-GAAGCUCUUCAGUUUCAdTdT-3' 
(SEQ ID NO: 12); 5'-GGCUGCUGGAUGCUCU-
GUACGGGAA-3' (SEQ ID NO: 13); and 5'-UUC-
CCGUACAGAGCAUCCAGCAGCC-3' (SEQ ID NO: 14). 
10. The method of claim 1, wherein the inflammasome 
inhibitor is selected from the group consisting of an inflam-
mosome inhibitor comprising a sequence selected from the 
sequences of SEQ ID NOS: 7 -16; an inhibitor of Caspase-1 
selected from VX-765, ML132, VX-740, VRT-018858, 
YVAD, WEHD; and a Caspase-1 inhibitor comprising the 
sequence of SEQ ID NO: 17. 
11. The method of claim 9, wherein the inhibitor is 
administered by intravitreous injection; subretinal injection; 
episcleral injection; sub-Tenon's injection; retrobulbar 
19. The method of claim 18, wherein the Caspase-8 
inhibitor is selected from the group consisting of Z-IETD-
FMK, Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-
Ala-Leu-Leu-Ala-Pro-Ile-Glu-Thr-Asp-CHO, Z-Ile-Glu 
so (OMe )-Thr-Asp(OMe )-CH2 F, and Cellular fas-associated 
death domain-like interleukin-1-~-converting enzyme-in-
hibitory protein (L). 
20. The method of any one of claim 18, wherein the 
inhibitor is administered by intravitreous injection; subreti-
55 nal injection; episcleral injection; sub-Tenon's injection; 
retrobulbar injection; peribulbar injection; topical eye drop 
application; release from a sustained release implant device 
that is sutured to or attached to or placed on the sclera, or 
injected into the vitreous humor, or injected into the anterior 
60 chamber, or implanted in the lens bag or capsule; oral 
administration; or intravenous administration. 
21. The method of claim 1, wherein the inhibiting NFkB 
comprises administering a NFkB inhibitor. 
22. The method of claim 21, wherein the inhibitor is 
65 administered by intravitreous injection; subretinal injection; 
episcleral injection; sub-Tenon's injection; retrobulbar 
injection; peribulbar injection; topical eye drop application; 
US 9,453,226 B2 
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release from a sustained release implant device that is 
sutured to or attached to or placed on the sclera, or injected 
into the vitreous humor, or injected into the anterior cham-
ber, or implanted in the lens bag or capsule; oral adminis-
tration; or intravenous administration. 
23. The method of claim 1, wherein the cell is in a subject. 
24. The method of claim 23, wherein the subject has 
age-related macular degeneration. 
25. An molecule selected from the group consisting of: 
an isolated double-stranded RNA molecule that inhibits 10 
expression of MyD88, wherein a first strand of the 
double-stranded RNA comprises a sequence selected 
from SEQ ID NO: 3, 4, 5, 6, and 56, and including 
about 11 to 27 nucleotides; 
an isolated double-stranded RNA molecule that inhibits 15 
expression ofNLRP3 and/or PYCARD, wherein a first 
strand of the double-stranded RNA comprises a 
sequence selected from SEQ ID NO: 7-14, and includ-
ing about 11 to 27 nucleotides; 
102 
an isolated double-stranded RNA molecule that inhibits 
expression of Pyrin, comprising the sequence of SEQ 
ID NO: 15, and including about 11 to 27 nucleotides; 
an isolated double-stranded RNA molecule that inhibits 
expression ofNALP3, comprising the sequence of SEQ 
ID NO: 16, and including about 11 to 27 nucleotides; 
an isolated double-stranded RNA molecule that inhibits 
expression of caspase-1, comprising the sequence of 
SEQ ID NO: 17, and including about 11 to 27 nucleo-
tides; 
an isolated double-stranded RNA molecule that inhibits 
expression of VDAC1 and/or VDAC2, wherein a first 
strand of the double-stranded RNA comprises a 
sequence selected from SEQ ID NO: 47 and 48, and 
including about 11 to 27 nucleotides; 
a polypeptide molecule that inhibits MyD88, comprising 
a sequence selected from SEQ ID NO: 60 and SEQ ID 
NO: 61. 
* * * * * 
